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Glutathione and glutathione-dependent enzymes play a central role in the protection of
cells from cytotoxic chemicals. In particular, reduced glutathione (GSH) and glutathione S-
transferases (GST's) have been studied in relation to intrinsic and acquired resistance of
tumours to cytotoxic drugs. There are however, other glutathione-dependent enzymes which
may also be involved in drug resistance: these include glutathione peroxidase (GPX) and the
enzymes, yglutamyltranspeptidase (yGT), y glutamyl cysteinyl synthetase (yGCS) and
glutathione reductase (GRD). The latter enzymes are involved in the maintainance of reduced
GSH levels within cells. GSH and the above glutathione-dependent enzymes have been studied
in a series of drug resistance models, a) drug resistant tumour cell lines generated in vitro and
in vivo: b) chemotherapeutic agent induced resistance in normal bone marrow cells; c) in
oxygen resistant lung cells and d) in preneoplastic foci, in order to evaluate whether GSH and
associated glutathione-dependent enzymes form part of an adaptive response involved in
protection against the environment.
Several models of drug resistance involving cell lines in culture were taken for study.
A CHO cell line resistant to chlorambucil, an ovarian cell line generated in vivo, resistant to
cis-Platinum and chlorambucil, and a sarcoma cell line resistant to adriamycin. In all these
cell lines GST, GSH and y GT were significantly elevated. In the latter two cell lines selenium
dependent GPX was also induced. In the CHO line the elevated GST activity was explained by a
40 fold induction of the alpha class Yc GST subunit and a 2 fold elevation in the Ya subunit. In
mouse bone marrow cells following the administration in vivo of a low 'primary dose' of
cyclophosphamide, transient increases in alpha Ya and particularly mu Yb GST subunits were
found. These increases have been associated with a subsequent protection against a higher
lethal dose of the same agent. The changes observed in GST isozyme composition were
confined to the granulocyte population.
Differences in selenium-dependent GPX, GSH and yGT were also found in cells
resistant to high oxygen, with only marginal changes in GST subunit profiles.
In preneoplastic foci, significant elevations in pi class Yf GST and also alpha Ya and mu
Yb were detected. Selenium-dependent GPX was decreased and, yGCS and GRD elevated in
this model. These studies indicate therefore:
1) GST levels in certain cells appear to be directly related to resistance to cytotoxic
chemicals;
2) Changes in GST expression associated with preneoplasia and in acquired drug resistance
are not confined to one sub group of GST enzymes;
3) Changes in GST expression are often paralleled by changes in GSH and other
glutathione-dependent enzymes;
4) The most consistant phenotypic changes observed in the drug resistant models studied
were in GSH and yGT levels;
5) There seemed to be an inverse relationship in the regulation of selenium and non-
selenium-dependent GPX activity in different drug resistant models.
GSH and glutathione-dependent enzyme changes in acquired drug resistance, appear to
be due to an adaptive response which may be of central importance in the resistance of
tumours to chemotherapeutic agents.
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A major problem in current cancer chemotherapy results from the ability
of a small proportion of malignant cells to survive exposure to cytotoxic drugs.
This type of drug resistance is categorised in several ways. In one situation, a
neoplastic cell within the population becomes resistant to chemotherapy (intrinsic
drug resistance). Alternatively, the cells may only become resistant after
exposure to the cancer chemotherapeutic agents. This is generally known as
acquired drug resistance. A wide variety of tumours fall into this latter category,
for example, childhood leukaemia, breast cancer, and small cell lung cancer. The
various mechanisms for these resistance phenomena have been postulated, as
illustrated in Figure 1. These include decreased drug uptake by changes in drug-
specific transport mechanisms (Kartner et al. 1983), decreased activation of
prodrugs, alterations in the drug's target enzymes, alterations in cellular
metabolism and repair mechanisms (Karran & Lindahl, 1985), and increased drug
detoxification (Hayes & Wolf, 1988).
Glutathione (GSH) and glutathione-dependent enzymes play a central role not
only in drug detoxification, but also in the protection of cells from toxic oxygen
metabolites (Chasseaud, 1979; Larsson et al. 1983a; Wolf et al. 1987a, 1987c;
Hayes & Wolf, 1988). These enzymes may, therefore, appear to be part of an
early protection mechanism that evolved to accommodate respiration. The
presence of GSH and glutathione-requiring enzymes in primitive organisms, such as
bacteria and yeast, substantiate their very early development. GSH, however, is
not essential for life, as certain bacterial mutants have been described lacking this
tripeptide (Fuchs et al. 1983).
There are some recent reports indicating that GSH and glutathione-
dependent enzymes may also play a role in drug resistance (Wolf et al. 1987a,
1987c; Hayes & Wolf, 1988). These studies have concentrated on reduced GSH and
the glutathione S-transferases (GST's). However, many other glutathione-
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dependent enzymes may also be important in this phenomenon. These include
proteins such as selenium-dependent glutathione peroxidase (GPX), y glutamyl
transpeptidase (y GT), y-glutamylcysteinlysynthetase (yGCS), and glutathione
reductase, all of which will determine the thiol status of the cell, ie. GSH:GSSG
ratio, but some are also involved in detoxification. Thiol status is important, as
many proteins which contain thiols at the active site - these being essential for
cellular function - require reduced conditions for their active state (Harrap et al.
1973; Kosower et al. 1978). Whether differences in the levels of the above
enzymes are a factor in drug resistance, is at present unclear. The respective
roles of these proteins in cellular function, and their potential role in
carcinogenesis and drug resistance, is discussed.
1.1.0 Glutathione
1.1.1 Historical
In 1888, de Rey-Pailhade (de Rey-Pailhade 1888a, 1888b) isolated a
substance containing sulphur from yeast which he called "philothion". Some time
later, Hopkins (1921) crystallised this compound, again from yeast, which he
renamed glutathione. The chemical composition of glutathione was described by
Pirie & Pinhey (1929) in 1929. Using different analytical techniques, Hopkins
(1929) and Kendall et al (1929) also described this structure as y-L-glutamyl-L-
cysteinyl glycine (Figure 2). Glutathione was finally synthesised in 1935 by
Harrington & Mead (1935).
1.1.2 Biochemistry of Glutathione (GSH1
GSH is ubiquitous and is the predominant intracellular, non protein
sulphydryl (NPSH), in both prokaryotic and eukaryotic cells (Larsson et al. 1983a).
The biosynthesis of reduced GSH occurs in two successive ATP requiring steps
(Meister, 1974). First, y-glutamyl-cysteinyl-synthetase catalyses the formation













glu + cys + atp « y-glu-cys
+ ADP + Pi (1)
GSH synthetase then mediates the reaction of glycine with the cysteine
carboxyl of y-glutamyl cysteine to form the tripeptide y glutamyl cysteine glycine
(equation 2).
y - glu - cys + gly + ATP^==^y-glu-cys-gly (glutathione)
+ ADP+Pi (2)
The rate limiting step in this biosynthesis is the intracellular pool of cysteine and
in the presence of excess cysteine also the activity of the Y-Q'utamyl-cysteinyl
synthetase (yGCS) enzyme (see Section 1.2.0).
In mammalian cells, GSH exists in at least three, or possibly four,
dynamically interchanging forms. Under normal steady state conditions, the
majority of GSH exists in the reduced form with concentrations ranging from 0.5
(tissue culture cells) - 10mM (foetal liver), and turnover rates varying from 0.5
(kidney) - 96 hours (mammalian erthyrocyte) (Kosower & Kosower, 1978). The
GSH contents of some cells are listed in Table 1. Oxidation of reduced GSH, either
non-enzymatically or through the action of glutathione peroxidase (GPX), yields
GSSG. Levels of GSSG are maintained at low concentrations within the cell, by
NADPH-dependent reduction of GSSG by glutathione reductase (GRD) (Douglas,
1987) and efflux from the cell (Sies & Ankerboom, 1984). The normal
concentration ranges between 5-50um, but, in some cases, concentrations can
reach as high as 100pim (see Table 1). A third form of GSH exists as mixed
disulphides with both protein and non-protein sulphydryl compounds. It was noted
by Guzman Baron (1951) over 35 years ago that the activity of some enzymes
appears to be regulated by the formation of protein disulphides, as shown below.
- 5 -
TABLE 1 GSH, GSSG and GSS-protein (mixed disutphides) content














Kidney (rat) 2.5mM 0.060mM 20 0.5












Nervous tissue 2-3.4mM 72
Abstracted from Kosower & Kosower, 1978.
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ENZSH + RSSR^i ENZSSR + RSH (3)
ENZ(SH)2 + RSSR ^ENZS2 + 2RSH (4)
A potentially significant fourth form of GSH can be found as thiol esters. The
evidence for the occurrence and metabolism of these thiol esters is still
preliminary. The identification, however, of at least three distinct thiol esterases
in human liver perhaps suggest functional significance (Uotila, 1973).
Reduced GSH is characterised by its reactive thiol group and its -/-glutamyl
bond where the glutamic acid is y-linked to the cysteine residue. It has been
suggested that this unusual orientation reduces the susceptibility of the glu-cys
bond to proteolysis. This is exemplified by the finding that reactions of reduced
GSH in mammalian cells can be divided into those involving the -/-glutamyl portion
of the tripeptide or those of the sulphydryl moiety. Those involving the sulphydryl
moiety can be further categorised into either oxidation reduction reactions (for a
review see Ziegler, 1985), or nucleophilic conjugation reactions, in which the
reduced sulphydryl reacts with an electrophile to form a thio ether (see Section
1.10.0). The reaction of reduced GSH with reactive electrophiles or peroxides,
generated by u.v., radiation, uncoupled mitochondria, or chemicals, can have a
variety of consequences. In the majority of cases this reaction is a detoxification
pathway, catalysed often by glutathione dependent enzymes; for example, the
glutathione S-transferases (GST) (Jakoby, 1978; Chasseaud, 1979; Ketterer,
1982) or GPX (Mills, 1957; O'Brien & Little, 1967; Tappel, 1978) for the
peroxides. In chemical carcinogenesis, the production of chemical-induced
mutations are reduced, and in chemical toxicity, the interaction with DNA or other
criticial target sites are prevented. The consequence of these reactions is that
intracellular GSH becomes suppressed. The maintenance of intracellular GSH is
therefore central to the cellular resistance to chemicals. Consequently, changes in
- 7 -
enzymes involved in the maintenance of GSH levels may occur to try to prevent
this decrease.
Apart from its role in the cellular protection from chemical toxins, a wide
variety of functions have also been attributed to GSH. Many of these, however,
are still speculative. These include the involvement of GSH and GSSG in protein
synthesis (Zehavi-Willner et al. 1970; Kosower & Kosower, 1973); in oxidative
phosphorylation (Painter & Hunter, 1970a, 1970b); in the regulation of the hexose
monophosphate pathway (Mills, 1957; Jacob & Jandl, 1966; Eggleston & Krebs,
1974) and in the GSH-dependent biosynthesis of deoxyribonucleotides in bacteria
(Holmgren 1979). In conjunction with the GST's, however, GSH is also involved in
the biosynthesis of leukotrienes (Bach et al. 1984) (see Section 1.10.6), and in
melanin (Agrup et al. 1977). It has been proposed that GSH in conjunction with y-
glutamyltranspeptidase (yGT), is involved in the translocation of amino acids
across the plasma membrane (Meister 1974), although this is still disputed by
Pellifigue et al (1976) (see Section 1.4.0). The involvement of GSH in cell
division process is also tentative through lack of good studies, but changes in GSH
levels during the cell cycle have been described in various species (for a review
see Szent-Gyorgyi, 1978). Why GSH levels change during the cell cycle is still at
present unclear, but this may involve changes in the different forms of GSH, as
described above.
Regulation of GSH levels within cells is thought to occur at the rate limiting
step of biosynthesis, ie., at the enzyme yGCS, where feedback inhibition by high
GSH levels, and high levels of intracellular cysteine, stimulate the formation of
the GSH precursor (see Section 1.2.0). Exchange of GSH between the cytoplasmic
and the smaller mitochondrial pool of GSH, may also influence the levels of GSH
(Meredith & Reed, 1982).
In experimental models, GSH can be regulated by a variety of means. The
administration of D-L-buthionine-S-R-sulphoximine (BSO), a potent, specific
- 8 -
inhibitor of yGCS (Griffith & Meister, 1979a; Dethmers & Meister, 1981), can
lead to a reduction in GSH levels. Conversely, cellular GSH levels can be increased
by the administration of L-2-oxotazolidine-4-carboxylate (Williamson & Meister,
1981), y glutamyl cysteine (Anderson & Meister, 1982), or glutathione monoethyl
esters (L-y glutamyl cysteinyl glycylethyl ester) (Puri & Meister, 1983). Such
modulation can protect against cytotoxic drug induced damage (Puri & Meister,
1983), and also radiation damage (Wellner et al. 1984). Regulation of GSH levels
is, therefore, important, as this may influence the overall response of cells to
cytotoxins.
1.1.3 Relationship between reduced GSH and olutathione-dependent
enzvmes.
Reduced GSH, and the glutathione-dependent enzymes discussed below, are
known to be involved in drug detoxification (Chasseaud, 1979; Larsson et al.
1983a; Wolf et al. 1987a, 1987c; Hayes & Wolf, 1988). Apart from this
important function, the enzymes are closely linked to the metabolism of GSH. In
particular, yGCS and yGT are involved in the biosynthesis and breakdown of GSH
respectively, forming part of the enzymes of the y-glutamyl cycle (Figure 3). It is
postulated that this cycle in the rat kidney, which consists of a series of six
enzymes, functions to transport amino acids across the membrane of the kidney.
The scheme shown evolved from the use of specific enzyme inhibitors, and also
from studying glutathione regulation in individuals with genetic defects for four of
the enzymes : y-GCS, glutathione synthetase, y-GT and 5-oxo-L-prolinase
(Larsson et al. 1983b). In contrast, glutathione peroxidase (GPX) utilises GSH in
the reduction of peroxides to form GSSG, while glutathione reductase (GRD)
catalyses the NADPH-dependent reformation of GSH to help maintain the thiol
status of the cell. The action of GST's is, effectively, to remove GSH from the cell
by catalysing its conjugation to electrophilic compounds, to form mercapturic
acids.
- 9 -
Figure 3 An outline of the metabolism and function of glutathione. Enzymes: (1)
y-glutamyltranspeptidase; (2) y-glutamylcyclotransferase; (3) 5-oxoprolinase; (4) y-
glutamylcysteine synthetase; (5) glutathione synthetase; (6) dipeptidase; (7)
glutathione S-transferase; (8) glutathione peroxidase; (9) glutathione reductase; (10)
transhydrogenases. AA = amino acids; X = compounds that react with glutathione to
yield conjugates, such as those that lead to the formation of mercapturic acids,


























Taken from Meister, 1983.
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Consequently, as shown in Figure 3, the glutathione-dependent enzymes
under discussion are involved in the metabolism of GSH. Alterations, therefore, in
the levels of any of these enzymes may influence not only intracellular GSH
concentrations, but also the action of other glutathione-dependent enzymes and
ultimately the response of the cell to cytotoxins.
1.2.0 y-G'utamylcysteinylsynthetase (y-GCS)
yGCS (EC 6.3.2.2.) is the rate determining enzyme of GSH biosynthesis in
rat liver, catalysing the conjugation of L-glutamate and L-cysteine to form y-L-
glutamylcysteine. Whether this enzyme is the rate limiting step for GSH
biosynthesis in cell lines or tumours has not been established.
Most studies on this enzyme have concentrated on its purification and
characterisation. y-GCS has been purified from hog, toad, rat and human foetal
liver (Johnston & Block, 1949; Davis et al. 1973; Rollins et al. 1981); rat kidney
(Orlowski & Meister, 1971a, 1971b; Sekura & Meister, 1977a); bovine lens
(Rathburn, 1967); and bovine, human, sheep and rat erthyrocytes (Wendel, 1974;
Majerus, 1974; Board et al. 1980; Seelig & Meister, 1984a, 1984b); wheatgerm
(Webster & Varner, 1954); E. Coli (Apontoweil & Berends, 1975) and Proteus
mirabilius (Kumagai et al. 1982). The most highly purified preparations are from
rat kidney, and rat and sheep erthyrocytes. The isolation procedure from rat
kidney involved ammonium sulphate precipitation, DE52 column and an ATP-
agarose column chromatography. A 37% yield and a purification of 140 fold is
reported (Seelig & Meister, 1985).
The molecular weight of the rat kidney enzyme, which comprises two
subunits, is about 104,000 (Seelig et al. 1984). The heavy subunit has a
molecular weight of 73,000, and the light subunit 27,000 (Sekura & Meister,
subunit contains all the catalytic properties of the isolated enzyme,
is
and, similar to the functional protein, ^feedback inhibited by GSH (Seelig et al.




polypeptide, and processed post translationally to form two subunits, associated by
a disulphide bond. This is consistant with Seelig & Meister (1984b), who
demonstrated in the kidney enzyme, the presence of one disulphide bond and also
two free sulphydryl groups, of which only one is involved at the active site. At
the molecular level, a gene for y-GCS from E. Coli has been cloned and expressed in
mammalian cells (Gushima et al. 1983), the human equivalent as yet, has not been
described.
The tissue distribution of -yGCS, especially in human tissues, has not been
studied in detail. Indications that it is found in all human tissues, however, are
based on the use of skin fibroblast biopsies for phenotyping for this enzyme.
Since individuals who lack this enzyme survive, this indicates that the function of
this enzyme, in the biosynthesis and regulation of GSH levels, may not be essential
for life.
yGCS is induced in rat kidneys by selenium supplementation, through a
mechanism that involves de novo protein synthesis (Chung & Maines, 1981).
Conversely, Hill & Burk (1982) have also shown that selenium deficiency induces
the activity of this enzyme. The expression of the E. Coli gene for yGCS in
mammalian cells will help to clarify these conflicting reports. The binding
specificity of the y-glutamate to the active site allows further regulation of this
enzyme by the feedback competitive inhibition site by GSH (Ki 2.3mM) (Davis al
ai, 1973; Rickman & Meister, 1975). The availability of the precursor, cysteine
(Thor et al. 1978; Vina et al. 1978; Beatty & Reed, 1980), also allows regulation
of the enzyme. The Km of y-GCS, for its substrates cysteine and glutamate, are
0.36mM and 2mM respectively (Rickman & Meister, 1975).
yGCS can, however, also be inhibited by certain analogues of its substrate
L-glutamate, such as D-glutamate (Sekura & Meister, 1977a), cysteamine (Seelig
& Meister, 1982), chloroketones (Beamer et al. 1980), and several analogues of
methionine sulphoximine e.g. propionine and buthionine (Griffith & Meister, 1979a;
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Griffith, 1982). The potency of inhibition is in the increasing order: methionine;
proprionine and buthionine (Griffith & Meister, 1979a; Griffith, 1982). Structure
of buthionine sulphoximine is shown in Figure 4. The role of this inhibitor in
depletion of GSH and modulation of chemotherapy is discussed later.
1.3.0 Glutathione Synthetase
Glutathione synthetase (EC 6.2.3.2) is the second enzyme involved in the
biosynthesis of reduced GSH, catalysing the conjugation of glycine to glutamyl
cysteine to form the tripeptide glutathione. Very little work has been carried out
on this enzyme, but it has been purified from a variety of sources, including human
erythrocytes (Majerus et al. 1974).
The enzyme from yeast, bovine erythrocytes, and rat kidney, exhibit
molecular weights of about 120,000, while a somewhat higher value was reported
for the human erythrocyte enzyme (150,000). The bovine and rat kidney enzymes
dissociate in the presence of SDS to a species of 60,000 molecular weight,
suggesting the enzyme is composed of two identical subunits. Interestingly, a
disease exists where patients who have severe glutathione synthetase defficiency
(5-oxoprolinuria) have symptoms that include mental retardation and excretion of
5-oxoproline (Larsson & Hagenfeldt, 1983).
1.4.0 y-Gutamyltranspeptidase (yGT)
yGT (EC 2.3.22) is an extracellular membrane bound protein that catalyses
the initial step in the degradation of reduced GSH and its derivatives (Puri &
Meister 1983). The y-glutamyl (y-glu) moiety of the tripeptide is transferred to
an acceptor molecule, which can be an amino acid (equation 5) (or dipeptide) or
GSH, itself (equation 6) producing a y glutamyl conjugate. If the nucleophile is
water (equation 7), hydrolysis occurs, resulting in the formation of glutamate.
These three general types of reactions are indicated below:-
y-glu-cys-gly + amino acid^=i. yglu-amino acid
(GSH) + cys-gly (5)
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2 y-glu-cys-gly^=±. y glu-glu-cys-gly + cys-gly (6)
y-glu-cys-gly + H2O > glutamate + cys-gly (7)
yGT has been purified from different tissues from various species (Revel &
Ball, 1959), but, so far, the kidney has the highest activity (Goldbarg et al. 1960).
Rat renal y-GT is a glycoprotein containing two distinct subunits. The renal enzyme
is attached to the brush border membrane via a short NH2 -terminal hydrophobic
region of the larger subunit, molecular weight 51,000. The smaller subunit
(molecular weight 22,000), contains the active site which is involved in the
formation of covalent y-glutamyl-enzyme intermediate. Pulse chase studies into
the biosynthesis, processing, and assembly of the heterodimeric yGT enzyme
indicates that yGT is initially synthesised as a glycosylated, single chain precursor
(molecular weight 78,000), which is subsequently cleared into the two polypeptide
subunits (Tate & Meister 1977; Nash & Tate 1982; 1984). The isolation of y-GT
cDNA clones (Laperche et al. 1986) and the generation of E. Coli K12 mutants
lacking y-GT (Suzuki et al 1987), will greatly facilitate studies into the processing
of yGT, and also its regulation and function. The human renal y-GT has also been
recently cloned, and mapped to chromosome 22 (Bulle et al. 1987).
y-GT has a wide tissue distribution, including the kidney, the biliary
epithelium, the lining of the small intestine, and other tissues which have a
secretory function, such as pancreas and seminal vesicles (Tate 1980; Hanigan &
Pitot, 1985). The proposed functions of this enzyme may be, in fact, related to
this distribution profile. The reaction catalysed by y-GT is, for instance,
important in the y-g'utamyl cycle (as mentioned in Section 1.1.3), a metabolic
pathway involved in the enzymatic synthesis and breakdown of GSH, and
constitutes one of the possible mechanisms for the transport of amino acids into
certain cell types (Orlowski & Meister, 1970; Meister & Tate, 1976; Meister,
1981; Meister & Anderson, 1983). This function still remains controversial,
however, as Pellefigue et al (1976) demonstrated that amino acid uptake still
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occurred in a y-GT deficient human fibroblast cell line. y-GT is also involved in the
formation of mercapturic acids from thioethers, with the removal of the y-
glutamyl moiety. This type of reaction also occurs in endogenous metabolism; for
example, in the formation of leukotriene D. This is the slow reacting substance of
anaphylaxis, and is synthesised from leukotriene A, which reacts with glutathione
to form leukotriene C. Subsequent removal of the y-glutamyl moiety of leukotriene
C by y-GT yields leukotriene D (Orning et al 1980). Analogous reactions involving
y-GT are also found in the metabolism of prostaglandins (Cagen et al 1976),
steroids (Kuss, 1969), and melanins (Agrup et al. 1977).
Cellular levels of y-GT can be modulated by a variety of factors; for
example, in transformation of rat hepatocytes with active ras oncogenes, or the 1q
vivo administration of aflatoxin Bi (Manson, personal communication)
glucocorticoids (Billion et al. 1980; Barouki et al. 1982) and the antioxidant
ethoxyquin (Manson et al. 1987) all lead to the elevation of yGT levels. The in
vitro vGT activity can be inhibited reversibly by L-serine in the presence of borate
(Revel & Ball, 1959), and L-y-glutamyl-(O-carbosyl) phenylhydrazide (L-OC). In
the latter case, the apparent Ki values is 8.5fim, compared with 1.45mM for L-
serine plus borate (Griffith & Meister, 1979b). y-GT is irreversibly inhibited in
vitro using glutamine antagonists L-(a-S,5 S)-a-amino-3-chloro-4,5-dihydro-5-
isoxazoleacetic acid (AT-125) (Griffith et al. 1980). The administration of L-OC
or AT-125 to mice leads to glutathionuria (Griffith & Meister 1979b), as well as
the urinary excretion of y-glutamylcysteine and cysteine moieties (Griffith et al.
1980). This indicates that y-GT has a function in the metabolism and/or transport
of these sulphur containing compounds, as well as glutathione (Griffith et al. 1980).
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1.5.0 y-Glutamylcyclotransferase
y-Glutamylcyclotransferase (EC 2.3.2.4) catalyses the conversion of y-
glutamyl amino acids to 5-oxoproline and the corresponding amino acid (equation 8)
(Meister & Anderson, 1983).
L-y-glutamyl amino acid —> 5-oxoproline + L-amino acid (8)
Although the enzyme has been purified from various sources, including human
erythrocytes (Board et al. 1978), the purified enzyme is unstable and,
consequently, very little work has been carried out on it. The molecular weight
has been estimated at 27,000 for the rat kidney polypeptide (Meister, 1985). The
enzyme forms part of the y-glutamyl cycle (see Figure 3).
1.6.0 5-0xo-L-prolinase
5-oxo-L-prolinase (EC 3.5.2.9) catalyses the ATP-dependent clearage of 5-
oxoproline to glutamate (equation 9)
5-oxoproline + ATP + 2H2O 5==^ Lglutamate + ADP + Pi (9)
K+(NH4+)
This reaction seems to be the only one presently known in which cleavage of ATP is
required for the cleavage of a peptide bond. ATP required is mandatory because of
the unusual stability of the internal bond of 5-oxoproline. 5-Oxoprolinase has been
purified from rat kidney and is a homodimer with a subunit molecular weight of
162,500 (Meister et al. 1985). The enzyme is found in a variety of mammalian
tissues, including kidney, spleen and liver (van der Werf et al. 1971). Again, this
enzyme has not been studied in detail. Patients with deficiencies in this enzyme
have also been found (Larsson et al. 1983b).
1.7.0 Dipeptidase
The dipeptidase cleaves the cysteinyl-glycine bond to release cysteine and
glycine. This peptidase has been purified from rat kidney (Stetson, 1975) and is
found to be widely distributed. Apart from the fact that it is involved in the y-
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glutamyl cycle (see Figure 3), and in the formation of mercapturic acids, it has
not been well characterised.
1.8.0 Glutathione reductase (GRD)
GRD (EC 1.6.4.2) is a flavoprotein which catalyses the NADPH-dependent
reduction of glutathione disulphide (GSSG) to glutathione (GSH) (equation 10)
(Racker, 1955).
NADPH + H+ + GSSG —-> NADP+ + 2GSH (10)
GRD has been purified from various sources, including rat liver (Calberg et al.
1981), yeast (Calberg & Mannervik, 1977) porcine and human erythrocytes
(Boggaram et al. 1979). The enzyme exists as a homodimer with a molecular
weight of 100,000 and contains one FAD molecule per subunit. The amino acid
sequence (Krauth-Siegal et al. 1982) and high resolution X-ray diffraction data of
the native human GRD (Thieme et al. 1981; Schulz et al. 1978; 1982) and the
enzyme:coenzyme/enzyme:substrate complexes (Pai & Schulz, 1983) has led to
detailed information on the reaction mechanism (Pai & Schulz, 1983). The GRD
gene for E. Coli has been cloned and sequenced (Greer & Perham, 1986) and is
highly homologous to the human GRD amino acid sequence (Perham, 1987). One of
the differences is, however, the substitution of a histidine at position 219 at the
catalytic site in the human enzyme for a lysine in the E. Coli enzyme. More
significant is the cysteine at position 90 in the human enzyme, which forms an
unusual intersubunit disulphide bridge (Thieme et al. 1981), which, in the E. Coli
protein, is replaced by threonine, resulting in a non covalently linked dimer. As
there is homology between the E. Coli GRD protein and the human GRD protein, site
directed mutagenesis of the E. Coli gene and the use of Fuchs' GRD deficient E. Coli
mutants (Fuchs et al. 1983), makes it possible to test some of the predictions
made by Pai & Schulz (1983) concerning the reaction mechanism, regulation and
function of the enzyme.
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GRD is found in almost all tissues and in all cells (Calberg et al. 1981), and
functions to maintain GSH levels in the reduced state. The enzyme has been shown
to be induced by compounds such as 12-0-tetradecanoylphorbol-13-acetate (TPA)
(Kumar et al. 1984), diethylnitrosamine (Pinto & Bartley, 1973), and metals such
as selenium (Chung & Maines, 1981). Inhibition of GRD in vivo in erythrocytes of
patients receiving chemotherapy with 1,3-bis(chloroethyl)-1-nitrosourea (BCNU)
was first reported by Frischer & Ahmad (1977). Further studies by Babson &
Reed (1978) demonstrated that inactivation of rat GRD only occurs when the
enzyme is in a reduced state (ie. in the presence of NADPH) and two thiol groups
are present at the active site. The inactivation of catalytic activity appears to
occur as a thio carbamate adduct forms between the isocyanate metabolite of the
nitrosourea and probably a distal thiol group at the active site of the enzyme
(Babson & Reed, 1978). This was confirmed by X-ray diffraction studies of the
enzyme inhibitor complex (Bilzer et al. 1984).
1.9.0 Glutathione Peroxidase (GPX)
Glutathione peroxidases catalyse the reduction of hydroperoxides (ROOH) by
GSH (Mills, 1957; Wendel, 1980; Flohe, 1982) Equation 11.
ROOH + 2GSH ----> ROH + H20 + GSSG (11)
R can be aliphatic, an aromatic organic group of hydrogen. The products generated
are an alcohol, water and GSSG. Regeneration of GSH from GSSG is catalysed by
GRD, as previously mentioned in Section 1.8.0.
Two major types of GPX have been identified. A selenoenzyme containing
selenium in the form of covalently bound selenocysteine at the active site
(Rotruck, 1973), and a non-selenium containing protein with negligible activity
towards hydrogen peroxide (H2O2) (Lawrence & Burk, 1976; Prohaska & Gunther,
1976; Hunter et al. 1976). This activity has been associated with the glutathione
S-transferase family of enzymes (Prohaska & Gunther, 1977). Discussion of the
latter enzymes is described also in Section 1.10.0.
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The selenium-dependent glutathione peroxidase (GPX) (EC 1.11.19) was
discovered in erythrocytes by Mills (Mills, 1957) and has since been purified
from a variety of sources, including rat liver and lung (Nakamura et al. 1974; Chiu
et al. 1976), bovine erythrocytes (Ladenstein et al. 1979), and human placenta and
erythrocytes (Awasthi et al. 1975; 1979). The bovine enzyme is a tetramer with
a molecular weight of approximately 80,000 (Flohe et al. 1971). Recently,
however, selenium-dependent GPX has been purified from human plasma (Kakahashi
et al. 1987). The enzyme, like the erythrocyte form, is tetrameric and contains 4
atoms of selenium/mole, but, unlike the erythrocyte protein, is glycosylated, and
subsequently, has a molecular weight of 100,000. The structure of the bovine
erythrocyte selenium-dependent GPX has been determined by X-ray diffraction
analysis (Epp et al. 1983). Its amino acid sequence has also been elucidated (Flohe
et al. 1984).
At the molecular level, the entire mouse selenium-dependent GPX gene has
been cloned and sequenced (Chambers et al. 1986). Evidence from this work
indicated that the selenocysteine at the active site of the enzyme is encoded by the
stop codon TGA. Sequence of a cDNA clone coding for the human enzyme confirmed
this finding (Mullenbach et al. 1987). The human selenium-dependent GPX gene has
also been mapped to a region on chromosome 3 (3p13 —-> 3q12) by use of mouse
and hamster somatic cell hybrids (Johannsmann et al. 1981; Wijnen et al. 1978).
The subcellular localisation of selenium-dependent GPX is important in its
function, as catalase can also metabolise H2O2 as substrate (see Figure 5). The
relationship between catalase and selenium-dependent GPX has been studied
(Wendel, 1980). In hepatocytes, catalase is primarily localised in the
peroxisomes, while selenium-dependent GPX is found both in the cytosol and
mitochondrial matrix. The two enzymes, therefore, appear to have complimentary
localisations and functions in the cell. GPX activity has been demonstrated in all



















most of the activity, but in certain species, such as guinea-pig liver, the selenium-
dependent enzyme is absent (Lawrence & Burk, 1978). The ratio between the
selenium-dependent and non-selenium dependent activity may vary, not just
between animal species, but also from tissue to tissue within the same species
(Carmagnol et al. 1983). The factors involved in the tissue specific expression of
selenium and non-selenium-dependent GPX is unclear. It is known,, however, that
selenium concentrations can influence the relative expression of these enzymes
(Masukawa et al. 1983).
The GPX enzyme functions to protect against toxic oxygen products
generated by radiation, U.V. light, and uncoupled mitochondria (Figure 5). In
particular, both forms of GPX catalyse the reduction of lipid hydroperoxides (Tan
et al. 1984), and of peroxidised DNA (Christophersen, 1969; Tan et al. 1986;
Ketterer et al. 1987). It is therefore postulated that GPX protects cells from
oxidative damage through the protection of the cell membrane against lipid
peroxidation (reviewed by Flohe, 1982), and in the protection of macromolecules
from oxidative damage (Flohe & Zimmerman, 1970; Tappel, 1974; Combs et al.
1975). Mitochondrial selenium-dependent GPX is also, however, involved in the
regulation of mitochondrial substrate oxidations (Sies & Moss, 1978) and
protection of mitochondrial enzymes and DNA against lipid peroxidative damage
(Timcenko-Youssef et al. 1985). Apart from the effect of selenium, no other
forms of regulation of GPX activity have been described. The use of GPX inhibitors
may, therefore, have a potential use in both anticancer therapy and in the
regulation of mitochondrial activity. Misonidazole (1,2-nitro-1-imadazolyl-3-
methoxy-2-propanol) a radiosensitiser, has shown to inhibit both forms of GPX in
vitro and in vivo (Kumar & Weiss, 1986) and may be of therapeutic use, as
specific inhibitors for selenium-dependent GPX have not yet been reported.
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1.10.0 Glutathione S-transferases (GST's)
As a lot of the work described in this thesis centres around the GST's, the
properties of these enzymes will be discussed in some detail.
1.10.1 Introduction
The glutathione S-transferases (GST, EC 2.5.1.18) are a multigene family
of dimeric proteins, which catalyse the conjugation of genotoxic and cytotoxic
xenobiotic electrophiles to GSH. Evidence that mammalian GST's are important in
xenobiotic metabolism has come from pharmacological and biochemical studies,
showing the GST's catalyse the first step in mercapturic acid formation (Booth
al, 1961) (Figure 6). These enzymes, however, also possess GSH-dependent
isomerase activity (Benson et al. 1977) and non-selenium-dependent GPX activity
-fc
(Prohaska &Ganther, 1977), which are also of impor^nce in the biological function
of these proteins (see Section 1.10.6).
GST was first identified by Booth et al (19611 as "an enzyme from rat liver
catalysing conjugations with glutathione", using a number of electrophilic
compounds, including 1,2-dichloro-4-nitrobenenze, benzyl chloride and
bromoethane. Multiple forms of GST was postulated, with each form being
specific for certain functional groups; for example, aryl, alkyl and epoxy groups
(Grover & Sims, 1964; Boyland & Williams, 1965). This was later found not to
be the case. In 1967, Ketterer et al (1967), isolated a carcinogen binding protein,
which was trivially named ligandin (Ketterer & Beale, 1971). It was not,
however, until 1974, following the discovery that 1-chloro-2,4-dinitrobenzene
(CDNB) was a substrate for essentially all GST's (Clark et al. 1973), that Jakoby
and co-workers identified ligandin as a member of this group of proteins (Habig a]
ai, 1974a). GST activity has now been detected in almost all living organisms
ranging from bacteria, yeast and plants to fish, birds and all mammalian species.
(Clark et al. 1973; Pabst et al. 1973; Kamisaka et al. 1975; Asaoka et al. 1977;
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Figure 6. Pathway of mercapturic acid biosynthesis.
(Taken from Chasseaud, 1976).



















Benson et al. 1978; Smith et al. 1980; Irwin et al. 1980; Yeung & Gidari, 1980;
Saneto et al. 1980; Mozer et al. 1983).
1.10.2. Characterisation of GST proteins.
The purification of GST's revolutionised the characterisation of these
enzymes. Purification is carried out using conventional techniques. However,
major advances were achieved using affinity chromatography and chromato
focussing steps. Affinity resins include immobilised GSH coupled through the
sulphur atom (Vander jagt et al. 1985), or immobilised S-hexyl glutathione coupled
through the a-amino group of the glutamyl residue (Guthenberg & Mannervik,
1979). Recent application of high performance liquid chromatography, and fast
performance liquid chromatography (h.p.l.c. and f.p.l.c.), (Hayes et al. 1987b),
allows quicker and easy resolution of the GST subunits from smaller samples.
GST's have now been purified from a variety of mammalian sources, including rat
liver (Hayes et al. 1981; Beale et al. 1983; Hayes, 1984; 1986; McCusker &
Mantle, 1987); kidney (Guthenberg et al. 1979) and brain (Singh et al. 1987);
mouse liver (Lee et al. 1981; Warholm et al. 1986; Hayes et al. 1987b; McLellan
& Hayes, 1987); human lung (Koskelo et al. 1981); liver (Stockman et al . 1985;
Stockman et al. 1987); placenta (Guthenberg et al. 1985; erythrocytes (Marcus
et al 1978; Stockman et al. 1985); kidney (Koskelo & Icen, 1984); skin (Del
Boccio et al. 1987) and thyroid (Del Boccio et al. 1986). Purified GST's have also
been obtained from other diverse sources such as corn (Timmerman & Tu, 1987)
and drosophila (Cochrane et al. 1987). This list is not meant to be comprehensive,
but illustrates the wide range of tissues and sources from which GST's have been
purified. As GST's were isolated by many different groups, it is important to
establish a nomenclature to allow comparison of forms.
1.10.3 Nomenclature.
Originally GST's were described on the basis of their function, for
example, GSH-S-aryl chloride transferase (Grover & Sims, 1964), GSH-S-
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epoxide transferase (Boyland & Williams, 1965), GSH-S-alkyl transferase (Booth
et al. 1961), GST-S-aralkyl transferase (Boyland & Chasseaud, 1967) etc. This
was, however, found unsuitable, as certain enzyme substrates were metabolised
by more than one protein, and vice versa the best example being 1,chloro-2,4-
dinitrobenzene (CDNB) which is a substrate for essentially all GST's (Clark et al.
1973). Using this substrate as a marker, GST's were isolated from rat liver
cytosol and named alphabetically, in reverse order of their elution from CM-
Cellulose (Jakoby et al. 1976). Bass et al (1977) showed that the three major
classes of GST subunits from rat liver had different apparent molecular weights on
sodium dodecyl sulphate (SDS) polacrylamide gels. These subunits were classified
as Ya, Yb, and Yc, in order of their increasing molecular weight- Y
represented the second peak of elution from the column on which they were
-first l*A< , Y W ~7L -+kx. -f/v.VJL.
initially purified, i.e. X,^ - This nomenclature has been further extended by
Hayes et al (1984; 1986) and Beale et al (1983). Mannervik and Jensen (1982)
described a nomenclature similar to that of Bass et al (1977) and Hayes et a I
(1984; 1986) where each subunit was given a single letter of the alphabet. Since
the GST's were shown to be a large complex multigene family of enzymes (Ketterer
et al. 1984), a numerical system was devised to allow for expansion of the
nomenclature to accomodate new GST's found (Jakoby et al , 1984). Table 2
illustrates the nomenclatures used for the rat GST's and the comparison between
rat, mouse, and human GST's.
The cloning and primary amino acid sequence, together with structural
homology based on antibody reactivity, has allowed classification of the cytosolic
GST's into three separate gene classes I, II, and III (Tu et al. 1987; Hayes &
Mantle, 1986b; Mannervik, 1985), If termed alpha, mu and pi (Mannervik
et al. 1985) respectively. A high degree of sequence homology is found between
GST's within a gene family, and also between homologous families between species
(Ketterer, 1986). Group IV contains the microsomal GST enzyme which, on the
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basis of immunoblotting, shows structural homology between all species studied so
far (Morgenstern, 1987; Hayes et al. 1987a; McLellan & Hayes, 1987).
In the context of this thesis, the human GST's will be referred to as alpha
(a-e, Bi), mu (p, \y, <f>) and pi class ( P, X, n). As suggested by their isoelectric
points on chromatofocussing gels, these classes are equivalent to basic, neutral,
and acidic GST's. The overlap of the isoelectric points for proteins in the neutral
group with those of the acidic protein (Table 2) does not allow the use of these
terms to classify the human GST's. The homologous proteins in rat and mice are
also given this terminology, but are also referred to by their subunit classification
(Table 2).
Identification of different GST subunits purified from different species into
one of the three main groups can be obtained by the use of specific substrates and
inhibitors (see Tables 3, 4). In general, cumene hydroperoxide is a diagnostic
substrate for alpha class GST's, while trans-4-phenyl-3-buten-2-one is for the
mu class, and ethacrynic acid for pi class (Mannervik, 1985). Class IV, the
microsomal GST, is unusual, in that the activity of this enzyme towards CDNB is
activated 15 fold upon treatment with N-ethylmaleimade (Morgenstern et al.
1987); however this group has high activity towards the substrates such as
hexachloro-1,3-butadiene (Wolf et al. 1984).
1.10.4 Tissue Distribution.
The tissue distribution of GST's is often quantitatively and qualitatively
characteristic of a tissue. In this regard, rat liver has been most studied, and at
least 10 different isoenzymes have been found (Mannervik, 1985). Differences in
the distribution of GST subunits even within a tissue, were observed, through
immunocytochemical staining, in both kidney (Boyce et al. 1987) and liver (Redick
et al. 1982; Boyce et al. 1987). The tissue distribution of the GST's will be




















































































































































































































































































































































































































































































































































































































































In rat tissues, many GST subunits have been identified in this gene family,
and are classified as Ya, Yc, Yk subunits etc. The rat Yc GST subunit has been
described in most tissues, including liver, kidney, lung, heart and testis. Ya, in
contrast, is found mainly in the liver, kidney, and small intestine. The Yk GST
subunit is found in most tissues, but at highest concentration in the lung (Hayes &
Mantle, 1986b). The mouse liver contains mainly Ya subunits (Hayes et al. 1987b;
McLellan & Hayes, 1987). In humans, alpha class GST's are found in the liver
(Stockman et al.1985: 1987), skin (Del Boccio et al. 1987), kidney, and testis
(Sherman et al. 1983).
(b) Mu class
In rat tissues, several subunits in this class have been identified; for
example, Yb-|, Yb2, Yn. The subunits Ybi and Yb2 are found in most tissues. The
Ybi subunit is, however, absent from the kidney. Another mu class enzyme, Yn, is
also found in the heart and spleen, and is the major form in the testis. In human
tissues, mu class proteins have been identified in the adrenal gland, testis, liver
and lung (Sherman, 1983; Haves et al. 1987b; Carmichael et al 1988), and is
polymorphic in man (see Section 1.10.7).
(c) Pi class
Most evidence indicates that there is only one protein in this GST group.
This pi class GST is present in almost all rat tissues, with the highest levels in the
colon, lung, and spleen (Hayes & Mantle, 1986b). This protein is also detected at
low levels in rat and human liver but, interestingly, is expressed in a sex specific
manner in the mouse, with male liver containing high levels of this subunit
(McLellan & Hayes, 1987). In man, this polypeptide also seems to be widely
distributed throughout tissues (for a review see Mannervik, 1985), and is present
at high levels in many tissues, although individuals may lack pi GST subunit in the
liver (Hayes et al. 1987c). The difference in the tissue distribution as described,
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and substrate specificities (see Section 1.10.6), can, therefore, influence the
response of a tissue to a particular cytotoxic compound.
1.10.5 Comparison of GST between species.
GST's are found in all species. However, they have been best
characterised in rat, man, and mouse. Structural homologous forms are found to
exist between all these three species (see Table 2). Studies in other species, such
as guinea pig, rabbit, and hamster, also identified alpha class Yc and mu class Yb
GST's present in the liver (Hayes & Mantle, 1986a; Igarashi et al. 1986).
Further investigation into comparison of GST's between species can now be
carried out using molecular analysis such as 'Northern' and 'Southern' blots.
Comparison of GST cDNA sequences would provide information not only about the
sequence homologies between species but also in determining functional regions of
the sequence. In particular, cDNA clones for GST's are available for rat liver
alpha class [Ya (Lai et al. 1984; Pickett et al. 1984) Yc (Tu et al. 1984)]; mu [Yb
(Ding et al. 1985)] and pi class (Sugioka et al. 1985) subunits; human alpha class
(Tu & Qian, 1986) and human pi class ( Kano et al. 1987) subunits; mouse alpha
class [Ya] subunit (Daniel et al. 1987); corn GSTj (Shah et al. 1986), corn GSTjjja
(Moore et al. 1986) and trematode shistosoma iaponicum (Smith et al. 1986).
Genomic clones are also available for rat Ya, Yb, and Yf (Telakowski-Hopkins et al.
1986; Masuda et al. 1986). In mouse GST Ya and Yf have been mapped to
chromosome 9 and 5 respectively (Czosnek et al. 1984; Lalley & McKusick,
1985), human pi has been mapped to chromosome 11 (Suzuki & Board, 1984), and
alpha to chromosome 6 (Board & Webb, 1987). Rat pi has been localised to
chromosome 1 q43-q51 (Masuda et al. 1986).
1.10.6 Substrate Specificity and Biological Function of GST's.
GST's are a multifunctional group of enzymes which carry out a wide
variety of physiological roles within an organism. These polypeptides can act as
enzymes or as binding proteins. In the latter case, GST can bind a variety of
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compounds such as haem, bilirubin, and bile acids (Hayes & Mantle, 1986c), as
well as exogenous carcinogenic polycyclic aromatic hydrocarbons; for example,
benzo(a)pyrene (Coles et al. 1967; Awasthi & Singh, 1987). Alpha class Ya and
Yc GST subunits are specifically associated with the binding of benzo(a)pyrene,
both in vivo and in vitro, in lung and liver tissues (Awasthi & Singh, 1987). It has
been proposed that this binding to GST's represents a detoxification reaction.
The enzymatic function of GST involves the metabolism of both endogenous
and exogenous substrates (xenobiotics), indicating functions in intermediatory
metabolism as well as detoxification.
a) Endogenous substrates
Although GST will catalyse the conjugation of many endogenous compounds,
in many cases the physiological significance of these reactions is not clear.
GST's catalyse the GSH-dependent isomerisation of double bonds; for
example, the conversion of A5-3-ketosteroids to the corresponding a,p-
unsaturated A4-3-ketosteroids (Benson et al. 1977). This activity, which may be
important in prostaglandin biosynthesis (Christ-Hazelhof & Nutgeren, 1979; Meyer
& Ketterer, 1987), is so far restricted only to the Ya subunits. The formation in
vivo and in vitro of some GSH conjugates of steroids, suggests that the reactive
intermediates of 17|3-estradiol (Marks & Hecker, 1969) and 2-hydroxy-17p-
estradiol (Elce & Harris, 1971), are physiological substrates for GST's. The
possibility that quinones are also substrates for GST's has long been recognised
both for oestrogen derivatives and for foreign compounds such as menadione
(Chasseaud, 1974). A GST-conjugate for dopaquinone has also been identified in
human malignant melanoma (Agrup et al. 1977), which suggests this is also a GST
substrate.
Leukotriene A4 is converted to leukotriene C4 by GST mediated GSH
conjugation (Bach et al. 1984). The latter compound plays an important role in the
mediation of local inflammatory reactions. In rats the Yb subunits appears to
- 33 -
catalyse this reaction, with both mu and alpha GST's in humans involved in the
conversion of leukotriene A4 methyl ester to the leukotriene C4 methyl ester
derivative (Mannervik et al. 1984). This illustrates perhaps one of the important
known physiological roles for the GST's. Another important physiological role of
the GST's may be to protect membranes from peroxide generated lipid peroxidation
(Ketterer et al. 1982; Tan et al. 1984). It is worthy of note that cholesterol a-
epoxide (5a,6a-epoxy-cholestan-3p-ol), which is a product of lipid peroxidation,
has been identified in the rat liver as a GST substrate, especially for the alpha
class Ya subunit (Meyer & Ketterer, 1982), and also aldehyde products of lipid
peroxidation, such as 4-hydroxy alkenals, will form GSH-conjugates (Esterbauer,
1982). In recent studies, Alin et al (1985) showed that a major product of
peroxidative degradation of polyunsaturated fatty acids, 4-hydroxynon-2-enal,
was a good substrate for cytosolic rat GST's; the most active subunit being the
Yb2 subunit. Although Ybi has modest activity towards 4-hydroxyaikenals, its
activity towards the highly mutagenic compound 4-hydroxypent-2-enal was found
to be high compared with other isoenzymes (Marnett et al. 1985). This is also
interesting as the Yb-| subunit appears to bind DNA and has been purified from rat
liver chromatin (Bennett et al. 1986). This polypeptide may, therefore, play a
role in the protection of DNA against peroxidative damage. Human mu class (p.) and
rat alpha class (Yc, Yk) GST's were also found to have high activity towards 4-
hydroxyalkenals of different chain lengths (Jensson et al. 1986; Danielson et al.
1987), with rat subunit Ya in particular having activity towards 4-hydroxydodec-
2-enal, the most toxic of these compounds (Marnett et al. 1985).
Apart from their involvement in lipid peroxidation, non-selenium dependent
glutathione peroxidase were also shown to reduce peroxidised DNA and were
identified as GST's (Ketterer et al. 1987). They differ from the selenium-
dependent enzyme in that they have low activity towards organic hydroperoxides
and none at all towards hydrogen peroxide (see also Section 1.9.0). The difference
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in specific activity, however, is more than compensated by the quantity of the
enzyme present, being 0.1-0.2mM in hepatic cytosol (Ketterer et al. 1986).
Cumene hydroperoxide activity is associated mainly with the alpha class (Ya, Yc)
subunits, although mu class Yb2 GST also has activity towards this substrate (see
Table 3). GST rat mu class subunits and human mu class (p.) protein were thought
to be the most effective in removing peroxidised DNA (Ketterer et al. 1987), but
the question of accessibility to peroxidised DNA is still unanswered,
(b) Exogenous substrates (xenobiQtics)
The reaction of GST's towards xenobiotics can be further subdivided into
those involving (i) detoxification; for example, alkylating agents (see Section
1.11.0), peroxides and other electrophilic compounds and (ii) toxification, i.e. the
conversion of a compound to more toxic products as a consequence of conjugation
with the GST's.
(i) Detoxification reactions
GST's also carry out protective detoxification reactions by catalysing the
conjugation of a wide spectrum of xenobiotics including anticancer drugs to GSH
(Jakoby, 1978; Chasseaud, 1979). Other electrophiles conjugated involve
exogneous epoxides (Jering & Bend, 1977; Hernandez & Bend, 1982) and also a
wide list of other foreign compounds (for a review, see Chasseaud, 1979). These
compounds include, for example, halogenonitrobenzenes, the herbicide 2-chloro-S-
triazine, aryl nitrocompounds, aralkyl halides, and alkyl halides such as
bromobenze etc. The carcinogenic compound aflatoxin Bi is also thought to be
detoxified by the GST's (Manson, Personal Communication), as is the drug
paracetamol (Mitchel, et al. 1973; Jones et al. 1978).
(ii). Toxification reactions
GST mediated reactions can also activate compounds. In particular, the
conjugation of GSH to compounds such as hexachloro-1,3-butadiene (Wolf et al.
1984) has been illustrated in this regard. The formation of the GSH conjugate of
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this compound is catalysed by GST's in the liver. It is transported from the liver
to the kidney, where it is acted upon by a variety of enzymes involved in
mercapturic acid formation, and, ultimately, by the cysteine conjugate p lyase
enzyme. The resulting product is a reactive sulphenium ion which acts as an
alkylating agent and binds to DNA inducing cytotoxic damage and tumour formation.
The substrate specificity and biological functions of the GST's, as described
above, will, in conjunction with the distribution and quantity of any particular
subunit, interact to influence the response of a cell to a particular cytotoxic
compound.
1.10.7 Modulation and regulation of GST expression-
The regulation of GST isoenzymes within both normal and tumour cells is
likely to be an important factor in determining their susceptibility to toxins and
carcinogens (WoljjJ 1987a; 1987c). Cellular levels of GST's have been shown to be
determined at both the genetic level and at the level of transcription. In particular,
the genetic element is due to the polymorphic nature of the GST's, while the
modulation of transcription element occurs through the action of both endogenous
and exogenous factors.
a) Polymorphism
Genetic studies of the human GST's indicated that the GST enzymes were
o
products of three autodial loci GST-|, GST2, and GST3 (Board, 1981a; 1981b)
which correspond to mu, alpha and pi GST proteins respectively. It is, at present,
unclear how many gene products there are, but Board (1981b) has reported that
the alpha GST's were polymorphic in man. It is thought, however, that this finding
could be explained by the increased expression of one alpha subunit (B^) over
another (B2), forming homo and hetero dimers (B1B1, B,B2) of the major protein
only (Stockman et al. 1985; 1987). It is noteworthy that significant individual
differences in the GST isoenzyme pattern are found in human subjects; that is, not
all livers contain the same alpha class GST proteins or have detectable pi class GST
- 36 -
or mu class GST levels (Hayes et al. 1987c). In particular, one of the mu class (p.)
GST subunits has been shown to be polymorphic in man and is absent in
approximately 40% of the Caucasian population (Board, 1981a; Warholm et al.
1983; Hussey et al. 1986). This enzyme has the highest specific activity towards
benzo(a)pyrene-4,5-oxide, a mutagenic arene oxide of a polycyclic aromatic
hydrocarbon (Warholm et al 1983; Ketterer et al. 1983). If the enzyme is nulled,
it could have both toxicological and physiological significance. These differences
may, therefore, have a bearing on the effectiveness of detoxification by GST's,
and the subsequent response of an organ or cell to cytotoxins and carcinogens, and
hence the suscepibility to cancer. In this regard, Seidegard et al. (1986) has
shown that smokers who he phenotyped to have low or no mu class (p.) GST were
more susceptible to lung cancer.
b) GST regulation
(i) Endogenous factors
Endogenous factors can play an important role in modulating GST levels. For
example, the lymphokine interferon showed preferential induction of the Yf subunit
in mouse liver and suppression of Ya, Yb, and Yc subunits (Adams et al. 1987), and
there are also many studies which indicate that hormones will regulate these
isoenzymes. In this respect, the pi class Yf subunit is expressed in a sex specific
manner in male mouse liver (Hatayama et al. 1986; McLellan & Hayes, 1987).
This effect is thought to be mediated by testosterone (Hatayama et al. 1986). In
contrast, the alpha class Ya subunit expression was found to be higher in female rat
and mouse livers (Hales & Neims, 1976; Igarashi et al. 1985; McLellan & Hayes,
1987). Evidence of Ya subunit regulation by hormones was substantiated by the
finding that hypophysectomy of thyroidectomy led to a two fold induction of this
subunit. Thyroxine would however, reverse this induction in both cases (Reyes
ai, 1971; Hales & Neims, 1976).
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Trace elements such as selenium are also known to influence GST isoenzyme
levels. Selenium deficiency was found to cause an induction of the rat Ya, Yc, and
Yb subunits (Arthur et al. 1987). Recent evidence also indicates that GST subunits
can be phosphorylated in vitro, which could represent a further regulatory
mechanism (Pyerin et al. 1987).
(ii). Exogenous factors
A wide variety of exogenous compounds, including those such as
phenobarbital (Arias et al. 1976), 3-methylcholanthrene (Reyes et al. 1971) and
trans-stilbene oxide (Guthenberg et al. 1981) are known to be inducers of cytosolic
GST's, in particular in rat liver. The induction pattern varies for different
subunits, indicating differential regulation of GST isoenzymes (Pickett et al.
1987). The rat liver Ya and Yb subunits tend to be those induced most significantly
both at the protein (Hayes et al. 1979; Ohmi et al. 1981) and mRNA levels (Pickett
et al. 1981; 1982a; 1982b). Examples of species specific induction also exist. For
instance, in humans treated by phenobarbital, no increased bromosulfopthalein
conjugating activity was observed. Further to this, it has been found that mice are
more responsive than rats, with increased bromosulfopthalein conjugation in vivo.
following phenobarbital administration.
Other P450 inducers, such as p-napthoflavone, 2-aminofluorene and a-
napthoflavone, have been shown to selectively induce the Ya, Yc, and Yb subunits in
rat liver (Dolan et al. 1988). In the same study, dexamethasone and p-
napthoflavone, suppressed and induced respectively, the expression of the Yf
polypeptide. This is the first report of the regulation of this subunit by an
exogenous organic molecule. In addition, the Ya and Yb subunit is markedly induced
in rats and mice respectively, by the ingestion of the phenolic antioxidants such as
2,(3)-ter-butyl-4-hydroxyanisole (BHA) and 2,6-ditertiarybutyl-p-cresol (BHT)
(Pearson et al. 1983; Patridge et al. 1983). The antioxidant ethoxyquin has also
been shown to increase GST activity (Benson et al. 1978). In particular, the alpha
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class GST's were elevated, and shown to be involved in the protection of rat liver
towards AFBi induced hepatocarcinogenesis (Manson, Personal Communication). It
is still unclear, however, whether the mouse Ya subunit can be induced by
xenobiotics. GST induction is not confined only to mammalian species. As in corn,
a GST is induced by chemicals used as antidotes to certain herbicides. The
isoenzyme regulated in this manner is undetectable in untreated corn cells (Mozer
et al. 1983).
More work is required, however, on the study of the regulation and
modulation of GST isoenzymes, both at the protein and molecular level, and, in
particular, in extrahepatic tisues. There are already described, however, complex
regulatory systems involved in GST expression. Hormonal regulation, for
instance, may be important in certain types of hormonal induced/dependent
cancers. Xenobiotics and trace elements, such as selenium, can also influence GST
levels, and, therefore, there is a possibility that these factors may influence the
response of cells to carcinogens and anticancer drugs.
1.10.8 Microsomal GST-
Microsomal GST, in contrast to the cytosolic GST's, is a trimeric protein,
with an apparent subunit molecular weight of 17,000. This protein was detected in
rat, mouse, and human livers (Morgenstern et al. 1987; Hayes et al. 1987a,
1987c; McLellan & Hayes, 1987) by both Western blot and substrate analysis on
microsomes prepared from these tissues. The function of this unusual enzyme is
thought to involve the protection of membrane associated proteins and protein
biosynthesis in the ribosomes from xenobiotics. The involvement of this protein in
drug resistance has not been investigated.
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1.11.0 Interaction of GSH and glutathione-dependent enzymes
with anticancer drugs.
GSH and glutathione-dependent enzymes can influence the therapeutic
efficacy of anticancer drugs in a variety of ways, which include modulation of
detoxification, toxification, delivery, or the action of the drugs concerned
1.11.1 Detoxification
(a) Nitrooen Mustards: Mechlorethamine. Melphalan. Chlorambucil.
The ability of alkylating agents such as the nitrogen mustards
mechlorethamine, melphalan and chlorambucil to react with a vareity of cellular
nucleophiles, including sulphydryl groups, has long been recognised (Hirono, 1961;
Connors, 1966). For example, there is evidence which indicates that increased
cellular GSH levels can protect against the toxic effects of melphalan. Calcutt &
Connors (1963) demonstrated a relationship between tumour growth inhibition by
merophan, an isomer of melphalan, and non protein sulphydryl content (NPSH), in
six murine tumours. Suzukake et al (19821 have also shown that a L1210
leukaemia cell line made resistant to melphalan contained a two fold higher
concentration of GSH. The resensitisation of these cells, by lowering the GSH
content, indicates a possible role for GSH in melphalan detoxification. Suzukake £i
al (1983) further demonstrated that the resistance to melphalan correlated with
both GSH content and enhanced conversion of melphalan to an inactive metabolite.
This conjugation of GSH to melphalan has been shown to be catalysed by glutathione
S-transferases (Dulik et al. 1986), although the isoenzyme involved was not
demonstrated.
(b) Oxazaphosphorines: cvclophosamide.
Cyclophosphamide (CP) is a widely used nitrogen mustard which undergoes
activation by cytochrome P-450's. The generally accepted scheme for the
metabolism of this compound (Friedman et al. 1979) involves oxidation to 4-
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hydroxycyclophosamide (4-OH-CP), which is in tautomeric equilibrium with
aldophosamide (Figure 7). Non-enzymatic cleavage of aldophosamide results in the
formation of two cytotoxic species, phosphoramide mustard, the therapeutically
active species, and acrolein, which is responsible for the urotoxicity of this
compound (Cox, 1979). Involvement of GSH, however, in the protection from the
metabolism-dependent urotoxicity of CP is well documented (Gurtoo et al. 1981),
and is shown to occur without interfering with the chemotherapeutic activity of the
antitumour drug (Berrigan et al. 1982). Deactivation of the 4-OH-CP metabolite of
CP with GSH has been reported (Draeger et al. 1976), a reaction which would
reduce the alkylating potential of this anticancer drug. Depletion of GSH levels, as
carried out by Crook et al (1986a: 1986b), indicated that this protection could be
reversed, and .consequently, cause potentiation of the cytotoxicity of the
activated CP compound, 4-OH-CP.
(c) Platinum compounds: cis platinum.
Cis platinum is thought to act therapeutically by cross linking DNA and
inhibition of essential proteins. There has been however, a considerable interest
in the role of GSH on both the nephrotoxicity and the anti-tumour effects of this
compound. Cis platinum reacts with both cysteine and GSH in a second order
reaction. Reaction half times are approximately 1 and 3 hours respectively, at a
concentration of 5mM and 37°C. The reaction between GSH and aquated cis
platinum, however, is essentially instantaneous (Dedon & Borch, 1987). This
suggests that direct participation of GSH in reducing cytotoxicity occurs via
reaction with metabolites, rather than with cis platinum itself.
Depletion of renal GSH levels by BSO increases cis platinum lethality, while
pretreatment with GSH causes a dose-dependent reduction in its lethal effects.
Hamilton et al (1985) has also shown that depletion of GSH levels in a cis platinum
resistant human ovarian carcinoma cell line (A2780) (exhibiting a 3 fold increase
in GSH levels over the wild type line), increased the cytotoxity to cis platinum.
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Figure 7. Metabolism of cyclophosamide: an abridged scheme
showing only the currently recognised biologically
important reactions and metabolites.
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Elevated GSH may not be a prerequisite for cis platinum resistance, as Andrews si
Si (1985) did not find any change in GSH levels in-f^e cis platinum resistant cell
line. In addition, the cells were not resensitised to cis platinum on addition of BSO.
There are, however, three possible explanations for the different responses to
glutathione depletion in these two groups. First, the removal of BSO during cis
platinum treatment by Andrew et al (1985) may have allowed GSH levels to
recover sufficiently to negate the effect of prior depletion. Second, depletion of
GSH may not have been low enough to allow potentiation of cis platinum
cytotoxicity, and, thirdly, other mechanisms of resistance may have existed in
those cells to allow further protection, such as elevated DNA repair capacity. In
addition, the capacity of cells to increase GST activity may be important, for
example, Teicher et al (1987) has shown that in a cis platinum resistant cell line
no difference in GSH levels was measured, but an increase in GST activity was
found. Whether the cell line was cross-resistant to other compounds was not
shown.
d) Anthracyciines; Adriamycin.
Antineoplastic quinone-containing drugs such as Adriamycin (Adr) are
thought to undergo metabolic activation by microsomal enzymes to free radicals,
which can interact with oxygen to generate reactive oxygen intermediates via
superoxide anion (Bachur et al. 1978). These drugs in the presence of iron can
cause lipid peroxidation (Sugioka, 1981; Doroshaw, 1983) and DNA strand
breakage (Berlin & Haseltine, 1981). Analysis of the anti-oxidant defences of
mouse heart has implicated selenium-dependent GPX as a major pathway for the
detoxification of reactive oxygen intermediates generated by adriamycin
(Doroshaw et al. 1980).
e) Nitrosoureas: 1.3-bis(2-chloroethv0-1 -nitrosourea (BCNLM
Nitrosoureas are a group of alkylating agents widely used against many
different types of cancers. In addition, however, the nitrosourea BCNU is also
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shown to inhibit glutathione reductase (GRD) (Frischer & Ahmad, 1977; see Section
1.8.0), which may have an important role not only in reducing free BCNU levels,
but also influencing the response of cells to other cytotoxic agents which could be
detoxified by GSH. For example, incubation of isolated rat hepatocytes with BCNU
with adriamycin concomitantly, leads to potentiation of Adr cytotoxicity (Babson
et al. 1981). This indicates the involvement of the redox cycle in the mechanism
of Adr induced cytotoxicity, and illustrates the importance of maintaining the thiol
status of the cell. Interestingly, there is also preliminary evidence to suggest the
conjugation of GSH to BCNU can be catalysed by GST's in the brain, and, in
particular, the mu class protein is thought to be involved (Smith et al. 1987).
f) 6-ThioPurine.
6-Thiopurine is metabolised to its active form by cytochrome P-450's.
This reactive metabolite binds irreversibly through a disulphide linkage to proteins
both in vivo and in vitro (Hyslop & Jardine, 1981a; 1981b). This binding is
decreased in the presence of GSH, and GSSG is formed. The proposed mechanism of
protection is thought to involve GSH competing with protein sulphydryl groups with
the drug metabolite purine-6-sulferic acid, forming thiopurine GSH mixed
disulphide. This metabolite reacts with another GSH molecule to regenerate 6-
Thiopurine and GSSG.
6-Thiopurines can also be metabolised by the purine de novo biosynthesis
pathway. In this situation, 6-Thiopurines act as antimetabolite anticancer drugs.
The involvement of GSH and glutathione-dependent enzymes in this metabolic




Azathiopurine is the precursor form of 6-Thiopurine, which is converted
into 6-Thiopurine and various methyl nitromidazole metabolites by thiolysis,
involving GSH (De Miranda et al. 1973).
b) Bleomycin-
Bleomycin is a mixture of two structurally similar glycopeptides, which is
thought to be cytotoxic by an oxygen-dependent mechanism of DNA cleavage (Onishi
et al. 1975; Sausville et al. 1978a; 1978b). Specifically, a ferrous iron-
bleomycin complex reduces molecular oxygen to generate a superoxide anion while
oxidising the iron atom. Caspray et al. (1981) demonstrated that GSH is able to
bind to the ferric iron/bleomycin complex and reduce it to the active ferrous form.
Similar oxidative-reductive metabolism of other anticancer drugs, such as




GSH can affect the rate of uptake of anticancer drugs. For example, the
uptake of Methotrexate (MTX) is increased in rat hepatocytes on the addition of
GSH to the medium (Leszczynska & Pfaff, 1982). This effect may be mediated by
effects on membrane sulphydryl groups, which are implicated in this process
(Leszczynska & Pfaff, 1982). Inhibition of uptake was seen if the cells were
exposed to the sulphydryl oxidising agent N-methyl diazenedi-carboxylic acid bis
(N-methyl piperazide). Addition of GSH reversed this inhibition, probably due to
reactivation of critical sulphydryl groups (Leszczynska & Pfaff, 1982).
The above discussion provides evidence that alterations in GSH content and
certain glutathione-dependent enzymes can affect the detoxification, toxification,
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transport, and effectiveness of a variety of anticancer agents. The enzymes which
maintain GSH levels will also, therefore, play a central role in these effects.
1.12.0 Drug Resistance.
In the context of this thesis the word drug is used in general terms, and is
defined as a toxic chemical, which also includes foreign compounds.
The development of drug resistance in tumours to anticancer drugs has been
recognised as one of the major obstacles to successful chemotherapy for a wide
variety of tumours. There are several reasons which will explain this effect,
which include: a) tumour growth: a low growth fraction of a tumour may be
refractory to treatment, as most anticancer drugs are proliferation-dependent in
their action; b) in vivo distribution of drug: sanctuary sites for the drug may
exist, such as the central nervous system and testis, where metastatic tumours
do not get exposed to the drug ; c) drug diffusion limitations: there are several
classes of anticancer drugs, such as the anthracyclines, which are hydrophilic in
nature and unable to penetrate into poorly vascularised and necrotic tumours; d)
hypoxia effects: poor vascularisation of the tumours will also affect both the
bioavailability of the drug and oxygenation, which is important for the therapeutic
action of certain anticancer drugs, such as bleomycin, and e) biochemical effects:
changes in the biochemical profile of the tumour may affect the response of the
tumour to the anticancer drug used. The possible biochemical mechanisms of drug
resistance include altered drug uptake and efflux (Kartner et al. 1983), DNA repair
(Karran & Lindahl, 1985), gene amplification (Stark & Wahl, 1984) and drug
detoxification involving glutathione-dependent enzymes as well as others
(Chasseaud, 1979; Larsson et al. 1983a; Wolf et al. 1987a; 1987c; Hayes & Wolf,
1988).
In view of its potential importance, recent studies on drug accumulation are
worthy of note. A protein has been identified in cells resistant to a wide variety of
structurally diverse cytotoxic natural products, such as colchicine, vinca
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alkaloids, actinomycin D and anthracyclines (multidrug resistance, MDR) (for
review see Beck, 1987; Gottesman & Pastan, 1988; Moscow & Cowan, 1988).
This protein is glycosylated, and termed GP 180 or P-glycoprotein (Juliano & Ling,
1976). The evidence that GP 180 mediates MDR resulted from studies which
showed that GP 180 was over expressed in cell lines (Bech-Hanson et al. 1976;
Harker & Sikic_1985; Cornwell et al. 1986; Gros et al. 1986). GP 180 has also
been identified in both normal and tumour tissues (Fojo et al. 1987).
It is important to note that mechanisms of resistance are not mutually
exclusive, and more than one mechanism may occur in any particular cell, or
population of cells, within a tumour. Other models of drug resistance have also
been described. These include the resistance of normal cells to a normally lethal
dose of chemotherapeutic agent, following a low protective dose (Miller et a I
1975; Boyd, 1980; Adams et al. 1985; Carmichael et al. 1986); the resistance of
liver cells to carcinogens (Farber, 1984a); resistance of cells to oxidative
challenge (Kimball et al. 1976; Sedgwick & Robins, 1980; Christman et al. 1985;
Morgan et al. 1986; Shelton et al. 1986); the resistance of cells to viral
infections, i.e. action of interferons (for a review see Revel & Chebath, 1986) and
heat shock (for a review see Lindquist, 1986). Whether these mechanisms of
resistance involve similar controlling factors has not yet been clearly established.
1.13.0 Adaptive Response.
It is, as yet, unclear whether tumour cell acquired drug resistance is
related to an adaptive response as a consequence of administration of the
anticancer drug, or to a selection for intrinsically resistant cells. The former case
results from an elevation of enzymes which protect against the cytotoxic effect of
the drug. It has been shown by Christman et al (19851. that GSH, and certain
glutathione-dependent enzymes, can be elevated following oxidative stress in
bacteria, which supports the possibility of an adaptive response. A similar
response has also been shown in mammalian cells (Sedgwick & Robins, 1980). The
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inducible repair pathway to counteract the effects of alkylating agents in bacteria
(Samson & Cairns, 1977; recent review, Lindahl, 1987) also provides evidence to
suggest that an adaptive response to alkylating agents involving the induction of a
series of enzymes in mammalian cells is not unreasonable.
1.14.0 Objectives of this study.
The major aim of this project is to study whether there is a common
underlying mechanism of drug resistance involving GSH and glutathione-dependent
enzymes, especially in the acquired drug resistance of tumour cells to cytotoxic
drugs. The extent to which such changes represent a common response will be
studied by investigating other drug resistant models. On the basis of previous
work carried out in the laboratory by Adams et al. (1985) and Carmichael et al.
(1986), there is evidence to suggest that GSH and glutahtione-dependent enzymes
may be involved in an adaptive response to cytotoxic compounds. In particular, it
was shown that GSH and GST activity was elevated in normal bone marrow cells in
response to a low dose of cyclophosamide, a chemotherapeutic agent, which
afforded protection against a higher lethal dose. One of the objectives of this
investigation is to look at this resistance phenomenon in more detail, to identify
which GST subunits are involved, and whether other glutathione-dependent
enzymes are also elevated. The other drug resistant models which will be
investigated include the response of liver cells to carcinogens, and the response of
lung cells following exposure to high oxygen concentrations. Whether the
mechanism of acquired drug resistance in tumour cells is due to an adaptive
response as a consequence of the administration of a cytotoxic drug, or to a
selection of intrinsic resistant cells, will also be determined.
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Chapter 2.0.0 MATERIALS AND METHODS
All chemicals were purchased from commercial sources and were of the
highest grade of purity available. Unless otherwise indicated, the chemicals
were obtained from BDH, Poole, Dorset.
2.1.0 Cell Culture
2.1.1 Growing and routine maintenance of cells.
All cell lines were taken from laboratory stocks except the Chinese
hamster cell lines CHO-K1/CHO-Chlr and the human sarcoma cell lines MES-SA
and DX5 which were obtained from Mr. C. Robson and Dr. I. Hickson, Cancer
Research Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne and Professor
B.I. Sikic, Stanford University, California, respectively. Human breast
carcinoma MCF7, ovarian adenocarcinoma PE01/PE04; bladder carcinoma, EJ;
lung carcinoma H322/H358; foetal lung fibroblast EF484 and colonic carcinoma
HT29 were grown in RPMI 1640 media (GIBCO Ltd., Paisley, Scotland).
LS174T, a human colonic carcinoma line was grown in minimum essential
medium (MEM) containing non essential amino acids (GIBCO Ltd, Paisley,
Scotland) and human hepatoma lines HEPG2 in Dulbecco modified eagles medium
(DMEM) (Northumbrian Biologicals Ltd, Newcastle). The two CHO cell lines
CHO-K1 and Chlr were maintained in Hams F10, and the human sarcoma lines
MES-SA and DX-5 and mouse hepatoma, Hepa 1 in Hams F12. Both media were
obtained from GIBCO Ltd., Paisley. All the media were supplemented with 10%
(v/v) foetal calf serum (FCS) (GIBCO Ltd., Paisley, Scotland), streptomycin
(100^g/ml) and penicillin (100 lU/ml) (GIBCO Ltd., Paisley, Scotland). Insulin
(2.5 mg/ml) SIGMA, Poole, Dorset) was also added to cultures of PE01 and
PE04. Cell lines were cultured at 37° C, 100% humidity and 5% CO2 . When
cells were not immediately used, they were cryopreserved in freezing mixture
of 90% newborn calf serum (GIBCO Ltd., Paisley, Scotland) and 10% dimethyl
sulphoxide (SIGMA, Poole, Dorset) at 50 to 100 x 106 cells/ml. Controlled
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cooling to -80°C was carried out before storage in liquid nitrogen. When used,
the cells were rapidly brought to 37°C and washed twice in the appropriate
medium to remove the dimethyl sulphoxide. Cells were seeded in a 1 x 25cm3
flask (GIBCO Ltd., Paisley, Scotland) and left overnight to settle before
refeeding. Cultures of cells were refed usually three times a week, and
subcultured as necessary. Subculturing (passage) involved harvesting the cells
with 0.1% (w:v) trypsin (Difco Labs., West Molesley, Surrey) and 0.001%
(w:v) versene (EDTA) 1:1 mix, and splitting the cell suspension, in order to
leave the cells in logarithmic growth. Cells were used experimentally only up
to 5 passages, after this period they were discarded and fresh cryopreserved
cells at an earlier passage were used. This was to avoid alteration in cell
phenotype, which may occur in cells grown for prolonged periods in culture.
2.1.2 Mycoplasma testing-
Periodic assays for mycoplasma were carried out routinely by the MRC
Clinical and Population Cytogenetics Unit, Western General Hospital, Edinburgh
and were always found to be negative. The assays involved the fluorescence
test and also the growth of mycoplasma on defined agar plates.
2.1.3 Harvesting, viability and counting of cells.
Cultures of cells in either 1 x 75cm3 or 1 x 175cm3 flasks (GIBCO,
Paisley, Scotland) were harvested with 0.1% (w:v) trypsin and 0.001% (w:v)
versene, 1:1 mix, washed three times in phosphate buffered saline (140MM
NaCL, 2.7 mKCI, 8MM sodium phosphate pH 7.4) (Oxoid, Basingstoke,
Hampshire) and resuspended in 10mls of phosphate buffered saline (PBS) for
counting and viability. Determination of cell number was assessed by using a
hemocytometer. Cell viability was determined by mixing 100|il of cell
suspension with 100|il of 0.5% (w:v) nigrosin (Sigma, Poole, Dorset) and
looking for viable cells under phase contrast microscopy. Viable cells do not
take up nigrosin dye and therefore appear bright, in contrast to dead cells
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which appear dark in colour: from this the viability of the cell preparation was
assessed.
2.1.4 Synchronisation of cells.
Flasks were seeded at 2 x 105 or 5 x 104 cells/ml to obtain either
confluent cells or cells in logarithmic growth respectively. Cell
synchronisation was achieved by arresting the cells in Go/G1 of the cell cycle
by reducing the concentration of foetal calf serum in the medium from 10%
(v:v) to 0.5% and leaving the cells for 6 days (Balkwill and Bokhonik, 1984).
Synchronised logarithmic growth was obtained by increasing the FCS
concentration back to 10%. Cells were then harvested 18 hours later as
described in Section 2.1.3.
2.1.5 Thymidine incorporation-
In order to confirm logarithmic growth phase, thymidine incorporation
into the DNA was measured using radiolabeled thymidine (Heyns et al. 1985).
Following incubation of the cells with medium containing 0.19 Mbq 3H methyl
thymidine for 4 hours, the cells were washed with PBS, harvested and 50^1
aliquots of the cell suspension (1 x 107 cells/ml) absorbed onto Millipore
filters. Samples were then washed sequentially with distilled water, 5% (w:v)
trichloroacetic acid, distilled water and methanol. Filters were oven dried,
1ml of unisolve (Sigma, Poole, Dorset) scintillation fluid added, left for 1 hour
and radioactivity determined by scintillation counting.
2.2.0 Cell Preparation for Biochemical Assays.
Cell cultures were harvested with 0.1% (w:v) trypsin and 0.001%
versene (EDTA) , 1:1 mix, washed three times in PBS and resuspended in
400jj.l of PBS. Cell viability was determined to be greater than 95% as
assessed by nigrosin dye exclusion. The cell suspension was lysed by
sonication with three 5 second pulses at maximal power (MSE Soniprep 150).
A 5 second cooling period at 4°C was included between each burst. The
resulting sonicate was spun at 18,000g average for 20 minutes (Eppendorf
5414) and the supernatant decanted. The supernatant (soluble fraction) and
pellets were collected and stored at -70°C until required.
2.3.0 Drug Resistance in Animal Models.
2.3.1. Chemotherapeutic druo induced resistance in normal hone
marrow cells.
Male CBA mice (23 to 28g) were obtained commercially from Bantin and
Kingman. They were allowed food and water ad libitum and kept in a controlled
environment with 12 hours light. Treated ('primed') animals received
PL
cyclophosfemide (Sigma, Poole, Dorset) as a non lethal 'priming' dose of
75mg/kg injected intra-peritoneally (i.p.) in a solution of 0.1ml 0.9% (w:v)
sterile NaCI solution (Saline) per 10g body weight. Control mice received just
saline injected i.p. Animals were killed by cervical dislocation on days 5 and 6
after i.p. injection.
(a) Preparation of bone marrow cells-
Bone marrow samples were obtained from femurs from 3 animals,
Buffer A (1.5ml) containing 20mM KP04, 2.3% KCI, 0.2mM EDTA pH 7.7 was
flushed through the severed femurs. Bone marrow cells were pelleted at
18,000g average for 5 seconds (Eppendorf 5414) and resuspended in 1ml of
buffer A. The cell concentrations in the bone marrow samples were determined
using a haemocytometer. These samples were respun and resuspended in 400pl
of KCI-phosphate (10mM KP04, 1.15% KCI, 0.1 mM EDTA pH 7.7), sonicated
with three 5 second pulses at maximal power to lyse the cells, with a 5 second
cooling period at 4°C included between each burst. The resulting sonicate was
spun at 18,000 g average for 20 minutes and the supernatant decanted. The
supernatant (soluble fraction) and pellets were collected and stored at -70°C
until required.
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(b) Preparation of peripheral erythrocytes.
Peripheral blood samples were obtained from treated 'primed' and
control 'unprimed' mice by 'eye bleeding' using a heparinised capilliary tube.
Blood was dropped into isotonic saline and spun in at 650 g average for 5
minutes at 4°C (Sorvall RT 6000). The serum and 'buffy coat' containing the
white cells were removed and the erthyrocytes resuspended in 1ml of KCI-
phosphate for cell determination as described for the bone marrow
preparations. The soluble fraction was obtained as described previously for
the bone marrow cells.
(c) Preparation of peripheral granulocytes.
Peripheral granulocytes were prepared by inducing granulocyte
accumulation in the peritoneum of mice by i.p. injections of 2ml of 0.2% (wrv)
calcium/sodium caseinate (Sigma, Poole, Dorset) (Watt et al. 1979) in isotonic
saline. After 3 hours the animals were killed by cervical dislocation and 5 ml
of isotonic saline injected i.p. The peritoneal exudate was withdrawn after
gentle peritoneal massage, and the cells were spun down at 650 g average for 5
minutes at 4°C. Pellet was washed three times with ice cold 0.168M NH4CI,
and left to stand for 10 minutes to lyse erythrocytes. Cell concentration and
preparation of soluble fraction were carried out as described for the bone
marrow cells. Purity of the sample was assessed using Giemsa staining. A
slide smear from a drop of the cells was air dried and the sample fixed with a
3:1 (v:v) of methanol and acetic acid. Slides were rinsed with buffered
distilled water, pH 7.0, and stained for 15 minutes with Giemsa stain diluted
1:10 (v:v) with buffered distilled water, pH 7.0, (stock Giemsa was prepared
by adding 4g of Giemsa powder [Sigma, Poole, Dorset] to 250 mis of glycerol
heated to 60°C, until dissolved. 250mls of methanol was then added and the
solution was stirred and left to stand for 7 days before filtering). Slides were
- 53 -
rinsed with^buffered distilled water, pH 7.0, and allowed to dry before
assessing purity of the preparation by phase contrast microscopy. The
peritoneal granulocyte fraction of cells was determined to consist mainly of
granulocytes.
(d) Preparation of peripheral lymphocytes-
Spleens were rapidly removed from 'primed' and control mice and
washed in buffer A, before scissor mincing in a small amount of istonic saline.
This was subsequently homogenised using a teflon/glass hand held homogeniser
and the homogenate filtered through a tea strainer. The resulting preparation
was spun at 650g average for 5 minutes in a sorvall RT 6000 refrigerated
centrifuge and the pellet resuspended in 4.5 mis of distilled water, and left for
12 seconds to lyse the erthyrocytes. Immediately, 0.5ml of 10X concentrated
PBS was added to the tube and was topped up with isotonic PBS. This was
respun at 650g average for 5 minutes and the last two steps repeated if
necessary, to remove any erythrocyte contamination. The resulting
lymphocyte pellet fraction was resuspended in 1ml of KCI-phosphate, and the
cell count determined as described for the bone marrow preparations. Giemsa
staining for purity was as mentioned for the granulocyte preparation, and was
found to contain mainly lymphocytes. The soluble fraction was obtained as
described for the bone marrow preparations.
(e) Fluorescence activated cell sorting of bone marrow cell types.
The fluorescence activated cell sorting of the bone marrow cell types
was carried out in collaboration with Dr. J. Ansell, Dept. Zoology, University
of Edinburgh.
For cell sorter (FACS IV; Becton Dickinson) analysis and sorting, bone
marrow cells were obtained by flushing femurs with 1ml of cold buffered
/
isotonic saline supplemented with 0.1% bovine serum albumen and 0.02%
EDTA. The various cell types from the bone marrow were separated on the
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FACS on the basis of the differential forward and right angle scattering
properties (Watt et al 1980; Ritclue et al 1983). The 488-nm line of an argon
ion laser was used for the excitation of both forward and right angle scatter
signals, and the samples were run at approximately 1,000'cells/second.
Appropriate gates were set around granulocytes, lymphocytes and a third
mixed cell population (mainly monocytes) from the bone marrow preparations,
and these populations were sorted into cooled eppendorf tubes (Figure 8).
Approximately 300,000 cells were obtained for the granulocyte and
lymphocyte populations. The soluble fractions were prepared as described for
the bone marrow cells except the cells were resuspended in 100^1 of KCI -
phosphate.
2.3.2 Resistance of normal luno cells to oxvaen.
The generation of the oxygen resistant rats was carried out in
collaboration with Mr. I. Wyatt, Biochemical Toxicology Section, ICI Pic,
Macclesfield, Cheshire.
Male, specific pathogen-free ALPK:AP (Wistar-derived) albino rats
(175-200g) were supplied from the colony maintained at Alderley Park,
Cheshire. They were allowed food, pellet Porton Combined (PC) diet, supplied
by Special Diet Services Ltd., Witham, Essex, and water ad libitum. Conditions
were kept at a 12 hour light/dark cycle with temperature and humidity at 21-
22°C and 40-60% respectively. Five treated rats were exposed to oxygen
(Air Products Ltd) from cylinders mixed with air to give a concentration of
85-90% (v:v) oxygen, in a circular whole body exposure chamber
(approximately 5 litres of oxygen per minute mixed with 600mls per minute of
air). The oxygen concentration was monitored and recorded continuously
throughout the exposure using a Beckman Field lab oxygen monitor. Control
rats were housed in the holding room under normal conditions. Seven days
later the rats were killed one by one with an overdose of fluorothane, the heart
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FIGURE 8. FACS Dot Plots of Cells from Bone Marrow
FACS IV dot plots of mouse bone marrow from untreated animals (a) and
animals treated 5 days previously with cyclophosamide (CP) (75mg/kg) (b).
The schematic scheme (C) indicates the position of the cell populations separated
as described in Materials and Methods (Section 2.3.1), I, erythrocytes; II,
lymphocytes; III, granulocytes; IV, mixed cell population.
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and lungs dissected out, and the lungs perfused with ice cold isotonic saline
containing 5mM EDTA (degassed with N2). The lungs were removed from the
heart, placed in tubes, and frozen at ■70°C until used. The livers were also
removed from the rats and treated similarily.
Lung tissues from the control and oxygen exposed rats were pooled to
give three separate samples; the livers were left individually. The tissue
samples were dried, weighed, and scissor minced in a ratio of 1:3 (w:v) tissue
to KCI-phosphate. The preparations were homogenised in a tissue grinder and
spun in a Sorvall RC-5B refridgerated superspeed centrifuge at 5000g average
for 20 minutes at 4°C. Supernatant was poured off quickly and the pellet
discarded, the resulting supernatant fraction was respun in the Sorvall
ultracentrifuge OTD 65B at 240000g average for 1 hour at 4°C. The soluble
fraction, obtained as the supernatant from the ultracentrifuge spin, was kept at
-70°C before being assayed.
2.3.3 Hepatic preneoplastic and neoplastic nodules-
Aflatoxin B1 (AFB1) induced preneoplastic and neoplastic lesions in the
rat were obtained from Dr. M. Manson, MRC Toxicology Unit, Carshalton.
Male Fischer F344 rats were used, bred at MRC Toxicology, Carshalton,
and were routinely maintained on MRC 41B diet ad libitum. The preneoplastic
foci were induced by the injection of 0.25mg/kg aflatoxin B1 (AFB-|) i.p.,
followed by 2 weeks on control diet and 17 weeks of AFB-| administered in the
diet at 1 part per million (1p/pm), using a mixture of 75% (w:w) of naturally
contaminated ground nut meal, 25% (w:w) powdered MRC 41B containing 2%
(v:w) arachis oil. The neoplastic foci were induced in a similar manner but
only had AFB-| in the diet for 14 weeks (1p/pm) and then left on control diet
for 1 year. Two different foci, Tumour A and B were obtained rom the same
liver using this method. Control livers were obtained from rats which were
age matched to those in which preneoplastic foci were induced. The
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preneoplastic and neoplastic foci were demonstrated, immunohistochemically
by Dr. M. Manson, to be yGT positive. Soluble fractions of the preneoplastic
foci and neoplastic livers were made by Dr. M. Manson from 20% (w:v)
homogenates of the tissue in 150mM KCI, and by centrifuging at 100,000g
average for 1 hour. Samples were stored at
-70°C before use.
2.4.0 Protein Estimation.
Protein content of samples were estimated by the method of Lowry et al
(1951) using bovine serum albumin fraction (IV) (Sigma, Poole, Dorset) as a
standard. The protein reagents used were as follows:
A) 70mM NaC03 IOH2O : 40mm NaOH
B) 40 mM CuS04 5H2O
C) 71 mM Na K tartrate
D) Stock Folin Coicalteau reagent diluted 1:2 (v:v) with distilled
water.
^ Alkaline copper solution which was made up fresh by adding
0.5ml of both B and C and making the volume up to 50mls with
Solution A.
Soluble fraction from the cells were diluted 1:20 (v:v) with 0.1 M NaOH
to give a final volume of 1ml, and soluble fractions from tissues were diluted
to give a value in the range of the standards. To 1ml of sample solution, 5mls
of solution E was added and vortex mixed. 10 minutes later, 0.5ml of solution
D was added, vortex mixed immediately and left for at least 30 minutes. The
absorbance reading of the solution at 600nm was determined in glass cuvettes.
The amount of protein in the sample was derived from reference to a standard
curve at 600nm, using 0, 25, 50, 80, 100, 120, 150, 200ug/ml bovine serum
albumin, generated by a programme in a Schimadzu UV 160 spectrophotometer.
A new standard curve was constructed for each new set of assays. If protein
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sample was very low, as was the case sometimes for the cell samples, or if
sample volume was low, a microassay was employed. This involved scaling
down the volume of sample and solutions used by a factor of 5.
2.5.0 SDS Polyacrylamide Gel Electrophoresis.
SDS-polyacrylamide slab gel electrophoresis (SDS-PAGE) was
performed according to the method of Laemmli (1970).
Glass plates (12cm x 14cm) and spacers were wiped with alcohol,
assembled into a gel sandwich and put into the Biorad protean 1 apparatus
(Biorad, UK Ltd). A 12% (w:v) polyacrylamide separating gel that
incorporated 0.32% (w:v) bisacrylamide was prepared using 14.8 mis of 30%
(w:v) acrylamide (Sigma, Poole, Dorset), 9.25mls of separating gel buffer
(1.5M tris, 0.5% SDS, pH 8.8) and 11.0 mis of distilled water. The
acrylamide, buffer and distilled water was mixed thoroughly. Ammonium
persulphate 2mls 1% (w:v) (APS) and 20pl of N,N,N1 ,N1-tetramethylethylene
diamine (TEMED) (Sigma, Poole, Dorset) were added, and the preparation mixed
again thoroughly. The gel was then poured immediately to a height of 12cm and
gently over-layed with distilled water. The gel was allowed to set for 30
minutes. If the separating gel was to be left overnight, the water over-lay
was replaced with separating gel buffer diluted 1:4 (v:v) with distilled water
and the gel sealed-off with clingfilm and placed at 4°C. In order to put on the
stacking gel, the overlay was completely removed and a 20 or 25 track comb,
which was rinsed with alcohol and dried, inserted. The 4.5% (w:v)
polyacrylamide stacking gel was prepared using 1.5mls of 30% acrylamide,
2.5 mis of stacking gel buffer (0.5M tris, 0.5% SDS, pH 6.8) and 5.7 mis of
distilled water. 0.3mls of 1% APS and 10pl TEMED was added, mixed and the
preparation poured onto the gel. After 30 minutes, when the stacking gel had
set, the comb was gently removed and the apparatus inverted to remove any
remaining stacking gel buffer. The slots were filled with electrode buffer
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(0.52M tris, 0.53 M glycine, 35mM SDS, pH 8.3) which had been diluted 1:10
(v:v) with distilled water before use and the gel attached to the upper
reservoir. To the lower reservoir of the protean apparatus 1 litre of the
diluted electrode buffer was added, and the gels and upper reservoir inserted.
Electrode buffer was subsequently added to the upper reservoir. Slots were
flushed to remove any debris and samples were loaded with a Hamilton syringe
(Hamilton Bonaduz, Bonaduz, Switzerland). The samples had been mixed 1:1
(v:v) with boiling mix (10% (v:v) stacking gel buffer, 2% (w:v) SDS, 5%
(v:v) p mercaptoethanol, 10% (v:v) glycerol and 0.005% (w:v) Bromophenol
blue) and heated at 100°C for 5 minutes prior to loading. Lid of the apparatus
containing the electrodes was placed on top, with the current run at 20mA/gel
while the dye front was in the stacking gel, and 30mA/gel in the separation gel.
If required, gels were stained for 1 hour with 0.25% (w:v) coomassie blue and
destained in 5% (vrv) methanol 7% (v:v) acetic acid to show the protein
pattern.
2.6.0 'Western' Blot Analysis.
'Western' blots were carried out using esentially the method described
by Towbin et al (1979), as modified by Adams et al (1985).
SDS-PAGE was performed as described in Section 2.5.0. Following
electrophoresis, the gels obtained were treated as follows. The stacking gel
was removed, the separating gel cut along the dye front at the bottom right
hand corner to allow correct orientation at a later period. Electroblotting
buffer (20mM Na2HP04, 20% (v:v) methanol) was put into the Biorad transblot
apparatus (Biorad UK Ltd) and the gel orientated in the presoaked transblot
cassette as follows:- cassette, scotchbrite pad, 3mm paper. 0.45um
nitrocellulose (Anderman Co. Ltd, U.K.), gel, 3mm paper and Scotch Brite pad,
cassette. The cassette was placed in the transblot apparatus with the
nitrocellulose nearest the anode, and blotted overnight at 0.25A. After
- 60 -
transblotting, the cassette was removed from the apparatus and placed on the
bench with the nitrocellulose below the gel. Nitrocellulose was cut to the exact
size of the gel, and the track boundaries marked as necessary. The gel was
discarded or stained, as described in Section 2.5, to determine the efficiency
of the protein transfer, and the nitrocellulose treated as follows.
Nitrocellulose filters were washed for two 10 minute periods in 50mM
Tris/ HCI, pH 7.9, 0.15 M NaCI, 0.05% (v:v) Tween 20 (Sigma, Poole,
Dorset) TBST, and blocked with 3% low fat milk for 1 hour. Following two
further 10 minute washes with TBST, nitrocellulose filters were incubated for
1 hour with the specific antibodies raised against the GST subunits (see Section
2.7.0). The antisera was diluted 1:500 (v:v) in TBST. Four 15 minute washes
with TBST were then carried out, followed by incubation for 1 hour with goat
anti-rabbit IgG antibody conjugated to horseradish peroxidase (Scottish
Antibody Product Unit, Glasgow, Scotland) at a dilution of 1:1000 (v:v) in
TBST. Antibodies were used approximately three times before discarding.
Following further washes with TBST, bands were visualised using either:
(a) Peroxidase staining using 4-chloro-1-napthol as substrate.
Filters were incubated at room temperature in 200mls of TBS
containing 3.4M 4-chloro-1-napthol (Sigma, Poole, Dorset) and 80|d of 30%
(v:v) hydrogen peroxide until the bands became visible. The reaction was then
terminated by placing the nitrocellulose filters into distilled water. Further
enhancement of the bands could be achieved by subsequent labelling with 125l
protein A followed by autoradiography.
(b) Autoradiography using 125l protein A-
Nitrocellulose filters were incubated with 50mls of TBST containing
0.19mBq 125l protein A (Amersham International PLC, Amersham, Bucks) for
1 hour. They were then washed with TBST until counts in the washes reached
background and the filters blotted dry. Filters were put onto blotting paper,
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covered in clingfilm and put into an X-ray cassette with intensifying screens.
A sheet of Kodak XAR 5 film (Kodak UK Ltd) was put on top, the cassette
closed, and put at -80°C. Films were developed at differing time periods as
necessary, either manually or using an Gevamatic 60 (Agfa-gevaert) automatic
developer.
2.7.0 Antisera Raised against Glutathione S-transferase
Subunits.
The antisera raised against the glutathione S-transferase (GST) subunits
used in this research, were generously given by Dr. J. Hayes at the Dept.
Clinical Chemistry, Edinburgh Royal Infirmary, Edinburgh.
Antisera used was raised against rat alpha class subunits Yc, Ya, Yk;
mu class Yb-|, Yn and pi class Yf subunits, and also against human alpha (BiB-|);
mu (u) and pi (X) subunits. Purification of the rat GST subunits, raising of the
antisera and the specificity of the antisera have been described by Hayes &
Mantle (1986b). Hayes & Mantle (1986b) described the cross reactivity of the
rat GST antisera using Western blot analysis. Both alpha (Yc) and pi (Yf)
antisera was specific for these GST isoenzymes, while the alpha (Yk and Ya)
and mu (Yb-|) cross reacted slightly with other GST's of a similar class, but
only at high antibody concentrations. Yn antisera reacted slightly weakly with
other mu class GST isoenzyme proteins (Ybi/Yb2).
The human GST subunits were purified and antisera raised as described
by Hayes et al (1983; 1987d) and Stockman et al (1985). Relative cross
reactivity of the various antisera, determined by radioimmunoassay, found no
cross reactivity with the other specific GST subunits (Hayes et al 1987c).
However, on 'Western' blots, both the B-|Bi and B2B2 antisera cross reacted
with the B-1B1 protein (Stockman et al 1987).
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2.8.0 Assays for Gutathione (GSH) Levels.
There are a number of procedures for the determination of glutathione
(GSH) and/or glutathione disulphide (GSSG) in biological samples. These include
chemical (Hissin & Hilf, 1976), enzymatic (Griffith, 1980) or chromatographic
procedures (Reed, et al 1980; Newton et al 1981; Nakamura & Tamura, 1982;
Demaster et al 1984). It was important, however, to choose an assay which
was quick, easy, and sensitive enough to detect GSH levels in cell lines.
Consequently, the fluorometric assay of Hissin & Hilf (1976) was used, with
the accuracy of the determination of GSH levels in cell lines confirmed by a
more sensitive and accurate h.p.l.c. method.
(a) Fluorcmetric assay using orthp-pthaldehyde-
Soluble fractions from cells or tissue samples were taken and mixed 1:1 (v:v)
with 10% (w:v) trichloroacetic acid to precipitate out proteins and acidify the
sample which prevents GSH auto-oxidation. Triplicate aliquots were taken and
diluted to 1 OOjj.1, and 1.8ml of 0.1 M NaP04:5mM EDTA pH 8.0 buffer added.
100pl of freshly prepared ortho-pthaldehyde 1mg/ml in methanol (OPT)
(Sigma, Poole, Dorset), was added to each sample tube, mixed and left in the
dark at room temperature for 15 minutes. Determinations of the fluoresence
intensity at excitation 350nm and emission 420 nm in these samples using a
Perkin-Elmer fluorescence spectrophotometer (Model LS-3) were carried out
in quartz cuvettes. Calculation of GSH levels were made by relating the
fluorescence intensities to a standard curve, obtained from replacing the
sample volume with known concentrations of GSH, which were made up fresh
daily. Standard final concentrations used were 5pm, 2.5pm, 1.25pm, 0.5pm,
and 0.05pm, and GSH. Values were corrected for any quenching of
fluorescence by 'spiking' the soluble fraction with a known concentration of GSH
before assaying.
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(b) H.p.l.c. assay using monobromobimane.
There are many different h.p.l.c. methods available for the
determination of GSH. These include post or precolumn derivatisationm of
samples; use of different types of chromatographic resins and different
detection systems. The assay used here involves the pre-column
derivatisation of samples with a compound monobromobimane (MBBr) which
reacts with thiols selectively to
form a fluorescent derivative (Figure 9). This method is the most rapid,
sensitive, and convenient h.p.l.c. method for thiol analysis and is based on the
technique of Newton et al (1981) as modified by Gaetjens et al (1984).
(i) Preparation of samples.
Cells were harvested, as described in Section 2.1.3, washed twice in
PBS, resuspended in 1ml of PBS, transferred to an eppendorf tube and
sedimented at 18,000g average for 1 minute in an Eppendorf 5414
microcentrifuge. Supernatant was removed using a syringe and needle, 40^1 of
acetonitrile (h.p.l.c. grade, Rathburns, Peebles, Scotland) was added slowly to
the cell pellet and the sample mixed using a 7mm magnetic bar. 15^1 0.5M Tris
HCI, 3.6mM EDTA pH 7.5 was added, and 5pl of 30mM solution of MBBr
(Calbiochem UK Ltd, Cambridge Science, Cambridge) in acetonitrile. Stirring
was continued for 20 minutes under subdued lighting and the derivatisation
terminated by the addition of 5jj.I of acetic acid. The assay mixtures were
diluted to a volume of 1ml with the water-methanol-acetic acid elution buffer
'A' of Newton et al (1981). Buffer A contained 100ml methanol (h.p.l.c. grade,
Rathburns, Peebles, Scotland) 2.5ml acetic acid, diluted to 1 litre with double
distilled deionised water, titrated to pH 3.9 with 50% NaOH, and filtered
through a 0.2uM millipore filter. This 1ml sample was centrifuged at 18,000g
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FIGURE 9. Fluorescent labelling of thiols with monobromoblmane
(mBBR. X = H) or monobromotrlmethvlammonloblmane
(qBBr. X = +N(CH^b)-
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average for 20 minutes, filtered and 50(xl of the supernatant subjected to
h.p.l.c. analysis. Derivatised samples could be stored for several weeks at
-80°C without loss of fluorescence.
(ii) High-performance liquid chromatography.
A Waters system consisting of two model 510 pumps, an automated
gradient controller, a data module (Model M730) which was linked to a
fluorescence detector (Model 420) fitted with a standard flow cell, and a
405nm filter, was used. The column was a waters Novapak C18 reverse phase
(3.9mm x 150mm) coupled to a guard column, containing a disposable 3cm
guard pak cartridge filled with u bondapak C18 packing. The water-methanol-
acetic acid elution programme used in the chromatography was as described
previously by Newton et al (1981), but modified as follows: 0-15 minutes, 3%
buffer B, isocratic, at 1ml/min, 15-17 minutes, 90% B, 17-25 minutes, 3% B
(column regeneration). Buffer B contained 900 ml methanol (hplc grade), 2.5ml
acetic acid and diluted and adjusted to pH 3.9 as previously described for
Buffer A. Both buffers were filtered and degassed, using a sonic bath, before
use.
A typical h.p.l.c. trace showing the GSH peak is illustrated in Figure 10.
The GSH peak was identified by using a standard concentration of GSH which
had been 'spiked' with tritiated 3H GSH (10^1 of 1MBq/ml) and also by showing
that the peak increased in area with increased amount of standard concentration
of GSH injected (Figure 11). This information was used by the data module to
calculate the amount of GSH in an unknown sample relative to a standard
concentration.
2.9.0 y Glutamylcysteinylsynthetase (yGCS) Assay.
The assay for yGCS was carried out according to the method of Seelig &
Meister (1984b), in which yGCS activity was determined from the rate of
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FIGURE 10. H.p.l.c. Trace of the Separation of MBBr
derivatives.
Samples were derivatised and separated by reverse phase h.p.l.c. as
described in Materials and Methods (Section 2.8.0). The chromatogram trace
shown was typical of those obtained from cell lines (ovarian, PE01 cell line in
this example). GSH-MBBr conjugate (GSH), MBBr hydrolysis product (H), and





FIGURE 11. Graph showing Linear Relationships between
Peak Area and GSH Concentration.
The graph presented shows the integrated peak area calculated by the
data module for GSH-MBBr peak, plotted against the amount of GSH derivatised
injected onto the reverse phase h.p.l.c. column. For derivatisation and h.p.l.c.
technique details see Materials and Methods (Section 2.8.0).
y = -1177.6 + 98.482X R = 1.00
GSH (pmoles)
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formation of ADP (assumed to be equal to the rate of oxidation of NADH) as
calculated from the change in absorbance at 340nm (equations 12,13,14).
OpQ
L-glutamate+L-a-aminobutyrate+ATP ■ » L-glutamyl aminobutyrate
+ADP+Pi (12)
ADP+Pi+phosphoenolpyruvate Pyruvate kinasg pyruvate+ATP (13)
pyruvate+NADH la.c'ate dehydrogenase Lac|a|e+NAD+ (u;
The final concentration of the components in the 1ml sample cuvette were as
follows:
100mM Tris/HCI, pH8.0, 2mM EDTA, 150mM KCI, 20mM MgCI2,
10mM L-glutamate, 10mM L-a-aminobutyrate (Sigma, Poole, Dorset), 0.2mM
NADH (Sigma, Poole, Dorset) 17^g pyruvate kinase (Sigma, Poole, Dorset),
17pg lactate dehydrogenase (Sigma, Poole, Dorset) and 2mM
mono(cyclohexylamonium) phosphoenol pyruvate. The reference cuvette
contained the same components as the sample cuvette, except no soluble
fraction was present. The change in absorbance at 340nm between these
cuvettes, without ATP present, gave the background rate. Addition of 50^1 of
100mM ATP to both the cuvettes gave the rate due to yGCS activity present in
the soluble fraction. Assays were run using a Schmidazu MPS 2000
spectrophotometer. The assay was verified by incubation of the soluble
fraction with the yGCS inhibitor buthionine-S-R-sulphoximine (10mM) (Sigma,
Poole, Dorset) for 4 hours at 37°C prior to the assay. An almost complete
inhibition in yGCS activity was measured.
2.10.0 y Glutamyltranspeptidase (yGT) Assay.
Cell sonicates (prepared as described in Section 2.2) and tissue
homogenates were used in the assay for yGT activity, using the sensitive
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fluorometric method described by Smith et al (1979) using the substrate L-
•yglutamyl-7-amino-4 methyl coumarin (equation 15).
yQ J
L-y-glutamyl-7-amino-4methyl coumarin + gly-gly - *
L-y-Glu-gly-gly- + 7-amino-4methyl coumarin (15)
Dilutions of the samples were made in 0.1m ammendiol/HCI buffer pH 8.6
(Ammendiol: 2 amino-2-methyl-1,3,propandiol, was obtained from Sigma,
Poole, Dorset). 100pl of these dilutions were incubated at 37°C for 10 minutes
with 250pl of 0.2mM y glutamyl-7-amino-4-methyl coumarin as substrate
(Universal Biologicals, Cambridge), diluted with
ammendiol/glycylglycine/triton buffer (100ml ammediol buffer, 20mM
glycylglycine 100pl triton X100) from a 10mM stock in 2-methoxyethanol
(Aldrich Chemical Co., Gillingham, Dorset). The reaction was stopped by the
addition of 2ml of ice cold 0.05M glycine buffer, pH 10.4, and fluorescence
determined using a Perkin-Elmer Model LS-3 fluorimeter at excitation 370nm
and emission 440nm. Values were quantitated from a standard curve, obtained
using varying concentrations of the fluorescent product 7-amino-4-methyl
coumarin (Sigma, Poole, Dorset) 0.2 - 20pm, diluted from a 10mM stock with
ammendiol/glycylglycine/triton buffer. The assay was verified by incubation
of the sample at 37°C for 10 minutes with yGT inhibitor 5mM serine/1 OmM
borate before assaying. This could almost completely inhibit all yGT activity
(90%).
2.11.0 Glutathione Reductase (GRD) Assay.
GRD activity (equation 10) was assayed in the soluble fractions by the
fluorometric method of Weiss et al (1980).
GSSG + NADPH+H+252 2 GSH + NADP+ (10)
The final concentration in the reaction mixture sodium phosphate buffer, 67mM
pH 6.7, were 0.5mM NADPH, 2.0mM nicotinamide, 3.0mM GSSG and 10pl of 1-
2mg/ml soluble fraction. The final volume was 40pl. The mixture was
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incubated at 37°C for 15 minutes and the reaction stopped with the addition of
40pl of 0.1 N HCI. Addition of HCI also destroys any unoxidised NADPH (Lowry
& Passonneau, 1972). Fluorescence of NADP+ was induced by adding 1.0ml of
6N NaOH containing 0.03% (v:v) H2O2 and heating the tubes to 60°C for 10
minutes. Fluorescence intensities were determined in Perkin-Elmer
fluorometric spectrophotometer (Model LS-3) at excitation 360nm and
emission 460nm. Concentrations of NADP+ 12.5pm, 25pm, 50pm, 100pm and
200pm were used to generate a standard curve to calculate NADPH oxidation
rates and therefore GRD activity. A blank was included in the assay, consisting
of reaction mixture minus the sample, and was subtracted from both the
standards and the sample assays, before drawing the curve.
2.12.0 Glutathione Peroxidase (GPX) Assays.
2.12.1 Total GPX activity (Selenium and non-selenium dependent
forms).
Total GPX activity in the soluble fraction of cells and tissues were
determined by the method of Paglia & Valentine (1967) at 37°C using cumene
hydroperoxide (CHP) as a substrate. Reaction buffer contained 100mM
Tris/HCI pH, 7.2, 3mM EDTA, 1mM sodium azide, 1.2mM CHP, 0.5mM NADPH
and 1 unit of glutathione reductase (Sigma, Poole, Dorset) in 1 ml final volume.
50|il of sample was added, and the oxidation of NADPH monitored at 340nm on
a Schimadzu MPS 2000 spectrophotometer.
2.12.2 Selenium-dependent QPX activity-
Two different assays were used, the fluorometric method of Weiss et al
(1980) and the spectrophotometric assay of Paglia & Valentine (1967).
(a) Fluorimetric assay.
This method was used initially only for determining selenium-dependent
GPX activity in PE01, PE04 and MCF7 ceil lines and was later substituted for
the more convenient spectrophotometric assay. The procedure was similar to
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that described in Section 2.11.0 for GRD. The reaction involved a coupled
assay as indicated in equations 10, 11.
GSSG + NADPH + H+—2GSH + NADP+ (10)
fiPX
2 GSH + H202 ———» GSSG + 2H20 (11)
Final concentrations of the components in 0.5M sodium phosphate buffer,
pH7.0, were 3.0mM GSH, 0.5mM NADPH, 2.0mM sodium azide, 4.0mM
EDTA, 4.0mM nicotinamide, 2.0ug/ml GRD (Sigman, Poole, Dorset, 240
units/mg protein) and 5ul of 3mg/ml soluble fraction, in a volume of 40(il.
Following a 10 minute preincubation period at room temperature, to activate
the sulphydryl enzyme, the reaction was initiated by adding H202 (final
concentration 0.5mM ). The reaction mixture was incubated at 37°C for 15
minutes, and terminated by the addition of 40pl of 1.0N HCI. Fluorescence of
NADP+ was induced by adding 1.0ml of 6N NaOH containing 0.03% H202, and the
tubes heated to 60°C for 10 minutes. Fluorescence was measured at excitation
360nm and emission 460nm. Activity was calculated from standard curves, in
which the soluble fraction was replaced with 25pm, 50um, 125^im, 250nm of
GSSG and 10|im, 25um, 50um, 100um of NADP+ respectively. A blank using
the reaction mixture without soluble fraction present was subtracted from all
the values. The rate of reaction with time was shown to be linear (Weiss et al
1980), and also the non-specific peroxide rate was found to be minimal.
(b) Spectrophotometry assay
This assay for selenium-dependent GPX activity was carried out
essentially as described for total GPX activity, except CHP was replaced with
0.25mM H202 as the substrate.
2.12.3 Non-selenium dependent GPX activity.
Non-selenium dependent GPX activity was determined by subtracting the
value for the selenium-dependent form from that for total GPX activity as
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described by Masukawa et al (1983). This activity has been shown to be
associated with alpha class GST subunits.
2.13.0 Glutathione S-transferase (GST) Assays.
2.13.1 Activity towards 1 .chloro-2.4-dinitrobenzene as a substrate.
Activity towards 1,chloro-2,4-dinitrobenzene (CDNB) as a substrate
was determined according to the method of Habig et al (1974b) (equation 16)
(please see separate page). 41 mg of CDNB (Sigma, Poole, Dorset) was
dissolved in 4ml ethanol, and added, drop by drop, to prewarmed 0.1m sodium
phosphate buffer pH 6.5 (196 mis). Aliquots of this buffer were put into both
the reference and sample cuvettes, together with 1mM GSH (final
concentration in 1ml volume) which was only added to the sample cuvette. The
non-enzymatic background rate, at 340nm, was then measured. 10(xl - 50pl of
diluted or undiluted soluble fraction was added to the sample cuvette, and the
enzymatic rate determined at 340nm. All measurements were carried out at
37°C, using a Schimcjazu MPS 2000 spectrophotometer.
2.13.2 Activity towards ethacrvnic acid (EA) as a substrate.
GST activity towards EA as a substrate was determined at 37°C
according to the method of Habig et al (1974b), which monitored the formation
of ethacrynic conjugate at 270nm (equation 17) (please see separate page).
The sample and reference cuvettes contained 0.1 M potassium phosphate
buffer, pH 6.5, to which EA was added to a final concentration of 0.2mM (final
volume 1ml) . EA was made up fresh in ethanol before use. GSH at a final
concentration of 0.25mM was added only to the sample cuvette, and the non-
enzymatic background rate monitored at 270nm. 50-100^1 of soluble fraction
was added to the sample cuvette and the rate determined.
2.13.3 Activity towards cumene hydroperoxide (CHP) as a substrate.
GST activity towards CHP as a substrate can only be used for purified
proteins and not soluble fractions. Purified GST protein activity towards CHP
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as a substrate was carried out as described in Section 2.12.1. CHP activity
can be indicative however of alpha-class GST levels, as mentioned in
Section 2.12.3.
2.14.0 Statistics.
Statistics, including degree of significance using the students T-test,
were carried out using the Statsworks programme on an Apple Macintosh Plus
computer.
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Equations 16 and 17
no-» + gsh
gst









Chapter 3.0.0 GLUTATHIONE AND GLUTATHIONE-DEPENDENT
ENZYME EXPRESSION IN TUMOUR CELL LINES.
3.1.0 Glutathione S-transferase isoenzymes in human
tumours and tumour derived cell lines.
3.1.1 Introduction-
It is likely that glutathione S-transferase (GST) levels and isoenzyme
composition will play a role in both the intrinsic and acquired resistance of
tumours to cytotoxic drugs. As a consequence, it is important to establish the
constitutive expression of these proteins in a variety of tumours and tumour
derived cell lines in order to provide information regarding their possible
responses to cytotoxic drugs. In this regard, Batist et al. (1986) have shown
that in a breast carcinoma cell line (MCF7), which was multidrug resistant to
adriamycin, a 40 fold elevation in a pi class subunit was found, but how
significant is this finding? Evidence from the GST subunit composition of other
cell lines may help to clarify this situation. This information would also be
useful with respect to the selection of recipient cells for transfection
experiments using expression vectors containing clones encoding for specific
GST subunits. This type of experiment would give valuable data regarding both
the regulation, and the effectiveness, of a specific GST subunit in drug
detoxification, and therefore a role in drug resistance.
Tumour derived cell lines are used as models for solid tumours,
especially in the screening of new anticancer drugs. Information concerning the
differences or similarities of GST subunit composition between the tumours and
tumour derived cell lines from the same tissue source would be of interest in
establishing the validity of this cell line model. It is important to remember,
however, that there are other limitations in using cell lines as models for
tumours, including the differences in morphology and characteristics of cells in
culture.
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In the study described here, in order to characterise the GST's in human
tumour tissues and cell lines, both total GST activity and subunit composition in
a series of six different human tumours and nine cultured human tumour cell
lines have been studied.
3.1.2. Results-
GST activity, using CDNB as a substrate, in nine human cell lines of
different tumour origin, and a mouse hepatoma cell line Hepa 1, is shown in
Figure 12. A large variation in activity between the lines was observed. The
breast cancer cell line, MCF7, had by far the lowest activity (3.5 nmoles CDNB
conjugated/min/mg protein), which was approximately 60 fold lower than the
ovarian adenocarcinoma cell line PE04 (210.3 nmols CDNB conjugated/min/mg
protein). The human clara cell derived lung line NCI H358, foetal lung EF484,
and the colon line HT29, all had high GST activity. A second group of cell lines,
consisting of the colon line, LS174T; bladder, EJ; liver HepG2 and lung NCI
H322, all had moderate GST activity. The mouse hepatoma line Hepa 1 had
activity in the range between the high and moderate GST containing groups of
cell lines. This difference in GST activity, more markedly seen between PE04
and MCF7, was also reflected in the GST subunit content. The pi class subunit
(X) was expressed in most of the cell lines (Figure 13). The expression of this
protein appeared to fall into two groups; cell lines which expressed high levels
of this subunit, and those where this enzyme was present at very low levels,
i.e. the MCF7, Hepa 1 and HepG2 lines. Slight differences were also observed in
the pi class subunit expression in the cell lines containing high levels of this
GST. All the ceil lines contained proteins which reacted with an antibody raised
against the alpha class (B-|) subunit. However, the level of this protein was
very low and could be only seen after developing the autorad after 96 hours
exposure. Interestingly, the human hepatoma line HepG2 was the only line to
contain high levels of this subunit. In most of the cell lines the mu class (p) GST
was present at very low concentrations and could only be identified on 96 hours
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FIGURE 12. GST Activity In Tumour Derived Cells.
Cell lines were derived from human tumours except HEPA1, which was
a mouse hepatoma cell line. 107 cells were harvested from confluent cultures
with trypsin.-versene, and prepared as described in Materials and Methods
(Section 2.2.0). GST activity was measured using CONB as a substrate (Habig
et al. 1974). Values are expressed as nmoles CDNB conjugated/min/mg
protein and are means from three separate experiments. Tumour tissue source
is indicated above the cell line value. The different cell lines were indicated as:
P = PE04, M = MCF7, E = EF484, EJ = EJ, H2 = NCI H322, HS = NCI H358,
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FIGURE 13. Glutathione S-transferase Subunlt Content In
Tumour Derived Cells.
107 cells were harvested from confluent cultures with trypsinrversene,
and prepared as described in Materials and Methods (Section 2.2.0). 50pg of
soluble protein with the exception of HT29 (25pg) was ran out on SDS/PAGE,
transferred to nitrocellulose and probed with specific antibodies raised against
the three known human GST isoenzyme classes: Pi (X), alpha (Bi), and mu (p).
The different cell lines were as indicated in legend to Figure 12. The exposure
times before developing the autorads were as indicated a) 12 hours; b) 96








S P M E EJ H2 H5 L S S H S HEP HT
- 79 -
exposure of the blots. The Hepa 1, the human lung fibroblast EF484 and HepG2
lines, contained significantly higher levels of this subunit relative to the other
lines tested.
Differences in GST subunit profiles between cell lines and tumours
derived from the same tissue source was observed (Figure 14). Interestingly,
the human breast tumours contained high levels of the pi class (X) subunit, in
contrast to the cell line. The expression of this GST was however high in the
majority of tumours and the homologous cell line. The concentration of this
isoenzyme in both the human hepatoma and normal liver tissue was low, but
present at levels higher than that found in the hepatoma cell line. Alpha class
(B-|) GST was found at high levels in the lung, ovary, and liver tumours, and
also in the normal liver sample, as expected. A low level of this polypeptide
was observed, however, also in the bladder tumour. The mu class (p.) protein
was seen at high concentration in only one breast tumour, the bladder, the liver
tumour and normal liver tissue samples. Low levels were detected in the lung
and the ovarian tumours. This concentration of the alpha and mu class subunits
in the tumours followed the cell line levels to some degree.
3.1.3 Discussion-
Cell lines are used extensively for both the screening of new anticancer
drugs and for the investigation into their mechanism of action. The reason for
this is that large amounts of tumour samples are often difficult to obtain, and
cell lines are easier to manipulate than tumours with regard to drug treatment.
It is important to remember, however, that cell lines derived from tumours
may change their phenotype and characteristics in culture, compared with the
original tumour, and therefore may no longer be representative of the tumour,
in addition to any changes in GST composition which may occur.
In view of the role of GST's in detoxification reactions, I have tried to
establish whether the detoxification capacity of a variety of commonly used
cell lines of different tumour origins was representative of that measured in
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FIGURE 14 Glutathione S-transferase Subunit Content in
Tumour Derived Cell Lines and Tumours derived
from some Tissue source.
107cells were harvested from confluent cultures with trypsin:versene
and prepared as described in Materials and Methods (Section 2.2.0). Normal
and tumour tissues were prepared in collaboration with Dr. L. Forrester. 50pg
(alpha and mu blot) or 25pg (pi blot) of soluble protein were ran out on
SDS/PAGE, transferred to nitrocellulose and probed with specific antibodies
raised against either alpha class (B-|), mu class (p) or pi class (X) subunits
respectively. Profiles were typical examples of the tumour types.
Abbreviations used are: C = cell line; T = tumour; N = normal tissue; STD =
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the original solid tumour, and also whether these cell lines will prove useful for
understanding the function and regulation of the GST's. (The soluble fraction
from the cell lines and the boiling mixes were prepared by myself, but the
soluble fractions from the tumours, and also the Western blot, were carried out
in collaboration with Dr. L. Forrester in our laboratory). Most of the solid
tumours studied contained high levels of the pi class GST (X) subunit, with
mainly small variations seen between individuals, in agreement with reports by
Kodate et al. (1986) for colon carcinoma and Shea et al. (1988) for breast and
renal carcinomas. The content of this enzyme in cell lines was very similar to
the tumour content, even in the liver samples where the hepatoma and
hepatoma cell line had low levels of this protein. The only exception was the
MCF7 cell line, which contained a much lower level of the pi class subunit than
the tumour samples. In terms of GST content and activity, this cell line would
not appear to be a model for breast tumours in their susceptibility to anticancer
drugs. Batist et al (1986), in his multidrug resistant cell line, would,
therefore, have only increased GST levels, and expression of the pi class
protein approaching that of most other cell lines and tumours.
The tumour levels of the mu and alpha class GST subunits is subject to
considerable individual variability (Carmichael et al. 1988). For example, in
lung cancer the tumour content of these enzymes appears to some degree to
seggregate according to tumour type (Carmichael et al 1988). It is, as a
consequence, probably not possible to use specific lung cell lines to be
representative of a particular tumour type. In contrast, the human hepatoma
cell line HepG2 has been used to study normal gene expression and function,
such as bile acid biosynthesis (Everson & Polokoff, 1986) and apolipoprotein
secretion (Zannis et al. 1981). GST's have been shown to be involved in
bilirubin transport and consequently the profile of the subunits detected in the
hepatoma cell line would be important in determining whether this line was
indeed a good model at looking at normal liver functions. The HepG2 cell line
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was found to contain levels of GST subunits similar to those found in normal
liver (Figure 14; Warholm et al. 1983; Stockman et al. 1985; Hussey et al.
1986). On the basis of this finding, the cell line may prove extremely valuable
for the study of the response of normal liver to cytotoxic and carcinogenic
compounds, and also of the factors which regulate hepatic GST levels in man.
The individual, however, from which this line was derived, would not appear
to be nulled for the mu class (p) protein, as this polypeptide was present in
high concentration. In fact, all of the cell lines contained this enzyme, and also
most of the tumours, and thus indicates that this polypeptide was not absent
from these individuals as well.
Transfection experiments, using GST expression vectors into recipient
cell lines, may only be carried out if the GST subunit composition is known.
Therefore, the results obtained above may allow these investigations to be
undertaken, and provide information about the role of these enzymes in drug
detoxification in cell lines. The differences in GST subunit profile between
tumour derived cell lines obtained from a variety of tumour sources, and
between cell lines and solid tumours, indicates that their response to cytotoxic
drugs may be different. The use of tumour derived cell lines as models for
solid tumours must only be used with caution as a consequence.
3.2.0 Acquired drug resistance in tumour cell lines, generated
in vivo and in vitro.
3.2.1 Introduction.
There are very few studies carried out where glutathione S-
transferases and other glutathione-dependent enzymes have been determined in
drug resistant cell lines. In the study described here, glutathione, and a range
of glutathione-dependent enzymes, have been characterised in three drug
resistant cell line modes. These are a) a Chinese Hamster Ovary (CHO) cell
line, made resistant to a nitrogen mustard, chlorambucil; b) an in vivo model,
where two ovarian adenocarcinoma cell lines were derived from a single patient
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patient before (PE01) and after (PE04) the onset of drug resistance and c) a
human sarcoma cell line which has the typical multidrug resistance (MDR)
phenotype.
(a) Chlorambucil resistant CHO cell line.
In a previous report, a chlorambucil resistant CHO cell line resistant to
other bifunctional nitrogen mustards was described (Robson et al. 1986). The
chlorambucil resistant cell line was selected by growing cells for 3 months in
the presence of progressively higher concentrations of chlorambucil. In
particular, the cell line was resistant to chlorambucil (24 fold) and cross
resistant to mechlorethamine (35 fold) and melphalan (13 fold). No resistance
was observed to other bifunctional alkylating agents which generate DNA cross
links via a reaction at the 06 of guanine, or to drugs like adriamycin. A
cytosolic protein, with a molecular weight of approximately 25,000, and an
isoelectric point of around 7.5, was overexpressed in the drug resistant line
CHO-Chlr. There was no change in the accumulation of the drug, indicating that
the resistant cell line did not express the MDR phenotype (Robson et al 1986),
and also no difference in DNA repair in the resistant cell line was observed
(Robson et al. 1987). In the study described below the possibility that an
increased rate of drug detoxification as a consequence of elevated GSH and
glutathione-dependent enzymes including the GST's was investigated.
(b) In Yivo drug resistant cell line model.
A significant problem in the study of drug resistance is establishing the
relevance of in vitro experiments, such as those indicated above, to clinical
observations in vivo. In this respect, two ovarian adenocarcinoma cell lines
were derived from a patient before (PE01) and after (PE04) the onset of drug
resistance to a combination of cis-platinum, chlorambucil and 5-fluorouracil
(Wolf, et al. 1987b). The PE01 cell line was, in fact, derived from ascites fluid
obtained after the relapse of a patient from initial chemotherapy. A complete
response was achieved however using the same previous course of treatment.
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Three months later the patient relapsed again, but this time the patient no
longer responded to treatment, including high dose cis platinum. The PE04 cell
line was derived from this second ascites sample. Using these cell lines it is
possible to establish whether differences in glutathione-dependent enzymes are
present which could, therefore, be an important factor in the clinically
observed acquired drug resistance.
In this model I have also studied whether detoxification enzymes are
modulated during the cell cycle, as there is evidence which shows altered
sensitivity of cells in logarithmic growth to alkylating and chemotherapeutic
agents, such as platinum compounds etc. (Frei & Harsano, 1967; Watanabe &
Harikawa, 1975; Edwards & Nias, 1986). As a consequence, the regulation of
glutathione-dependent enzymes during cell division, to establish whether this
may be a factor in the differential sensitivity to cytotoxic drugs, has been
undertaken in these lines.
(c) Human sarcoma cell line showing multidrug resistant phenotvpe.
The development of broad cross-resistance to cytotoxic drugs has been
observed recently in several mammalian lines, including the human sarcoma
line DX5 (Harker & Sikic, 1985). Batist, et al. (1986) has shown, however,
there can be simultaneously more than one mechanism of resistance in cells
made resistant to anticancer drugs, with the over expression of GP180 and
GST's found in his MDR MCF7 cell line. It is of interest, therefore, particularly
in the case of the DX5 cell line, to look at the role of GSH and GSH-dependent
enzymes in the resistance mechanism, as the degree of resistance in this line
cannot be accounted for by increased expression of P-glycoprotein (GP180)
alone (Sikic, et al. 1988). The possibility exists that there is a relationship
between GP180 and GST's, as Thorgeirsson, et al. (1987) and Sikic, et al.
(1987 unpublished) have shown that GP180 is overexpressed in
hepatocarcinogenesis and regenerating rat liver, two models in which GST's are
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also overexpressed. Whether this occurs in drug resistant cell lines, as
indicated by Batist, et al. (1986), has to be shown more conclusively.
3.2.2 Results.
(a) Chlorambucil resistant CHO cell line.
Glutathione S-transferase (GST) activity, using 1-chloro-2,4-
dinitrobenzene (CDNB) as a substrate, was measured in the wild type (CHO-K1)
and resistant (CHO-Chlr) cells. Table 5, Figure 15, showed that the CHO-Chlr
cells had a 2.7 fold higher total GST (p<0.02) and a 1.8 fold higher GSH (carried
out by Dr. A. Hall) content than the wild type line. In order to identify which of
the GST isoenzyme subgroups were overexpressed, assays were carried out
using substrates which show a degree of specificity for the pi, alpha (B-|) and
mu gene families, (see Table 3) although care must be noted with respect to use
of these substrates for CHO GST's . No activity towards styrene oxide (a
marker for the mu class isoenzyme) was found. In contrast, however,
significant elevations in cumene hydroperoxide (5.2 fold, p<0.005) and
ethacrynic acid (1.9 fold p<0.07) activities were seen. These activities are
indicative of the alpha and pi class GST isoenzymes respectively, although more
than one class of GST may have activity with these substrates in the Chinese
hamster (see Table 3). The elevation in glutathione peroxidase activity
towards cumene hydroperoxide appeared to be completely due to differences in
GST expression, as the selenium-dependent activity measured using hydrogen
peroxide (Table 5, Figure 15) was similar in both lines. Of other glutathione-
dependent enzymes involved in maintaining reduced GSH levels within cells,
glutathione reductase (GRD), y-glutamyltranspeptidase (yGT) and Tglutamyl-
cysteinylsynthetase (yGCS), only yGT was significantly elevated (3.5 fold,
p<0.005) in the drug resistant line CHO-Chlr. Evidence from the enzymatic
analysis indicated that alpha GST's were overexpressed in the CHO-Chlr ceil
line. In support of this, the protein staining pattern of cytosolic samples from




















































































































FIGURE 15. Relative Expression of Glutathlone-Deoendent
Enzvmes In CHO-ChlrCella.
The CHO-Chlr values shown are expressed as percentages of the CHO-K1 wild type




FIGURE 16 Protein Staining Pattern of CHO-K1 and CHO-Chl'"
Samples were separated by SDS-PAGE. 50pg of soluble protein was loaded
per track. The standards shown are the rat subunits molecular weights 28500 Yc,




elevation in a protein with the same mobility as the rat alpha class Yc GST
subunit in the resistant CHO-Chlr line. Western blot analysis confirmed a
dramatic increase of the alpha class GST subunits (Figures 17,18). Both the
alpha, Ya and Yc subunits in the CHO-Chlr cell line, appeared to be expressed at
higher levels. A slight increase in the pi and mu proteins was also observed
(Figure 17). In the blot shown in Figure 17, the antibody raised against the
human alpha (B^) GST subunit only reacts weakly with CHO alpha Yc subunits.
The increase in the expression of the Yc subunit on the other hand, was easily
seen when an antibody raised against the rat Yc protein was used (Figure 18).
A forty fold induction of this protein, determined by densiometer scanning, was
found in the CHO-Chlr cell line compared with the wild type CHO-K1 line. The
antibody raised against the rat Ya subunit did not react strongly with the CHO
homologue (Figure 18), although an elevation in this subunit was again observed
in the resistant cell line, in agreement with Figure 17.
A protein was isolated by Dr. Ian Hickson from the resistant CHO-Chlr
cell line. This protein was found to have identical mobility to the alpha class
rat Yc subunit on Western blot analysis (Figure 18). No cross reactivity of this
purified protein was found with either antibodies raised against the human pi
class, or mu class proteins (data not shown). Specific activities of this
purified protein towards CDNB, ethacrynic acid, cumene hydroperoxide and
hydrogen peroxide (Table 6) indicated that this protein is likely to be of the
alpha class GST's (Table 3, Mannervik, 1985) providing Chinese hamster GST's
have similar substrate specificities. No activity was detected with hydrogen
peroxide as a substrate using the purified protein.
(b) Druo resistant ovarian lines generated in vivo.
Measurement of GSH levels and glutathione-dependent enzymes in drug
sensitive (PE01) and resistant (PE04) cell lines, were initially carried out on
confluent cultures (Table 7, Figure 19), and in all cases where differences
were found, the PE04 cell line had the higher activities. GSH levels were
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FIGURE 17 Glutathione S-transferase Subunit Content In CHO-K1
and CHO-Chlr
Western blots were carried out as described in the Materials and Methods
(Section 2.6.0) using 50pg of soluble protein per track. The bands were identified
using specific antibodies raised to the human alpha class (B-|)and mu class (p)
subunits. STD represents human GST standard. K1 and Chlr are the wild type and
resistant cell line respectively.
PI (Yf) ALPHA (Ya) MU (Yb)
STD K1 Chlr STD K1 Chlr STD K1 Chlr
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FIGURE 18 Comparison of Gutathlone S-transferase Subunit
Content in CHO-K1 and CHO-Chlrand the Purified
Protein.
Western blots were carried out as described in the Materials and
Methods (Section 2.6.0). Yc and Ya are rat standards; K1 and Chlr are the
wild type and resistant cell lines respectively. P is the GST protein purified
from Chlr. Antibodies used were specific to the alpha class rat Ya and Yc
subunits (anti Yc and anti Ya).
Yc Ki Chlr P P P P P P Ki Chlr Ya
anti-Yc anti-Ya
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a activity of the purified protein from CHO-Chlr cells with each of the



























































































































































































FIGURE 19 Comparison of Glutathlone-Deoendent Enzvme
Activities between PE01 and PE04 In Confluent
Cultures.
The PE04 values shown are expressed as a percentage of those obtained

























significantly higher in PE04 (1.4 fold, p<0.01) and concomitantly with this, a
6.3 fold (p<0.001) increase in yGT activity was also observed. Other
glutathione-dependent enzymes were studied in these lines. Increases in GST
activity (1.9 fold, p<0.001) towards the general substrate CDNB, and
selenium-dependent glutathione peroxidase activity towards hydrogen
peroxide, (2.3 fold, p<0.001) were also found in the resistant line. The
activities, however, of GRD and yGCS enzymes were essentially unchanged in
both of the cell lines studied. In addition to the increase in GST activity
towards CDNB, the metabolism of other GST model substrates ethacrynic acid
and cumene hydroperoxide were also carried out, and were elevated. The
activities being 40.0 ± 6.8 and 58.4 ±_3.4 nmol/min/mg for ethacrynic acid and
14.6 ± 5.4 and 26.1 ± 8.1 nmol/min/mg for cumene hydroperoxide for PE01
and PE04 respectively.
In order to establish the GST subunit composition of the two ovarian
adenocarcinoma cell lines, and also to determine whether the differences in GST
activity towards CDNB, ethacrynic acid, and cumene hydroperoxide in thePE04
cell line could be associated with differences in the expression of known GST
subunits, Western blot analysis was carried out.
Both cell lines were found to contain high levels of the pi GST when an
antibody raised against the human pi class (X) subunit was used (Figure 20) in
the Western blot analysis. The human alpha class (B-|) subunit could also be
detected in both lines, and was expressed on the blots at approximately 1/16th
of the amount of the pi class protein. In either line, however, the mu class (u)
protein could not be detected at any significant amounts. The content,
therefore, of the pi class (X) and alpha (B-|) type subunits were similar in both
lines, although the level of the Bi subunit did appear to be slightly higher in the
resistant PE04 cell line. This data indicates, as a consequence, that the levels
of these known subunits are not responsible for the difference in GST enzymic
activity found in PE04.
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FIGURE 20 Glutathione S-transferase Subunlt Content In
PEQ1 gnd PEQ4.
Western blots were carried out as described in the Materials and
Methods (Section 2.6.0) using 50pg; A and C or 25jj.g; B of soluble protein per
track. The bands were identified using the specific antibodies raised to the










GSH levels have been shown to change during the cell cycle (Szent-
Gyorgyi, 1978). Consequently, it was of interest to investigate which of the
glutathione-dependent enzymes were also subject to such regulation, especially
as they could contribute to the differences between the cell lines and also be a
factor in their sensitivity to cytotoxic drugs.
Tritiated thymidine incorporation into both cell lines was measured to
verify that the cells were either in confluency or in logarithmic growth. A two
to three fold increase in tritiated thymidine incorporation in both cell lines,
synchronised into logarithmic growth, compared with confluency, was found
(Table 7, Figure 21). It was also shown, however, that there was a large
difference in thymidine incorporation between PE01 and PE04, indicating a
higher rate of DNA synthesis in PE04. In both PE01 and PE04, a significant
elevation in reduced GSH levels was found in the lines during logarithmic
growth (Table 7, Figure 21). The increase was 1.6 (p<0.01) and 2.1 (p<0.001)
fold, relative to the confluent cultures for PE01 and PE04 respectively. In
cultures in logarithmic growth, GSH content was higher in PE04 by 1.8 fold
compared with PE01, the difference being slightly higher than that observed for
confluent cultures. A significant increase in GSH levels (1.9 fold) was also
observed for the breast cell line MCF7 during logarithmic growth. An increase
from 34.2 ±_17.4 nmoles GSH/mg protien to 64.7 + 17.0 nmoles GSH/mg
protein. Concomitant with the increase in GSH levels an increase (1.4 to 2 fold)
in yGCS activity was found in all three cell lines (Table 7, Figure 21). The
enzymatic activity increased 1.8 fold from 7.1 ±_ 2.3 to 13.0 ±_ 3.7
nmol/min/mg protein for the MCF7 cell line. The selenium-dependent GPX was
also found to change in the cell lines in logarithmic growth. GPX activity, using
hydrogen peroxide as a substrate, was elevated in dividing cells in all three cell
lines, (Table 7, Figure 21) 1.9 to 3.4 fold, GPX activity being increased in
MCF7 cell line from 34.1 £ 10.1 nmol GSH oxidised/min/mg protein to 76.8 ±
21.7 nmol GSH oxidised/min/mg/protein. Other glutathione-dependent
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FIGURE 21 Cell Cvcle Effects on Glutathlone-Danandant
Enzvme Activity
Logarithmic and confluent cell cultures of PE01, PE04 and MCF7 were
harvested with trypsinrversene and prepared as described in the Materials and
Methods (Section 2.2.0). All the assays were carried out on the soluble
fraction. Activity of cells in logarithmic growth is expressed as a percentage
of the confluent culture. Values are given in Table 6 and in the text of Section
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enzymes studied, however, GST, g GT and GRD, were all unchanged during the
cell cycle (Table 7).
(c) Human sarcoma cell line showing multidrug resistant phenotvpe.
GST activity was measured using CDNB in the wild type (MES-SA) and
multidrug resistant (DX5) cells showed that DX5 cells had a 2.4 fold higher
activity (p<0.001) and a 1.3 fold higher GSH content than the wild type line
(Table 8, figure 22). Assays involving model substrates, which give an
indication of which GST isoenzyme subgroups were overexpressed in the
resistant line, were also carried out. The activities towards cumene
hydroperoxide and ethacrynic acid were unchanged in the resistant DX5 line,
(Table 8), compared with the parental line MES-SA. Selenium-dependent
glutathione peroxidase activity towards hydrogen peroxide was, in contrast,
significantly elevated in DX5 (12.7 fold, p<0.001). Consequently, total
glutathione peroxidase activity, which was found unchanged between the lines,
must be completely due to the non-selenium-dependent activity of alpha class
GST's present in the MES-SA wild type line. Other glutathione-dependent
enzyme activities i.e. yGCS, GRD and yGT, were determined in both of the cell
lines, but only yGT activity was found to be significantly elevated (6.7 fold,
p<0.001) in the drug resistant DX5 line.
As in the in vivo ovarian adenocarcinoma cell line model, Western blots
were carried out to establish the GST subunit composition of the wild type
MES-SA and the multidrug resistant DX5 cell lines, and also to determine
whether the difference in GST activity towards CDNB and the activities
towards the model substrates ethacrynic acid and cumene hydroperoxide could
be associated with differences in the expression of known GST subunits (Figure
23). In both cell lines, high levels of the pi class (X) GST was detected, using
antibodies raised against the human pi class protein. Similarly, the mu class
(ji) protein was found at the same levels in both MES-SA and DX5 cells, but at













































































































FIGURE 22 Relative Expression of Glutathlone-Dependent
Enzymes in PX5 Cells,
The DX5 values shown are expressed as percentages of the MES-SA wild
type line. See Table 7 for further details.




FIGURE 23 Glutathione S-transferase Subunit Content in MES-SA
and DX$
Western blots were carried out as described in the Materials and Methods
(Section 2.6.0) using 50pg of soluble protein per track. The bands were identified
using specific antibodies raised to the human pi class (X), alpha class (B-|) and mu
class (p) subunits. STD represents human GST standard. MES and DX5 are the wild
type and resistant cell lines respectively.
Pi (A.) Alpha (B-j)




(B-i) GST expression, with the human alpha protein found in MES-SA and not in
the resistant DX5 line. The Western blot data, therefore, confirmed that the
enzyme increase in GPX activity was not as a result of increased expression of
the alpha class GST subunits.
3.2.3 Discussion.
The elevation of GST's in drug resistant cell lines has been shown by
several groups (Wang & Tew, 1985; McGowan & Fox, 1986; Batist, et al.
1986), but the identification of which GST subunits are overexpressed in these
resistant lines has not been identified in all cases. Batist, et al. (1986) has
shown that the pi class (X) protein was elevated in his drug resistant MCF7 cell
line, the same class of GST which has been shown to be elevated in
experimental models such as preneoplasia (Kitahara, et al. 1984). In this
study, however, where GSH and glutathione-dependent enzymes, such as the
GST's, have been characterised in a CHO cell line made resistant to
chlorambucil, it is the alpha class Yc GST subunit that was found to be
overexpressed. This finding is in agreement with a study carried out by Buller,
et al. (1987) who has preliminary evidence to show differences in the GST
subunit composition between a wild type and chlorambucil resistant Walker 256
rat mammary carcinoma cell line. These differences included an increase in
alpha class Yc subunit in the resistant line, although this was not conclusively
proved. The involvement, therefore, of alpha class Yc subunit in the
detoxification of chlorambucil, is likely. Further evidence for this possibility
comes from studies which have shown that melphalan, which is a nitrogen
mustard structurally similar to chlorambucil, is a substrate for the GST-
catalysed conjugation with GSH (Dulik, et al. 1986). A further extension to
this work would be to use the purified alpha Yc GST subunit to show directly
whether chlorambucil is detoxified by this subunit to a GSH-chlorambucil
conjugate. This would provide conclusive evidence of a direct role for the
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action of alpha class Yc subunit in the resistance of the CHO-Chlr cell line to
nitrogen mustards.
The purified alpha class Yc subunit from the resistant CHO-Chlr line,
which is the first GST subunit to be purified from Chinese hamster, was only
partly characterised due to limitations in time. It was, however, shown to be
equivalent to the rat alpha class Yc subunit by Western blotting and model
substrate analysis. Molecular weight of the purified alpha class Yc subunit was
27,500, which is slightly higher than the 25,000 molecular weight
overexpressed protein found in the CHO-Chlr resistant line by Robson, et al.
(1986).
Specific activity values for model substrates for the purified alpha
class Yc subunit were found to be lower than expected for other purified rat
GST's (Mannervik, 1985). There may be several explanations for this; a) the
CHO Yc protein may have lower turnover numbers for the substrates than the
equivalent rat enzyme, or b) the S-hexyl glutathione used to elute the purified
protein from the S-hexyl glutathione affinity column may not have been
completely removed, and therefore may have inhibitied the enzyme during the
activity measurements. In support of the second possibility, purification of
rat and hamster liver GST's, using S-hexyl glutathione to elute the proteins
from the S-hexyl glutathione affinity column, results in lower CDNB activity
than if the subunits were purified using a glutathione affinity column (Hayes,
personal communication). The ratio of the model substrate activities for
cumene hydroperoxide and ethacrynic acid to CDNB activity, are similar to
alpha class rat GST's (Mannervik, 1985). The identity of the purified GST
subunit could have been verified by NH2-terminal sequence analysis also.
Inhibitor studies using inhibitors which tend to be specific for certain GST
subunits (Table 4) could also substantiate whether the purified protein was
indeed an alpha class Yc subunit.
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It would have been of interest to establish whether a low dose of a
selective agent, in this case chlorambucil, to the wild type CHO cells would
have induced a transient increase in the alpha class Yc subunit expression, and
whether this increase in GST subunit concentration could protect the cell line
against a higher, more toxic, dose of chlorambucil. This type of experiment
has been carried out in normal bone marrow cells, with results described in
Section 4.1.0.
Cloning of the gene coding for this over expressed alpha Yc GST subunit
would also have provided important information relating to the regulation of
expression of the GST's in drug resistance, and also whether this protein can
confer resistance towards chlorambucil. The over expression of the Yc GST
subunit was, in fact stable, in that the cells did not need to be cultured in the
presence of chlorambucil.
Apart from the increase in alpha class Yc subunit in the resistant cell
line, an increase in reduced GSH was also found. This elevation in GSH levels is
consistent with other reports where elevated GSH levels has been reported in a
melphalan-resistant L1210 cell line (Suzukake, et al. 1983). The elevation in
GSH was also associated with increased melphalan breakdown. In the
chlorambucil resistant CHO-Chlr cell line, therefore, it appears that the
resistance is due to a combination of increased GSH, alpha class Yc GST subunit
and yGT levels.
Similar changes were also observed in the ovarian cell lines obtained
before, and after, a patient became resistant to chemotherapy. In this model,
other glutathione-dependent enzyme changes were also observed.
The two ovarian cell lines used in this study represent a valuable in vivo
model for the investigation of drug resistance. Karyotype analysis showed that
the cell lines were of the same clonal origin, but they diverged from each other
either before or during drug treatment (Wolf et al. 1987b). Although it is not
clear how representative the cell lines are of the original tumour, the
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information in this study provides evidence that the tumour cells isolated from
a patient who had become resistant to drug therapy contained higher levels of
reduced GSH, and a variety of glutathione-dependent enzymes, than those
obtained from the same individual prior to the onset of drug resistance. It is
important to remember, however, that the limitation in using cell lines is that
phenotypic changes may occur in the cells during the transition into culture.
Cis platinum resistant PE04 cell line was found to have elevated
selenium-dependent GPX activity, an enzyme which has been shown to be
involved in the protection of cells from cytotoxic chemicals (Smith, et al.
198^), and, in particular, in the reduction of organic and lipid hydroperoxides
generated from such compounds as anticancer drugs (eg. adriamycin).
Interestingly, the cis platinum-resistant PE04 cell line was also found to be
cross resistant to adriamycin (Hayward, PhD Thesis 1987, Edinburgh), unlike
the CHO cell line CHO-Chlr which was sensitive to adriamycin. The increase in
selenium-dependent GPX activity may, therefore, have a direct role in the cis
platinum resistant PE04 cell line, in determining the cross resistance to
adriamycin.
There is a growing body of evidence which indicates that reduced GSH
content may be an important factor in determining the susceptibility of tumour
cells to a wide range of distinct cytotoxic drugs. In regard to the resistance of
cells to cis platinum, there are conflicting reports as to the relationship
between drug susceptibility and GSH levels (Andrews, et al. 1985; 1986;
Louie, et al. 1985) (see also Section 1.11.0). In the study described here,
there was an approximate two fold increase in reduced GSH levels in the cis
platinum resistant PE04 cell line, compared with the sensitive PE01 line, in
agreement with the study of Louie et al. (1985). There is also strong
evidence to show that GSH plays an important role in the protection against
alkylating agents. This is particularly the case for ovarian cancer where Ozols
and Co-workers have demonstrated that GSH depletion will sensitise cells to
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the toxic effects of melphalan, cis platinum and adriamycin (Green, et al. 1984;
Hamilton, et al. 1985).
A substantial difference between the cell lines was observed in GST
activity, which was not directly attributable to expression of any of the
isoenzymes studied. Whether novel forms of these enzymes are present in
ovarian tissue, or whether Western blots did not reflect the active enzyme
concentration, is at present unclear. A further experiment which could have
been carried out to clarify the situation, would have been to use antibodies
raised against the three known human GST subunit classes to immunoprecipitate
the respective proteins, and look to see whether this will abolish the
differences between the lines. There is, however, evidence in reports,
indicating that the expression of GST's within tumours is an important factor in
determining their sensitivity to anticancer drugs such as melphalan (see
Section 1.11.0) (Hayes & Wolf, 1988; Dulik, et al. 1986), cyclophosamide
(Adams, et al. 1985; McGowan & Fox, 1986) and also, as indicated above,
chlorambucil (Robson, et al. 1987). In addition, a human squamous carcinoma
cell line, resistant to cis platinum, had a 3 fold higher GST content than the
sensitive line. However, the GST subunit involved was not identified (Teicher,
et al. 1987). Higher GST levels in the cis platinum resistant PE04 cell line
may, therefore, contribute to the differences in drug sensitivity observed. In
this regard, it is interesting that both cell lines contained relatively high levels
of the pi class subunit (X) which has often been discussed in relation to the
resistance of cells to toxic compounds (Kitahara, et al. 1984; Batist et al.
1986; Hayes & Wolf, 1988). It would have been interesting to have made the
sensitive PE01 cell line resistant to cis platinum, to determine whether the
same changes in GSH and glutathione-dependent enzymes, such as yGT,
selenium-dependent GPX and GST occur, as was observed in the PE04 cell line.
GSH concentration, and the activity of yGCS and selenium-dependent
GPX, were elevated in dividing cells. These changes were observed in both the
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ovarian lines and a MCF7 cell line. In general, PE01 and PE04 cell lines were,
however, affected in a similar manner, although the extent of the cell cycle
effects were slightly different. This may play a role in the relative sensitivity
of the cell lines to cytotoxic drugs; however, the effect was not sufficiently
pronounced to make a clear conclusion. Cell cycle differences in the effects of
cytotoxic drugs and carcinogens are well documented (Frei & Harsano, 1967;
Watanabe & Horikawa, 1975), and the over expression of GSH could explain the
increased resistance of dividing cells to certain carcinogens (Dunn, 1972;
Fohlmeister et al. 1984). The increase in GSH concentration found in the cell
cycle may be due to the direct consequence of the increase in rate determining
activity of yGCS. The cell cycle effects observed in this study, exemplify the
need for carefully controlled conditions when measuring, and comparing, GSH
and related enzymes in cell culture.
The changes which occurred in the multidrug resistant DX5 cell line
were similar to that of the ovarian PE04 cell line, with increases in GSH, yGT
and selenium-dependent GPX activity. The MDR cell line was initially made
resistant to adriamycin; therefore, one of the possible defence mechanisms
against this drug, apart from the over expression of GP180, could be the
increase in selenium-dependent GPX activity. As described for the PE04 model,
there was also higher GST activity towards CDNB, detected in the MDR DX5 cell
line, compared with the wild type MES-SA line, which could not be accounted
for by an increase in expression of any of the GST isoenzymes studied by
Western blotting or model substrate analysis. The purification of these GST's
would have been desirable, but not possible, with the time available.
Interestingly, it was observed by Western blot analysis that a human alpha
class (Bi) protein was detected in the wild type MES-SA line which was not
present in the MDR DX5 line. One explanation for this could be that selenium
metabolisim is different in the lines, as it has been well described that selenium
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levels can modulate both alpha class GST levels and selenium-dependent GPX
levels (Masukawa et al. 1983).
Evidence from this study indicates that, as well as the DX5 line
exhibiting characteristic MDR phenotype, and the over expression of GP180,
this particular cell line also has increased levels of GSH and glutathione-
dependent enzymes, including the GST's. In this report, it agrees with Batist el
ai (1986) study, in which an adriamycin resistant MCF7 cell line had higher
levels of glutathione peroxidase, and GST activity. The GST involved,
however, was suggested to be a novel pi class GST, although this was not
clearly demonstrated. This may allow the postulation of the theory of possible
co-ordinate regulation of drug induced detoxification systems, such as GP180
and the GST's, as Thorgeirsson, et al.f19871 has shown the elevation of GP180
in liver preneoplastic foci and regenerating liver, two models in which GST's
have also been shown to be elevated. In order to substantiate this theory, a lot
more experimental work would have to be carried out, including looking at more
MDR cell lines for changes in GSH and glutathione-dependent enzyme levels.
Similar changes in GSH and glutathione-dependent enzymes were found
in both the in vivo and in vitro models of drug resistance as discussed above;
however, it is important to note that the levels of drug resistance were higher
in the in vitro model compared with in vivo. In vivo drug resistance, of which
this is the first study carried out, only requires a small increase in the
resistance of a tumour to an anticancer drug (1.5 - 3 fold) to be of clinical
significance, as the dose currently used is already at the limit of tolerated
toxicity. A remarkable similarity, however, in the phenotypic changes in
glutathione-dependent enzymes in the cells made resistant in vivo or in vitro to
cytotoxic drugs, was observed. The molecular mechanisms of these changes in
protein levels, found in all three models, are not clear. It is possible that
various cells which over express these proteins are selected during the
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generation of these lines, or that phenotypic changes occur during prolonged
exposure to that cytotoxic agent ie. an adaptive response (see later).
In this study, however, the most consistant inductions in all three
models were GST's, and in particular GSH and yGT levels. The elevation in GSH
levels found in the resistant lines may be a direct consequence of large
increases in yGT activity, as this enzyme has been implicated in the regulation
of cellular levels of this co-factor (Griffith & Meister, 1979c; Meister, 1983;
Ahmad, et al. 1987). Recently, it has been determined in mouse lymphoma
L1210 cells, made resistant to L-phenylalinine mustard (L-PAM), that there
was a close correlation between yGT levels and levels of GSH observed
(Ahmad, et al. 1987); this data is consistant with the findings here.
As indicated above, GSH levels were also found to be elevated in all the
drug resistant cell line models studied; this is consistant with other work in the
literature which has indicated, for example, that in L1210 cells resistant to
melphalan, there is an elevation in reduced GSH levels. In a human ovarian
cancer cell line, however, where elevated GSH levels were shown, the cells
could be resensitised by using BSO (Green, et al. 1984; Hamilton, et al. 1985).
Use of BSO to deplete GSH levels in CHO-Chlr (Robson, et al. 1987) did not
sensitise the cells to any great extent. This indicates, therefore, that GSH may
play only a small, direct, role in the resistance mechanism. It is more likely
that GSH is involved in the resistance mechanism by acting as a cofactor for
other glutathione-dependent enzymes which are involved in the detoxifcation
process.
Selenium-dependent GPX activity was found to be increased in both DX5
and PE04, both cell lines which showed resistance to adriamycin, an anticancer
drug which is thought to act through generation of superoxide radicals.
Interestingly, however, in these lines the alpha class GST's, which also have
GPX activity, were observed to be either decreased, or unchanged, as in the
PE04 cell line. In contrast, however, in the CHO-Chlr cell line selenium-
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dependent GPX, activity was found to be unchanged, with a dramatic increase
in the alpha class Yc GST subunit. There is, therefore, a possibility that there
could be coordinate inverse regulation between selenium-dependent, and non-
selenium-dependent GPX (alpha GST activity) activity in the different cell lines.
Selenium levels, as mentioned previously, can affect the differential
expression of the two types of GPX activity; it is, therefore, possible to
speculate that different cytotoxic drugs may influence either the regulation of
expression of the GPX activities, or affect selenium levels, which, in turn, may
influence the expression of the two types of GPX activities.
In conclusion, evidence was presented demonstrating higher levels of
expression of GSH and glutathione-dependent enzymes in all three cell line
models, following the acquisition of resistance to cytotoxic drugs. It is of
importance to note that a variety of glutathione-dependent enzymes, in
addition to GST, were also elevated in the drug resistant lines, and these may
also play an important role in drug resistance. These enzymes may be elevated
in an adaptive response to the cytotoxic drugs used.
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Chapter 4.0.0 GLUTATHIONE-DEPENDENT ENZYMES IN ADAPTIVE
RESPONSE TO CHEMICALS.
4.1.0 Chemotherapeutic drug Induced resistance in normal bone
marrow cells.
4.1.1 Introduction-
The use of cytotoxic agents in cancer chemotherapy is often limited by
the action of these agents on the normal homeostatic proliferating cells of the
body, particularly those of the bone marrow. It has been known for many
years, however, that exposure of animals to a low dose of a cytotoxic
compound, such as anticancer drugs, have the ability to protect against a
normal lethal dose of the same, or in some cases structurally different,
cytotoxins (Miller, et al. 1975; Kimball, et al. 1976; Boyd, 1980). These so
called 'priming' effects are found to be independent of tissue and have been
described for a variety of toxins which are specific for the lung, gut and bone
marrow. In particular, cyclophosamide (CP), a chemotherapeutic agent which
causes myleotoxicity, has recently been studied in this regard. This effect
represents an adaptive response to chemicals which results in resistance to a
subsequent normally lethal dose.
Characterisation of these changes, in GSH and total GST levels in mouse
bone marrow following a 'priming' dose of CP, has been carried out by Adams £j
al, (1985). These workers have shown an elevation of GST (2-3 fold) and GSH
(2-3 fold) occurs exactly at the same point as maxiumum protection against a
lethal dose of the same compound, that is on day 5 and day 6 after the 'priming'
dose. This change was observed to be localised within the granulocyte
population (Carmichael, et al. 1986).
In the study described here, the specific GST subunit which was
involved in the resistance mechanism of the 'priming' phenomenon was
determined, and also whether glutathione-dependent enzymes such asyGT,
yGCS, GRD and GPX are also elevated.
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4.1.2 Results.
GST activity using CDNB as a substrate was determined in the soluble
fraction of bone marrow cells taken from 'primed' and 'unprimed' (control)
mice on days 5 and 6, i.e. on the days of maximal protection against CP (Adams
et al. 1985). As indicated in Table 9, Figure 24, GST activity was
significantly elevated (2.9 fold p<0.002) on both days in the 'primed' samples.
In addition, the peroxidase activity towards cumene hydroperoxide was also
elevated (1.5,p<0.007; 1.8 fold p<0.01 for days 5,6). The increased
glutathione peroxidase activity appeared to be due to differences in the
expression of the GST as the selenium-dependent activity (determined using
H2O2 as a substrate) was similar in both 'primed' and control bone marrow
samples. Pi class GST activity towards ethacrynic acid was found to be
unchanged in both the samples, as were the other glutathione-dependent
enzymes studied.
The change in GST activity appeared to be due to an elevation in the
alpha class and mu class (Yb) subunits. The protein staining pattern of soluble
fraction clearly showed a significant elevation in the primed samples of a
protein with a mobility similar to that of the rat Yb GST subunit and a slight
elevation in an alpha GST subunit in the primed samples on both days (Figure
25). Western blotting using specific antisera raised against human alpha (B-|),
mu (pi), and pi (X) GST proteins showed a 2 fold increase in the level of a mu
GST subunit, as determined by densiometer scanning, and also increase in a
protein equivalent to rat alpha (Ya), in the 'primed' samples. Levels of the
alpha class GST were not seen in the control samples, but relatively high levels
of the pi and mu class GST proteins could be observed (Figure 26).
Carmichael et al. (1986) indicated that the differences observed in
'priming' were confined to the granulocyte population. As a consequence,


















































































































FIGURE 24 Relative Expression of Glutathlone-Dependent Enzvmea
In fA) Bone Marrow. (B) Peripheral Granulocyte and (CI
Peripheral Lvmphocvte Cells taken from 'Primed' Mice
on Davs 5 and 6.
The values shown are expressed as percentages of the control 'unprimed'



































FIGURE 25 Protein Staining Pattern of 'Primed' and Control Bone
Marrow.
Samples were separated by SDS-PAGE. 100^g of soluble protein was loaded
per track. The mobilities of the rat Yc, Yb and Yf standards are also shown. P and
C represent the primed and control samples respectively, on days 5 and 6.
*~~Yf
Day 5 Day 6
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FIGURE 26 Glutathione S-transferase Subunlt Content In 'Primed'
and Control Bone Marrow.
Western blots were carried out as described in the Materials and Methods
(Section 2.6.0) using 100pg of soluble protein per track. The bands were identified
using specific antibodies raised to the human pi class (X), alpha class (B-|) and mu
class (p.) GST subunits. Standards used were rat Yf, Yc and Ybi GST subunits. P
and C were 'primed' and control samples respectively on days 5 and 6.
Pi (A.) Alpha (B-j) Mu (p)
PC P C Yf PC P C Yc
DY5 DY6 DY5 DY6





•primed' and control mice, on which GST and glutathione-dependent enzyme
assays were determined. CDNB was 2 fold higher (p<0.006, p<0.003 Day 5, 6
respectively) in the peripheral granulocyte and unchanged in the peripheral
lymphocyte population of cells from the 'primed' mice on days 5 and 6 (Tables
10, 11 and Figure 24). Glutathione peroxidase activities in these samples
towards cumene hydroperoxide were unchanged. Other glutathione-dependent
enzymes were also found to be unchanged in granulocytes, although an
elevation in both yGT (1.3, p<0.02; 1.6 p<0.01 for days 5,6) and GRD (1.5,
p<0.001; 1.3 p<0.05 for days 5,6) was found in the peripheral lymphocytes
(Tables 10, 11 and Figure 24).
Western blots using the antibodies against the human alpha, mu and pi
class GST proteins, indicated changes in GST subunit expression not only
between 'primed' and control peripheral granulocytes, but also between
peripheral granulocyte and peripheral lymphocyte cells (Figure 27). On day 5
and 6 following priming, there was an increase in the levels of Yb protein, and
also a faint increase in Ya GST subunits in the peripheral granulocytes. No
change in the pi class GST was detected. In contrast, no changes in GST
subunits was observed in the peripheral lymphocytes. Interestingly, there
were differences in GST subunit expression between the peripheral granulocyte
and lymphocytes (Figure 27). Both cell types contained mu GST's, but the
peripheral lymphocytes contained high levels of the pi protein. The converse
was observed, however, for the alpha GST subunit expression.
As indicated, differences in GST subunit expression were observed in
peripheral granulocytes and peripheral lymphocytes (Figure 27). Populations
of these cell types were sorted on a fluorescence activated cell sorter (FACS),
in conjunction with Dr. J. Ansell, Dept. Zoology, University of Edinburgh, from
the 'primed' and control mouse bone marrow cells. Unfortunately, not enough




































































































































































































































FIGURE 27 Glutathione S-transferase Subunit Content In 'Primed'
and Control (A). Peripheral Granulocytes and (Bt
Peripheral Lymphocytes.
Western blots were carried out as described in Materials and Methods
(Section 2.6.0) using 100pg of soluble protein per track. The bands were identified
using specific antibodies raised to the human pi class (X), alpha class (B-|) and mu
class (u) GST subunits. Standards used were rat Yf, Yc and Ybi GST subunits. P
and C were 'primed' and control samples respectively.
(A) PERIPHERAL GRANULOCYTES
PiM Alpha (B-j) Mu (p.)
f
PC P C Yf PC PC Yc PCPCYb
DY5 DY6 DY5 DY6 DY5 DY6
(B) SPLEEN LYMPHOCYTES
Pi M Alpha (B-|) Mu (p)
P C P C Yf
DY5 DY6
PC P C Yc
DY5 DY6
P C P C Yb
DY5 DY6
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sample to detect GST activity. Bone marrow cells also contain a population of
erythrocytes. It was not possible in this study, however, to look at the GST
subunit composition in peripheral erthrocytes taken from the 'primed' and
control mice, due to the presence of large amounts of haemoglobin, which
affects the amount of protein loaded.
4.1.3 Discussion-
GSH has been shown to be involved in the deactivation of 4-hydroxy
cyclophosamide (4-OH-CP) and acrolein (see Section 1.11.0), both metabolites
of CP (see Figure 7). Ai)6blein is highly toxic, and is most probably the cause
of the myleotoxic side effects of CP, including granulocytopenia. Higher levels
of GSH and glutathione-dependent enzymes would, therefore, play an important
role in protecting the cells of the bone marrow against the toxic side effects of
CP.
The cross reactivity of the mouse GST subunits, with the antisera
raised against the human GST isoenzymes, has been determined by Adams et al
(1986) and McLellan & Hayes (1987), who found alpha class (Ya), mu class
(Yb) and pi class (Yf) subunits in mouse liver. In the study described here,
alpha, mu and pi class GST subunits were also detected in mouse bone marrow
using these antibodies to the human GST subunits. Peripheral lymphocytes had
high amounts of pi class (Yf) and mu (Yb-|), but no alpha class GST's. This GST
subunit composition is similar to the finding of Seidegard et al. (1985), who
identified mu subunits in human lymphocytes. The presence of pi class GST,
also in human lymphocytes (not shown), is as suggested by Seidegard et al
(1987). In confirmation of the report by Adams et al (1986) a 2 fold elevation
of GST activity was found on days 5 and 6, following CP administration.
Differences in the levels of these GST subunits would, therefore, influence the
response of the cells to the cytotoxic agent used. In response to a low dose of
the alkylating agent CP, an increase in mu (Yb) and alpha (Ya) GST subunits
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were observed. Whether this change in GST subunit profile is involved in the
increase in the resistance of bone marrow to a high dose of the same
chemotherapeutic agent is unclear. However, GST's are implicated in the
detoxification of nitrogen mustards (see Section 1.11.0). These changes in GST
subunit composition were also found in the peripheral granulocyte population, in
contrast to peripheral lymphocytes, where no change in GST profile was
observed. This evidence is consistant with the finding that the granulocyte
population of the bone marrow is resistant to the higher lethal dose of CP
(Carmichael, et al. 1986). Interestingly, the only cell population in which
glutathione-dependent enzymes, apart from GST's, were found to be changes
was in the lymphocyte population. It may be possible, therefore, that the
increases in yGT and GRD involved in the maintainance of GSH levels found in
this population were related to the defence mechanism of the lymphocytes to
the chemotherapeutic drug.
The bone marrow is a mixture of many different cell types. It is a
possibility that changes in the proportions of these cell types may, in fact,
influence the changes in glutathione-dependent enzymes observed in the bone
marrow. Carmichael et al. (1986) using a fluorescence activated cell sorter
(FACS), separated out the different populations of cells from the bone marrow
in primed and control mice and found that the erthyrocyte population remained
unchanged, while a marked loss of lymphocytes and an increase in the
granulocyte population was determined. This change in the granulocyte
population profile (Figure 8), and more importantly, the changes in GST
subunits within the granulocyte cells, would probably be involved in resistance
of the bone marrow cells to the myleotoxic effects of CP.
Further FACs experiments to sort out bone marrow cell populations
would have confirmed the changes observed in this study. It is also possible
that changes occurred in the erythrocytes. However, in order to study this it
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would have been necessary to remove the haemoglobin from the erythrocyte
samples, to see whether differences in GST subunit profile of these cells
existed, and therefore be involved in the resistance to the chemotherapeutic
agent. It is, however, very unlikely to be the case, as it is known that
erthyrocytes contain mainly pi class GST subunits (Marcus, et al. 1978) and in
the study described here the pi class GST was unchanged in the bone marrow
and in both lymphocytes and granulocyte cells on priming.
It is noteworthy that the overexpression of the GST subunit in the bone
marrow are transient, in that the protection afforded to the myleotoxic effect
of CP is also transient, with maximal resistance to the lethal dose of CP
occurring on days 5 and 6 after the low 'priming' dose. This transient increase
in GST subunits is different from other drug resistance models such as
preneoplasia (see Section 4.3.0) and acquired drug resistance in cell lines
(Section 3.2.0) where the elevation in GST subunits are immortalised. Perhaps
this indicates a different mechanism of induction and regulation of expression in
these models, compared with the chemotherapeutic drug induced resistance in
normal cells.
Similar changes to those described for the chemotherapeutic agent CP
have also been found for other cytotoxic drugs, such as arabinofuranosyl-
cytosine (ara-c) and myleotoxic doses of radiation (Adams, et al. 1985). In
addition, it has been shown in other cell types e.g. hepatocytes, that a low dose
of carbon tetrachloride can protect against a normally toxic dose of this
hepatotoxin, and the elevated expression of GST is also observed (Di Simplicio,
1982), although the GST subunits were not identified. This may indicate,
therefore, that the transient elevation of GST subunits, as described here, to a
low dose of a cytotoxic compound, may form part of a general adaptive
response which confers resistance to further cytotoxic insults. This type of
adaptive response is of clinical value, in that the myleotoxicity of certain
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chemotherapeutic agents is overcome by giving an initial 'priming' dose of the
compound to protect the bone marrow. The method of protection is unknown,
but this data may provide an explanation for the phenomenon. Unfortunately, it
is not known whether such low doses of anticancer agents may also 'prime'
tumours in a similar manner, and, therefore, protect the tumour from the
cytotoxic drugs being used.
4.2.0 Adaptive Response to Oxygen
4.2.1 Introduction.
Oxygen-derived toxic molecules like 02", OH* , and H2O2 are
continuously produced in cells. Their steady-state concentration is currently
unknown, due to technical problems in their measurement (Chance et al. 1979).
These free radicals are chemically unstable and very reactive. They attack
unsaturated double bonds in DNA, proteins, and especially polyunsaturated
lipids, which are sensitive to peroxidation (Tappel, 1978). The production of
these toxic molecules stems from the auto-oxidation of a variety of biological
reactions, such as hydroquinones, catecholamines, and ferredoxin, etc; the
activity of oxidase enzymes, such as xanthine or aldehyde oxidase; the
electron transfer on the inner mitochondrial membrane (Turrens & Boveris,
1980); the cytochrome P-450-dependent system; and also from external
agents such as radiation and a wide variety of foreign chemicals, including
anticancer drugs such as anthracyclines. Anthracyclines, such as adriamycin,
can be enzymatically activated to free radical semiquinones that either react
directly with biological targets, such as DNA and RNA, or generate cytotoxic
oxygen-dependent free radicals such as superoxide anions or hydroxyl radicals
(Bachur et al. 1978; Sinah et al. 1984; see also Section 1.11.0). In order to
protect against the intermediates generated as a result of aerobic metabolism
and cytotoxic stress, various defense mechanisms have evolved. The enzymes
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superoxide dismutase, catalase and glutathione peroxidase (GPX) appear central
in this protection mechanism.
In a study similar to that described in section 4.1.0, Kimball et al.
(1976) have shown that rat lung tissues exposed to hyperoxia, caused an
induction in lung 'antioxidant' defences, which were important in decreasing the
susceptibility of the lung tissue to a higher dose of toxic oxygen. In particular,
it was shown that reduced GSH, superoxide dismutase, glucose 6-phosphate
dehydrogenase, and the glutathione-dependent enzymes GRD and GPX were
elevated in response to hyperoxic conditions.
In this study, carried out in collaboration with Mr. I. Wyatt, I.C.I, pic,
Macclesfield, rats were exposed to similar hyperoxic conditions, as described
by Kimball et al (1976), in order to look at the role of reduced GSH and other
gluathione-dependent enzymes, such as yGT, 7GCS as well as GRD and GPX, in
the adaptive response to high oxygen conditions in both lung and liver tissues.
In particular, GST activities were also determined in order to establish
whether they were also part of this adaptive response to oxidative stress. In
this regard, an involvement of the GST's may be expected.
4.2.4 Results.
GSH and glutathione-dependent enzyme expression in high oxygen and
control treated rat lung and liver tissues is shown in Table 12 and Figure 28.
Using CDNB as a substrate, no difference in GST activity was detected in the
but
hyperoxic treated livers, while there was a slight \ significant (p<0.05)
decrease in GST activity in the hyperoxic lung samples. The peroxidase
activity towards cumene hydroperoxide was significantly elevated (1.5 fold,
p<0.05) in the high oxygen treated lung samples, with no difference seen in the
liver tissues. The increased GPX activity could be accounted for by an increase
in the selenium-dependent GPX enzyme, since a 1.6 fold (p<0.005) elevation in



















































































































































FIGURE 28 Relative Expression of Glutathlone-Eeoendent Enzvmes In
Hvoeroxlc Exposed Rat Lung and Liver Tissues Following
Exposure to High Oxygen.
The values shown are expressed as percentages of the control. See Table
11 for further details.




substrate. GST activity towards ethacrynic acid was found to be unchanged in
both the samples.
The evidence therefore indicated there was no change in GST
composition as a consequence of hyperoxia. The protein staining pattern of both
the liver and lung samples clearly showed no major elevations of any GST
subunits under hyperoxic conditions (Figure 2.9). In order to confirm this
finding, Western blot analysis was carried out using antibodies raised against
the rat GST subunits of the three main GST families; alpha (Yc, Ya, Yk); mu
(Ybi, Yn) and pi (Yf).
Using the specific antibody raised towards the rat Yc subunit, no
difference in the expression of this protein was found, either in lung or liver,
under high oxygen conditions (Figure 30). The antibody raised towards the rat
Ya GST, however, was also found to cross react with the Yc protein present in
the lung and liver samples, and also with the purified alpha Yc/Ya standard.
This blot using the antibody towards the Ya subunit (Figure 30) indicated that
very little Ya GST was found to be present in the lung, but was the major
protein present in the liver. In both tissues, however, this subunit was
unaffected by hyperbaric conditions. In contrast, the Yk GST protein was found
to be suppressed in the high oxygen treated rat lung, but unchanged in the liver.
This protein was found at higher levels in the lung than in the liver (Figure 30).
In the control and high oxygen treated rat lung samples, no expression
of the Yn protein was found, and no change in the hepatic level of this subunit
was observed (Figure 31). A slight decrease in the Yb subunit was detected in
the hyperbaric lung samples. In the liver, no change in the expression of this
subunit was observed. Interestingly, an induction of the Yf protein was found in
high oxygen treated rat livers, but no difference was detected in the lung
samples compared with the liver (Figure 32).
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FIGURE 29 Protein Staining Pattern for Hvoeroxlc and Control
Exposed Rat Luna and Liver Tissues.
Individual rat liver and pooled rat lung samples were separated by SDS-
PAGE. 50pg of soluble protein was taken per track. Mobilities of Yc, Yb and Yf
standards are also shown (STD). Hyperoxic and control treated lung and liver
samples are as indicated.
" ■ Tn' 11 '
CONTROL HYPEROXIC S CONTROL HYPEROXIC
LIVER LUNG
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FIGURE 30 Glutathione S-transferase Isoenzyme Expression In
Hypgrpxlg gntf Control Exposed Rgt Long and Liver
Tissues using Antibodies Raised against Alpha Class
Proteins.
Amount of soluble protein was loaded as indicated, subjected to SDS-PAGE,
transferred to nitrocellulose and probed with specific rat antisera raised against a)
Yc, b) Ya and c) Yk subunits. Standards used were indicated by subunit
designation. C is control and H is high oxygen treated rat and liver samples.
Bands were visualised using 125l protein A, and autorads developed at various
time periods. Other details are described in Materials and Methods (Section 2.0).
(A) ANTI-Yc
c H Yc C H Yc
LIVER (10|ig) LUNG (50|j.g)
(B) ANTI-Ya
C H Yc C H Yc
LUNG (50ng) LIVER (50ng)
(C) ANTI-Yk
Yk H C Yk H C
LIVER (25jig) LUNG (25|ig)
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FIGURE 31 Glutathione S-transferase Isoenzyme Expression In
High oxvoen and Control Exposed Rat Luna and Liver
Tissues using Antibodies Raised against Mu Class
Protein?.
Amount of soluble protein was loaded as indicated, subjected to SDS-PAGE,
transferred to nitrocellulose and probed with specific antisera raised against a)
Yn, and b) Ybi subunits. Standards used were indicated by subunit designation. C
is control and H is high oxygen treated rat lung and liver samples. Bands were
visualised using 125l protein A, and autorads developed at various time periods.
Other details are described in Materials and Methods (Section 2. 0).
(A) ANTI-Yn
c H Yb C H Yb








FIGURE 32 Glutathione S-transferase Isoenzyme Expression In
High Oxvoen and Control Exposed Rat Luna and Liver
Tissue using Antibodies Raised against PI Class
Protein?.
Amount of soluble protein was loaded as indicated, subjected to SDS-PAGE,
transferred to nitrocellulose and probed with specific antisera raised against rat pi
class Yf subunit. Standard used was rat Yf and is indicated as such. C is control
and H is high oxygen treated rat lung and liver samples. Bands were visualised
using 125l protein A, and autorads developed at various time periods. Other
details are described in Materials and Methods (Section 2. 0).
ANTI-Yf
Yf H C Yf H C





Reduced GSH, which is an important cofactor in the protection of cells
against toxic oxygen molecules, was significantly elevated in high oxygen
treated rat lung tissues 2.0 fold (p<0.005), and was also slightly higher in the
hyperbaric liver samples, but not significantly. It was intriguing that, in
conjunction with the elevation in GSH, yGT was also considerably elevated (2.1
fold, p<0.01). The other glutathione-dependent enzymes, 7GCS and GRD, were
found to be unchanged in both the lung and liver high oxygen treated rat
samples, compared with the controls (Table 12, Figure 28).
4.2.3 Discussion.
Reduced GSH value, determined for the control liver, was similar to
those reported in Ihe literature, but at the lower end of the range, 5-7 ^imole/g
tissue (Sies et al. 1983). The normal lung GSH level was equivalent to that
described by Meister (1983) 1.5 ^mole/g tissue, while yGT, GRD and GPX
activities towards cumene hydroperoxide and hydrogen peroxide, were all
similar to those reported by Jenkinson et al (1987).
Enhanced resistance to oxygen induced damage, by pretreatment of lung
cells with a lower exposure of oxygen, has been shown by Kimball et al (1976;
Sedgwick & Robins, 1980; Christman et al. 1985; Morgan et al. 1986; Shelton
et al. 1986). These workers correlated this effect with an increase in reduced
GSH superoxide dismutase, and also the enzymes glucose 6-phosphate
dehydrogenase, glutathione reductase and GPX. In agreement with this work, a
similar elevation in GPX activity was observed here. This increase in GPX
activity was confined to the selenium-dependent enzyme, as no change in the
GST mediated activity was measured. Reduced GSH was also significantly
elevated in the lung tissue as a consequence of hyperbaric oxygen exposure.
This is also in agreement with the findings of Kimball et al (1976). Hepatic GSH
levels was not altered in treated animals in contrast.
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GSH levels form an important part of a protection mechanism
against oxygen toxicity, by either reacting directly with oxygen radicals, or
acting as a cofactor for glutathione-dependent enzymes which remove
peroxides. The increase in GSH levels as a consequence of hyperbaric oxygen
therefore appears to be an important part of the adaptive response to elevated
oxygen conditions. Concomitant with the increase in reduced GSH, a significant
elevation in yGT was observed. It is of interest, that in almost all cases where
GSH is elevated, yGT is also changed. In contrast to the findings of Kimball et al
(1976), no increase in GRD activity was found. It is possible that rat strain
differences could account for this discrepancy, although unlikely. It is
probable, however, that tho changes in GRD, if any, are extremely small, as
only a marginal induction was observed in the study of Kimball et al (1976).
Rat lung GST activity measured here towards CDNB and ethacrynic acid
TKc GST aS iobs+ra-te.
was similar to that reported by Hayes & Mantle (1986b). ^CDNBj^was
significantly lower in animals exposed to elevated oxygen concentrations. In
agreement with a study carried out by Hayes & Mantle (1986b), where the
distribution of different GST subunits was determined in liver and various
extrahepatic tissues, such as lung, different subunits were found to be
expressed at differing levels in the control lung and liver tissues. Ybi subunit
was found to be expressed at higher levels in the liver than the lung. Another
mu class protein (Yn), however, was only present at very low levels in the
liver, and not detectable in the lung. The pi class Yf subunit was expressed in
high levels in the lung, but only at low levels in the liver. In contrast the alpha
Ya subunit was, in agreement with the findings of others (Mannervik et al.
1985; Hayes & Mantle, 1986b), the major form present in rat liver, with
only a small amount of Ya detected in the lung. The other alpha class GST
subunits, Yc and Yk were found in both the lung and liver, with Yk higher in the
lung, and Yc probably higher in the liver.
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These alpha class GST subunits have been shown to have high non-
selenium dependent GPX activity; therefore any changes in the profile of these
isoenzymes under high oxygen conditions would be perhaps important in
mediating the protection of the cells to high oxygen concentration.
Under hyperbaric oxygen conditions, changes in the levels of GST
subunit expression in both rat lung and liver were observed. Surprisingly,
however, an induction of the pi class Yf subunit was observed in the liver. The
reason for this induction is unclear, but it is possible that either oxygen
metabolites direct, or byproducts produced in the lung or liver alter the hepatic
level of expression of this protein. It is interesting that it is this protein which
is induced in the liver in preneoplasia, and also, that as yet, very few inducers
of this subunit have been found. The enzymatic data did not, however, show a
corresponding increase in either CDNB or ethacrynic acid activity. In the lung,
a significant decrease in Yk GST subunit was detected. This protein, which was
purified by Hayes (1986) i,s characterised by low CDNB and high ethacrynic
acid activity. This isoenzyme is thought to play a role in cellular protection
against lipid peroxidation, as it has been shown to have high activity against
toxic lipid peroxidation products, such as 4-hydroxyalkenals (Danielson et al.
1987). It is therefore, of interest, that this particular GST subunit was
suppressed in the high oxygen exposed lung samples, while the selenium-
dependent GPX activity was significantly elevated, indicating, perhaps
speculatively, that some form of relationship between these types of enzymes
exist. It may also indicate that the role of Yk in the protection against lipid
peroxidation may not be as important as first thought. The apparent intriguing
inverse relationship between selenium-dependent GPX and GST in an adpj&tive
response is worthy of further study. It is possible that selenium plays a role in
the regulatory mechanism.
- 137 -
Selenium levels are known to affect the levels of expression of these
two types of GPX enzyme (Masukawa et al. 1983) and could be a factor. For
example, oxidative stress may influence selenium levels and, in turn, influence
the distribution of the selenium and non-selenium dependent forms of GPX. It
would have been interesting to have investigated the changes observed in rats
fed selenium deficient diets exposed to high oxygen conditions. In addition the
exposure of cells in culture to H2O2, in the presence and absence of selenium,
may have given further clues to the possible relationship. Whether stable
expression of these factors exist in cell lines made resistant to high oxygen
(oxidative stress) would also have been interesting to investigate.
It is important to note that other oxygen induced adaptive enzymes may
also be very important in the resistance mechanism against high oxygen stress
(Kimball et al. 1976). These enzymes include superoxide dismutase and glucose
6-phosphate dehydrogenase. In addition, however, the study described here has
shown that GSH and glutathione-dependent enzymes, such as yGT and GRD, are
induced as an adaptive response to oxygen, and may form part of a more
general response. This finding is strengthened by the knowledge that it has been
previously shown that GSH and glutathione-dependent enzyme, such as
selenium-dependent GPX, are induced in bacteria in response to oxidative
stress. In particular this adaptive response in bacteria to H2O2 involves the
induction of a series of proteins including catalase and GRD, under the regulation
of oxyRI regulon (Christman et al. 1985; Morgan et al. 1986) (see also Section
5.1.0).
4.3.0 Resistance of Liver Cells to Carcinogens
4.3.1 Introduction
Chemical hepatocarcinogenesis is known to be a multistep process in
vivo (Pitot & Sirica, 1980; Farber, 1984b). The sequence of events is
believed to be initiation, followed by promotion of some initiated cells. Major
- 138 -
-fU.
conceptual problems exist, however, whenjmutation-selection concept is used
to explain this multistep nature of the carcinogenic process, and the
mechanistic role or position of precancerous lesions. If the mutational events
occurring during the process of initiation have generated an initiated cell, which
displayed 'spontaneous' growth, then the multistep carcinogenic process could
be explained by the progression of new genetically altered cells for increasing
ability to grow 'spontaneously'. Unfortunately, this hypothesis is not
consistent with the many observations in this area in the literature (Farber,
1984b). For example, efficient initiation of carcinogenesis with a relative
small dose of carcinogen does not generate any altered cells with any growth
autonomy, thus reflecting the well established need for another operation such
as a promoting environment.
An alternative hypothesis to the random mutation-selection theory, is
the physiological adaptation concept (Farber, 1984a; 1984c). In this theory,
carcinogenesis is divided into stages, and the long pre-cancerous phase of
cancer development is described as a form of adaptation of the cells to a
hazardous environment. In particular, this form of acute adaptation to
xenobiotics, such as carcinogens, is thought to occur through the induction of
new enzyme patterns which are related to their metabolism and detoxification
(Farber, 1984a; 1984c). This adaptation concept has mainly been studied in
rat liver carcinogenesis models.
There are many different models of liver carcinogenesis but the most
commonly studied are those induced by chemical mutagens. The Solt-Farber
model (Solt & Farber, 1976) describes the commonly used strategies for
inducing liver carcinogenesis. The preneoplastic foci induced by chemical
carcinogens, have been shown to have adapted to the cytotoxic environment by
altering their enzymatic profile. Biochemcially, the preneoplastic foci have
elevated levels of various phase II drug metabolising enzymes (e.g. GST, DT-
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diaphorase and epoxide hydrolase); however, phase I metabolising enzymes
(cytochrome P450's), which are often involved in activation of carcinogens,
are depressed (Cameron et al. 1976; Roomi et al. 1985). Enhanced
GSH content is also found in the high yGT positive, preneoplastic foci (Demi &
Oesterle, 1980). This elevation in GSH, yGT and phase II drug metabolising
enzymes is consistent with the observation that persistent hepatocyte foci are
more resistant to the cytotoxic effects of carcinogens, as compared to normal
liver (Spiewak & Eriksson, 1983; Spiewak, 1984; Roberts et al. 1983).
GST expression in preneoplastic foci and
in neoplastic nodules was studied here to establish similarities between this
method of adaptive response, relative to the others described in this thesis.
The glutathione-dependent enzymes yGCS, selenium-dependent GPX and GRD
were also studied in these models.
4.3.2 Results.
After the induction of yGT positive preneoplastic and neoplastic nodules
using aflatoxin Bi (AFB-|), as determined by Dr. M. Manson, M.R.C. Toxicology
Unit, Carshalton, using histochemical staining, GST activities towards the
general substrate CDNB were markedly increased 1.9 and 2.5 fold
respectively, compared to control rat liver (Table 13, Figure 33). Other model
substrates, such as ethacrynic acid and cumene hydroperoxide were also used
in this study.
Although other classes of GST isoenzymes can utilise the substrate
ethacrynic acid (EA), this substrate tends to be diagnostic for pi class Yf
isoenzyme activity. In preneoplastic foci, pi class activity using this substrate
was elevated 2.3 fold, but an even higher 9.4 fold increase was observed in the
rat neoplastic nodules. The peroxidase activity towards cumene hydroperoxide
in both preneoplastic foci and neoplastic nodules was decreased. This decrease

















































































































































FIGURE 33 Relative Expression of Glutathlone-Denendent Enzvmes
In Rat Preneoplastic Foci and Neoplastic Nodule Cells.
The values shown are expressed as percentages of the control. Value taken
for the neoplastic nodule cells is the average of both tumour A and B determinations



























GPX activity, as the activity of this enzyme to the substrate hydrogen peroxide
was also decreased. A more marked decrease in this activity was observed,
however, in the neoplastic nodules compared to the preneoplastic foci.
As non-selenium dependent GPX enzymes cannot metabolise hydrogen
peroxide as a substrate, an overall 1.5 fold increase in non-selenium dependent
GPX activity was calculated to occur in neoplastic nodules. This activity tends
to be associated with alpha class GST isoenzymes.
The evidence, therefore, seemed to show that significant elevations, in
particular GST isoenzymes, seemed likely in both preneoplastic foci and
neoplastic nodules. The comparison of the protein staining patterns of control
liver, preneoplastic foci and two neoplastic nodules, Tumour A and B taken
from one rat, indicated dramatic changes in the GST isoenzyme profile in the
preneoplastic foci and neoplastic nodules compared to the control liver (Figure
34). In particular, a large increase in a protein with a mobility equivalent to Yf
subunit was observed in both the neoplastic nodules A and B. Other changes in
GST isoenzyme levels, especially in alpha Ya subunit could also be seen. In
order to confirm these changes in GST isoenzyme profiles, Western blot
analysis was carried out using antibodies raised against rat GST subunits from
the three main GST classes; alpha Yc and Ya, mu Yb and pi Yf.
The results from the Western blots confirmed, as indicated in Figure 35,
that there were changes in GST isoenzyme profile between control liver
samples, and those from preneoplastic foci and neoplastic nodules. Using
antibodies raised against the Yc subunit, no difference in expression of this
subunit was observed in the preneoplastic foci, or neoplastic nodules. In
contrast, however, Ya subunit levels were increased in the neoplastic nodules
compared to the control liver and preneoplastic foci samples. Similarly, an
increase in Yb GST was also detected in the neoplastic nodules. In particular,
however, an elevation in the Yf GST subunit, which is normally only detected at
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FIGURE 34 Protein Staining Pattern for Preneoplastic Foci.
Neoplastic Nodule and Control Rat Liver.
Samples were separated by SDS-PAGE. 50|ig of soluble protein was taken
per track. Mobilities of rat Yc, Ybi and Yf are indicated. C represents control; P,
preneoplastic and TA and TB neoplastic nodules A and B respectively.
C P TA TB
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FIGURE 35 Glutathione S-transferase Isoenzyme Expression in
Preneoplastic Foci. Neoplastic Nodules and Control Rat
Liver.
50(ig of soluble protein was loaded, subjected to SDS-PAGE transferred to
nitrocellulose and probed with specific antisera raised against rat:
a) Yc; b) Ya; c) Ybi and d) Yf subunits.
Standards used were as indicated by subunit designation. C is control, P is
preneoplastic foci, and TA and TB are neoplastic nodules A and B respectively.
Bands were visualised using 125l protein A, and autorads developed after 8 hours.
Other details are described in Materials and Methods (Section 2.0).
(A) ANTI-Yc (B) ANTI-Ya
C P TA TB Yc C P TA TB Ya
(C) ANTI-Yb (D) ANTI-Yf
C P TA TB Yb C P TA TB ~ Yf
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low levels in control rat liver, was seen in both preneoplastic foci and more
markedly, in the neoplastic nodules. This change in GST isoenzyme profile may
therefore influence the response of the preneoplastic foci and neoplastic cells to
the effects of carcinogens and cytotoxic compounds. Other glutathione-
dependent enzymes may, however, also influence the response of these cells to
carcinogens, and as a consequence these were studied in control, preneoplastic
foci and neoplastic cells also.
yGCS and GRD are both glutathione-dependent enzymes which are
involved in maintaining reduced GSH levels within cells. Only in neoplastic
nodule cells were 7GCS (3.2 fold) and GRD (1.7 fold) elevated compared to
control activities. No changes in these enzymes were observed for
preneoplastic foci derived cells (Table 13, Figure 33).
4.3.3 Discussion.
It was documented in all the different models of rat liver carcinogenesis
that a well defined sequence of a variety of tissue and cellular changes can be
observed. These include the focal proliferation of hepatocytes, hepatocyte
nodules, hyperplastic nodules, neoplastic nodules, adenomas and, finally, the
formation of a malignant tumour. In the study described here, glutathione-
dependent enzyme expression was determined in an AFB1 induced neoplasia and,
in particular, in two different progressive stages of carcinogenesis i.e. in
preneoplastic foci and neoplastic nodules. In this regard, Kitahara et al (1984)
and Sato et al (1984; 1987) have carried out the most detailed studies into the
changes in GST isoenzyme profiles during hepatocarcinogenesis.
-H* s+yAi «.«► o-f
It was not clear, however, fromjKitahara et al (1984) , which
stages of hepatocarcinogenesis were taken, except that livers with foci and
nodules were investigated. In this study, Kitahara et al (19841 indicated by
purification, SDS-PAGE and two dimensional SDS-PAGE that, during early
hepatocarcinogenesis, an elevation in Yb, Ya and Yf subunits were observed,
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with no change in Yc subunit. Pi class Yf was also shown to be elevated in
preneoplastic lesions by Western blot analysis, and proposed to be a useful
preneoplastic marker enzyme for chemical hepatocarcinogenesis by Sato et al
(1984; 1987). Overall, Kitahara et al (1984) found an increase in GST
activity, towards the substrate CDNB, of 2 fold in the hepatocarcinogenic
livers. In agreement with this finding, I found a 1.9 fold and a 2.5 fold
elevation in GST activity in preneoplastic foci and neoplastic nodules
respectively. This change in GST activity was associated with an increase in
both Yf subunit levels, and activity towards ethacrynic acid as a substrate in
preneoplastic foci cells. The change in GST profile pattern was much more
dramatic for the neoplastic nodule cells, with an elevation in the Yf GST subunit
observed not only by Western blot analysis, but also by SDS-PAGE and
enzymatic assay. An increase in Yf and Ya GST subunits, and activity for the
alpha class GST, was found in the neoplastic nodule liver also; this was in
complete agreement with the elevations observed by Kitahara et al (1984)
using their two dimensional gel electrophoresis system. Pickett et al (1987)
has also shown, at the molecular level, an increase in message transcript for
Ya (2.8 fold) and Yb (5.3 fold) by Northern blot analysis, which again fits in
with findings observed here in this study at the protein level. As GST's have
been shown to be involved in the detoxification of carcinogens (Smith et al ,
1977; see also Section 1.10.6), elevation in these isoenzymes within the
preneoplastic foci and neoplastic nodules would probably play an important role
in the resistance of these cells to the effects of the carcinogens, Other
glutathione-dependent enzymes are also known to be involved in drug
detoxification (Larsson et al. 1983a; Wolf et al. 1987a, 1987c; Hayes & Wolf,
1988) and therefore may also be involved in the resistance mechanism.
The expression of other glutathione-dependent enzymes such as GPX,
yGCS and GRD, which are involved in the maintenance of reduced GSH levels,
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have not been studied to my knowledge in early hepatocarcinogenesis. In the
study described here, however, an increase in yGCS and GRD activities were
found in neoplastic nodules. Interestingly, a decrease in selenium-dependent
GPX activity in both preneoplastic foci, and particularly in neoplastic nodules,
was seen. As the alpha Ya GST (exhibits non-selenium dependent GPX activity)
was shown to be elevated in the neoplstic nodules, this again raises the
possibility of an inverse relationship between non-selenium dependent and
selenium-dependent GPX activity in cells. Whether this is due to a direct effect
of the carcinogen itself, or an effect of the carcinogen on selenium levels within
the nodules, which in turn influences the distribution of the two different forms
of GPX is at present still unclear.
The preneoplastic foci and neoplastic nodules were induced by AFB^: it
would have been interesting to have extended this to include other induction
model systems. Comparison of data regarding GST isoenzyme expression,
however, with that of Kitahara et al. (1984), who used diethylnitrosamine and
2-acetyl aminofluorene to induce hepatocarcinogenesis, indicates that the
changes observed are a general response. The most studied changes in the
different experimental models of induction of chemical hepatocarcinogenesis are
in 7GT and reduced GSH. In a study by Roomi et al (1985), in all four of the
models he looked at, there was a consistant elevation of yGT and GSH. In
particular, Demi & Oesterle (1980) have demonstrated that enhanced GSH
content occurs in the histochemical 7GT positive enzyme altered islands induced
by carcinogens. This finding further exemplifies the theory that yGT is
important in maintaining reduced GSH levels, especially in drug resistant cells
(Ahmad et al. 1987). yGT positive histochemical staining was identified in both
the preneoplastic foci and neoplastic nodules used here by Dr. M. Manson,
M.R.C. Toxicology Unit, Carshalton, but, unfortunately, as the samples were
prepared in the MRC Unit, it was not possible to determine GSH levels in these
- 148 -
samples. It would have been of interest to look at other models of liver
carcinogenesis not involving chemical mutagens, such as the choline-
methionine-deficient model (Rogers & Newberne, 1975; Sells et al. 1979).
In summary, the adaptive response in liver cells to a carcinogen
involves the induction of a series of glutathione-dependent enzymes, including
the GST's which are known to be involved in drug detoxification. In particular,
a dramatic elevation in the Yf GST isoenzyme was observed. This isoenzyme
was demonstrated to be elevated in cell lines made resistant to anticancer
drugs (Batist et al. 1986), and also to be highly expressed in tumours which
tend to show resistance to chemotherapy (Carmichael et al. 1988). Other
GST's, such as Ybi and Ya, were elevated in this model also. Interestingly,
selenium-dependent GPX activity was decreased in the neoplastic nodules
studied. The changes in glutathione-dependent enzyme expression (and also
other drug detoxification enzymes) in the preneoplastic foci, and particularly in
neoplastic nodules, would probably be important in making these liver cells
resistant to the effects of carcinogens, giving them a selective advantage for
growth. A second initiation or factor would, however, be involved in the final
progression of the cells to a tumour.
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Chapter 5.0.0 DISCUSSION AND CONCLUDING REMARKS
The aim of this study was to investigate whether there was a common
underlying mechanism of drug resistance involving GSH and glutathione-
dependent enzymes, especially in the acquired drug resistance of tumour cells
to cytotoxic drugs, and also whether this mechanism could be related to an
adaptive response as a consequence of the administration of a cytotoxic
compound, or to a selection for intrinsically resistance cells. The evidence
presented in this thesis shows that GSH and giutathione-dependent enzymes
were altered in an adaptive response to chemical induced insult (Table 14) in all
the drug resistant models investigated, and, therefore, may form part of a
general protection mechanism against a cytotoxic environment. This has
enabled the generation of a model which can be compared with other known
adaptive responses, such as heat shock, viral infection, alkylating agent
induced DNA repair and oxidative stress. By looking at how these other
adaptive responses are regulated, it will be possible to generate ideas about
how the adaptive response described here for GSH and giutathione-dependent
enzymes, is regulated.
5.1.0 The Adaptive Response
The best characterised adaptive response at a molecular level is that of
heat shock (for reviews see Burdon, 1986; Lindquist, 1986). Cultured cells,
or, indeed, whole organisms, respond to elevated temperatures by synthesising
a number of highly conserved proteins, the heat shock proteins or hsp's. This
response is universal, and has been observed in every organism in which this
response has been looked for so far. The proteins can also be induced by a
variety of other agents, including ethanol (Li et al 1983) and heavy metals
(Burdon, et al 1982), and seem to play a role in normal growth and
development (Burdon, 1986). The regulation of hsp's genes has been studied by+K*. olck*K«A.
of v/ar'rovf^


















































































































































































































































































sequence elements responsible for regulating the induction of hsp gene
transcription (Pelham, 1985; Ayme et al. 1985). In drosophilia, the organism
in which heat shock has been most studied, a conserved sequence located 20
nucleotides upstream of the promoter region has been identified (Pelham,
1982). This sequence shows homology with upstream sequences of other
drosophila hsp genes, and a minimal consensus sequence has been derived:
C--GAA--TTC--G. This is referred to by Pelham (1985) as the heat shock
element, or HSE. Similar sequences have been found in other species (Pelham
1985). A HSE binding protein, heat shock transcription factor (HSTF), (Parker
& Topol, 1984), is, however, essential for the transcription of these genes.
This use of a consensus sequence for the regulation of the heat shock adaptive
response is similar to the mechanism identified for the effect of interferons
(IFNS).
In the case of viral infection of cells, the cells respond by producing
IFN's which, in turn, induce a set of proteins which may be involved in the
resistance to viral infection, by inhibiting viral replication. In humans the IFN
activated genes for these proteins have flanking sequences which, at the 5'




The transcription factor involved in the interaction with these sequences has,
as yet, not been isolated. In contrast, however, in the alkylating agent induced
DNA repair system in bacteria, the messenger of the induction of the genes has
been identified.
The adaptive response in E. coli to low, non lethal dose of an alkylating
agent, provides resistance to a higher lethal dose. This has been shown to be
under the control of the regulatory ada gene (Jeggo, 1979), and increases the
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\ bacteria to repair alkylating agent induced DNA damage at 06 guanine. A
second alkylation event to the protein, 06 alkyl guanine DNA
alkyl transferase, is thought to convert protein to a transcriptional
activator for the genes involved in the inducible response to alkylating agents
(Teo, et al. 1986; Nakabeppu & Sekiguchi, 1986). This protein has been shown
to bind to a specific sequence (AAANNAAAGCGCA) present in the promoter
regions of the genes involved in the inducible adaptive response, at a site
immediately 'upstream' of the binding site for RNA polymerase (Teo et al.
1986). This inducible adaptive response system to alkylating agents has only
been described in bacteria and, in spite of extensive study, there is at present
no evidence that it exists in eukaryotic cells.
In the adaptation of bacteria to oxidative stress, the induction of
proteins such as superoxide dismutase, catalase, glutathione reductase, and
alkylhydroperoxide reductase has been shown. This response is regulated by
the positive control of a regulon (OXYR) (Christman et al. 1985; Morgan et al.
1986). This system has also only been found in bacterial systems.
All the evidence suggests that in adaptive response mechanisms,
transcriptional activation results from the binding of a transacting factor to
consensus sequences 'upstream' of the genes involved. A model for the
regulation of the adaptive response to cytotoxic agents involving GSH and
glutathione-dependent enzymes, as described in this thesis, may be based on a
similar mechanism. Sequences in the 5' flanking regions of the genes for the
glutathione-dependent enzymes may provide evidence that this is the case i.e.
whether any consensus sequences exist, and also whether DNA binding
proteins are induced in response to chemical stress which bind to the 5'
flanking regions.
The finding that not all glutathione-dependent enzymes were induced in
all the models studied, and also that in some models the changes were
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transient, indicates that the regulation mechanism may be complex.
Mechanisms other than transcriptional activation, such as mRNA stabilisation,
and the influence of external modulators, may also play a role. Many
glutathione enzymes are also regulated by complex feedback control
mechanisms, and these may also play a role. Interestingly, there appeared to
be a relationship between 7GT and GSH levels and selenium and non-selenium
dependent GPX activity (see Sections 5.2.0 and 5.3.0).
Adaptive response mechanisms may overlap, indicating common
regulatory pathways for certain of the induced proteins. For instance, in heat
shocked Chinese hamster HA1 cells, resistance to adriamycin is also observed,
(Li et al. 1982) and in oxidative stress in bacteria, certain heat shock proteins
are also induced (Christman et al. 1985; Morgan et al. 1986). It would have
been important, therefore, if time had permitted, to look at GSH and
glutathione-dependent enzymes in heat shocked cells and whether this conferred
resistance to chemicals. Another example of overlap in these systems is the
finding that the GST can be modulated by IFN's (Adams et al. 1987).
Preliminary work, which I carried out with Dr. S. Thomas, showed an
elevation in pi class GST in a lymphoblastoma cell line (DAUDI). Further
characterisation should be carried out to determine whether GSH and other
glutathione-dependent enzymes are also changed.
On the basis of the above discussion, it is possible to suggest that the
adaptive response of GSH and glutathione-dependent enzymes in mammaliam
drug resistant models described here may be a more general response, with
similar responses to be found in drug resistant bacteria, plants, insects and
yeast.
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5.2.0 Relationship between y glutamyitranspeptidase (yGT)
and reduced glutathione (GSH) levels.
One of the interesting findings here was the consistent elevation in yGT
and GSH in almost all the models studied. There are also indications from
reports which indicate a relationship between yGT activity and GSH levels.
This has been shown in preneoplasia, in interorgan regulation of GSH levels by
yGT in the kidney, and in drug resistance.
yGT has been associated with early neoplastic changes in murine and
other animal models (Jaken & Mason, 1978; Dawson et al. 1979; Jalenko &
Ruoslahti, 1979; Ohmori et al. 1981). Increased expression of yGT seemed to
be a common feature of both preneoplastic and neoplastic lesions of many
tissues, including skin, pancreas, (De Young et al. 1978) and mammary
carcinomas (Jaken & Mason, 1978; Dawson et al. 1979). In preneoplastic foci
in the liver, induced by a variety of different chemicals, large increases in yGT
activity have been reported (Roomi et al. 1985). This data was in agreement
with histochemical work reported by many research groups including Solt &
Farber (1976) and Cameron et al. (1976). Interestingly, concomitant with
elevated yGT levels, increased GSH levels have also been demonstrated (Demi
& Oesterle, 1980). Whether this increase in GSH levels is dependent on the
elevation in yGT activity, and not just due to altered general phenotype of the
preneoplastic foci, is at present unclear, although the evidence concerning the
involvement of yGT in the regulation of GSH levels and increase in GSH levels
in drug resistant cells, tends to support the former posibility.
The kidney is the tissue which contains the highest level of yGT (Tate,
1980). It has been demonstrated by Rankin et al (1983) that the kidney is
involved in the regulation of plasma GSH levels, with the catabolism of GSH by
renal yGT to form the constituent amino acids for intracellular GSH
biosynthesis. The kidney has been shown to have both relatively high levels of
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of GSH and a higher GSH turnover rate (Sekura & Meister, 1974) compared to
the liver, perhaps as a consequence of the high yGT levels. The most
compelling evidence for a relationship between yGT levels and GSH levels
comes from drug resistant cell lines.
Ahmad et al 119871 demonstrated a correlation between increased
levels of GSH within a phenylalaninej^drug resistant L1210 cell line, and the
increased activity of yGT. In particular, an increase in the Km of the yGT in
the drug resistant cell line for extracellular GSH, and an increase in the
intracellular cysteine pool was, as a result, (a rate determining factor in GSH
biosynthesis) related to the increase in intracellular GSH levels. These
experiments would have been more definitive if yGT inhibitors, such as L-
(aS,5S)-Y-amino-3-chloro-4,5-dihydro-5-isoxazole acetic acid (AT-125), had
been shown to alter GSH levels. The most conclusive experiment on the role of
7GT in modulating GSH levels would have been the expression of a cDNA for 7GT
in a yGT deficient (or low yGT activity) cell line.
The consistent elevation in GSH levels concomitant with the increase in
yGT activity, together with the finding that tumours tend to have high yGT
activity, allows the possibility to speculate ways of modulating this activity to
affect tumour response to chemotherapy. These proposals are discussed in
Section 5.4.0.
5.3.0 Relationship between selenium and non-selenium
dependent glutathione-peroxidase activity.
The summary in Table 14 indicates an inverse relationship between
selenium and non-selenium dependent glutathione peroxidase (GPX) activity. For
instance, if selenium dependent GPX activity was increased, non-selenium
dependent GPX activity was either unchanged or decreased in the drug resistant
model studied and vice versa. The mechanism of this effect, is at present,
unknown. It has been demonstrated, however, that selenium concentrations can
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influence both GPX enzymes. An increase in selenium level causes an increase
in the selenium-dependent form and a decrease in the non-selenium dependent
enzyme (GST form) (Kasukawa et al. 1983). Whether selenium levels are
modulated to a differing degree by different cytotoxic stresses, such as
anticancer drugs and oxygen radicals, to change the levels of the two GPX
proteins, has not been studied; this could be a possible mechanism of
regulation. The effect of high and low selenium concentrations on the levels of
these two forms of GPX in different drug resistant models would be interesting
to investigate. Another possible explanation for the inverse relationship
between the GPX activities is the differential induction of one of the enzymes in
response to a particular cytotoxic stress, and the changes observed, depending
on the model studied. This could be through*activator of repressor elements'at
the 5' flanking sequences in the respective genes.
The changes in levels of the two forms of GPX in drug resistance may be
important in the overall response to cytotoxic drugs, and may also be
important in human tumours. Ways of exploiting these changes and circumvent
drug resistance in tumours are discussed below in Section 5.4.0.
5.4.0 Sensitisation of tumour cells to cytotoxic drugs by
modulating GSH and glutathione-dependent enzyme
levels.
The changes in GSH and glutathione-dependent enzymes may be of
central importance in the resistance of tumours to chemotherapeutic agents
(Hirono, 1961; Calcutt & Connors, 1963; Suzukake et al. 1982; Wolf et al.
1987a, 1987b, 1987c). On this basis, it is possible to postulate various
ways of modulating chemotherapy in order to circumvent drug resistance.
Buthionine sulphoximine (BSO) will deplete GSH levels in tumour cells
and sensitise them to anticancer drugs (Green et al. 1984; Somfai-Relle et al.
1984; Hamilton et al. 1985; Crook et al. 1986a; 1986b). The benefits of this
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treatment in the clinic may be limited, however, by the serious side effects
attributed to this compound. Calvin et al. f19861 indicated that administration
of BSO to mice, for example, had led to cataracts. As GSH is involved in
normal cellular function, other serious toxic side effects may also be found. In
this regard, patients who suffer from GSH deficiency syndromes can suffer
from severe nervous system damage, including serious mental retardation
(Larsson et al. 1983b; Larsson & Hagenfeldt, 1983). In addition, it has not
proved possible to deplete cellular GSH levels below 20% of control levels,
which may not be sufficiently low, to allow complete sensitisation. The
problem of BSO toxicity could possibly be overcome by the use of rescue
agents to quickly reverse the effects of the yGCS inhibitor BSO (Anderson et al.
1985); glutathione esters could be used in this manner. Conversely, the
higher level of intracellular GSH in tumours could be used to selectively
activate pro drugs.
A major limitation in the effectiveness of cancer chemotherapy is the
toxic effects to normal cells. Some compounds which contain sulphydryl
groups are used clinically to reduce this effect. Mercaptoethane sulphonate
(MESNA), for example, is used to protect the bladder against the cytotoxic side
effects of cyclophosamide and ifosphamide (Brock et al. 1982). The compound
N-acetylcysteine has also been shown to be effective in this regard (Berrigan £]
al, 1982). This protection allows higher doses of the chemotherapeutic
compounds to be given. Drug 'priming', which modulates GSH and GST's
levels in the 'primed' normal cells, has also been used clinically as a strategy
for protecting the bone marrow and intestine against high doses of melphalan.
Initial clinical studies have also shown the usefulness of y-L-glutamyl-L- Dopa
(y Gludopa) as a protective agent against the nephrotoxicity of cis platinum.
This relies on the fact that yGT activity is high in the kidney. yGluDopa is
actively absorbed into the kidney (Wilk et al. 1978), and metabolised to
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dopamine which stimulates the dopaminergic response which, in turn,
increases the rate of cis platinum excretion. High yGT levels in tumours and
in drug resistant models, as demonstrated here, compared with normal tissues
(the kidney being the only exception), allows the prospect of a novel approach
to chemotherapy using y-glutamyl pro drugs to selectively target for tumours.
Nephrotoxicity, which may be associated with this therapy, could be rescued
with subsequent administration of yGluDopa. Use of yGT inhibitors to modulate
tumour GSH levels may also be useful in sensitising tumours to chemotherapy.
GST's were involved in the adaptive response to cytotoxic drugs, but
the changes observed were often parallelled with changes in GSH and other
gluathione-dependent enzyme activities. The changes in GST expression in the
drug resistant models, however, were not confined to one particular GST
subgroup, although only certain GST's were elevated in response to a particular
cytotoxic agent. As a consequence, expression of different GST subunits
within a tumour may, therefore, modulate the response of the tumour to
chemotherapy. Phenotyping the tumour for GST composition before giving
chemotherapy, and even after the onset of drug resistance, may allow
modification of the chemotherapy regime to optimise the response of the
tumour to treatment. It may be possible to modify the response of the tumour
to treatment by other means, such as pretreating the patient with high
selenium, in order to selectively increase selenium-dependent GPX activity and
decrease non-selenium dependent GPX activity before giving chlorambucil, a
nitrogen mustard which may be detoxified by alpha class GST's (Robson et al.
1987; Buller et al. 1987). In addition, selenium deprivation may have the
opposite effect, decreasing selenium-dependent GPX activity and increasing
alpha class GST, allowing the treatment with adriamycin to have a greater
effect.
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Changes in GSH and glutathione-dependent enzymes may, therefore, be
important in the modulation of the response of tumours to chemotherapy.
These changes could occur as part of an adaptive response to cytotoxic drugs,
as shown in the drug resistant models investigated in this project. It is hoped
that this research, and the ideas put forward as a result, may contribute to the
stimulation of future investigations into the role of glutathione and glutathione-
dependent enzymes in tumour drug resistance, and, consequently, to an
improvement in the effectiveness of cancer chemotherapy.
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regulation of glutathione and various glutathione-
>ndent enzymes has been studied in two ovarian adeno-
■inoma cell lines derived from a patient before (PE01) and
- (PE04) the onset of drug resistance to m-platinum,
-rambucil and 5-fluorouracil. Reduced glutathione levels
t higher in the drug resistant cells (PE04). This could
=ibly be attributed to a much higher (6.5-fold) y-glutamyl-
peptidase activity. In addition, glutathione-S-transferase
■D and glutathione peroxidase were 2.9- and 2.3-fold
-er in this cell line. Analysis of the GST subunit composi-
-showed both cell lines contained high levels of the acidic
and lower conccnti ations of a basic isozyme. The
-rence in GST activity between PE01 and PE04 did not
-ar to be related to the levels of these GST subunits. GSH,
mthione peroxidase and 7-glutamyleysteinyl synthetase
all found to be regulated during the cell cycle, higher
» being detected in logarithmic versus confluent cultures
L01 and PE04 and MCF7. This did affect some of the
-fences between PE01 and PE04 and therefore may be
—tributing factor to the differential sensitivity of these cells
■totoxic compounds. The above data provide the first
=-nce that tumour cells obtained from a patient before and
the onset of drug resistance have significant differences
■■itathione-dependent enzyme content.
■—duction
—ired drug resistance represents a major problem in the
lent of various cancers which are initially responsive to
>y. Such cancers include small cell lung cancer, breast
r and adenocarcinoma of the ovary . A variety of factors
leen discussed in relation to this phenomenon. These include
i tumour vascularity and oxygenation, a selection for
icalix resistant cells and drug-induced phenoty pic changes
result in the over-expression of genes which confer
nee (1). In the latter case various mechanisms have been
*ed including increased drug efflux (2). DNA repair (3)
ttoxificalion (4).
athione and glutathione-dependent enzymes are know n to
central role in drug detoxification (4 — 7). In relation to
esistance. particular attention has been given to reduced
lione (GSH*) and the glutathione-S-transferases (GST)
viations: GSH. reduced glutathione: GST. glutathione-S-transferases.
Vglutamylcysteiny] synthetase: yGT: 7-glutamyltranspeptidase: GPX.
■ne peroxidase: GRD. glutathione reductase: CDNB. l-chloro.2.4-dinitro-
: AMC. 7-armno-4-methy I coumarin.
(4.7—15). Indeed, there are several reports describing increased
expression of GST and GSH in drug resistant cell lines (12-15).
The GST are a multigene family of dimeric proteins which
catalyse the conjugation of GSH to a wide variety of reactive
electrophiles. including anti-cancer drugs (16). Characterization
of the GST enzymes in human tissues has identified three distinct
gene families of proteins which can be classified unambiguously
by their subunit compositions as acidic, GST YfYf (subunit
Mr 24 800), neutral, GST YbYb (subunit Mr 26 700) and basic.
GST YaYa (subunit Mr 26 000) (17—19). In relation to drug
resistance particular emphasis has been placed on the expression
of the acidic GST which has been shown to be over-expressed
in drug resistant breast cancer cells, as well as in experimental
models such as preneoplasia (12,20). However, other GST
subunits may also be important; for example, a CHO cell line
made resistant to chlorambucil showed a marked elevation in the
Ya/Yc subunits (15). Although the role of GST in conferring
diug resistance in preneoplasia and cancer chemotherapy is
circumstantial, there is strong evidence from other models that
they are an important contributing factor (7).
In previous reports we have discussed the possibility that the
altered expression of GSH and glutathione-dependent enzymes
may represent a general protective response to cytotoxic insult
(10,21). Other enzymes such as glutathione peroxidase (GPX)
and glutathione reductase also protect cells against cytotoxic
compounds, particularly those which generate toxic oxygen
intermediates such as superoxides and peroxides (eg. adriamycm
(22—24). The levels of these enzymes in tumour cells may also
determine their susceptibility to a variety of cytotoxic drugs
A significant problem in the study of drug resistance is
establishing the relevance of in vitro experiments to clinical
observations in vivo. In this study we have taken two ovanan
adenocarcinoma cell lines, derived from a patient before (PE011
and after the onset of resistance (PE04) to a combination of cis-
platinum. chlorambucil and 5-fluorouracil (25) to establish
w hether differences in GSH-dependent enzymes can be observed
and therefore be a potential factor in the clinically observed
acquired drug resistance.
Glutathione has been shown to be regulated during the cell cycle
(26). In view of the altered sensitivity of cells in logarithmic
growth to alky lating and chemotherapeutic agents (27.28) we haye
investigated the regulation of glutathione-dependent enzymes
during the cell division to establish whether this may be a factor
in the differential sensitivity to cytotoxic drugs.
Materials and methods
All chemicals were purchased from commercial sources and were of the higher-
grade of punts available.
Details of the derivation and general charactenzation of the cell lines PE C
and PHU has been desenbed previously (25) The PE04 cell line was more resists.-.:
to both vis platinum and chlorambucil and also showed cross resistance to a s aner,
of other chemotherapeutic agents including adriamycin. No difference in the
sensitivity of the lines to 5FU was observed. These ovarian cells, and the MCF-"
human breast cancer cell line, were cultured at 37°C. 1009) humidity and 5^
CO; in RPMI 1640 supplemented with 107c (v/v) fetal calf serum (FCS■.
'ress Limited. Oxford. England
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athione levels and gluiathione-dependent enzy me activiues in logarithmic and confluent cultures of PE01 and PE04
IActivm 4- I
incorporation GSH yGCS yGT GRD GST GPX
3805 ± 387 27.8 ± 6.7 16.8 ± 0.64 0.06 ± 0.01 62.3 ± 5.8 74^ ± 9* 11.6 ± 0.7
12236 ± 1232* 42.9 ± 3.3** 23.1 ± 5.6** 0.08 0.03 62.9 ± 5.0 95 w ± 30 38.9 ± 1.9*
29577 a 6174 37.4 5.2*+ 12.2 ± 0.8 0.39 ± 0 04+ 87.4 ± 12.3 215 ± 15+ 27.0 ± 0 00+
72682 ± 12260* 77.7 ± 19 4* 23.6 ± 4.7* 0.33 ± 0.07 89.5 ± 16.2 213j~± 39 52.1 ± 2.1*
corporation is expressed as cpm per mg protein GSH concentration is expressed as nmol'mg soluble protein. Enzyme activities are expressed as
protein with the exception of yGT which is expressed as nmol/min/10g(tells. Other details are given in Materials and methods section,
used are -yGCS. y-gluumy lcysteinyl synthetase: yGT. 7-glutamyltranspeptidase; GRD. glutathione reductase. GST. glutathione S-transferase
lg CDNB: and GPX. glutathione peroxidase measured using H:0;. C and L are confluent and logarithmic cultures, respectively. The values are
ins ± standard deviations from three separate experiments carried out in triplicate,
different from confluent culture P < 0.001
y different from confluent culture. P < 0.01.
different from PE01. P < 0.001.
ly different from PE01. P < 0.01.
(100 ng'ml) and penicillin (100 IU/ml). Insulin (2.5 mg/ml) was
cultures of PE0I and PE04.
lavs for mycoplasma were carried out routinely and were always
legative. Flasks were seeded at 2 x Kp or 5 x 104 cells'ml to
onfluent or logarithmic cultures respectively. Cell synchronisation
by arresting the cells in Gq-'G, of the cell cycle by reducing the
of fetal calf serum from 105 to 0.51? (29). Logarithmic growth
by then increasing the FCS concentration to 105. Cells were
1 later.
vested with 0.1 5 (w/v) trypsin. 0.001 5 (w:v)versene mix. washed
phosphate buffered saline (140 mM NaCl. 2.7 mM KC1. 8 mM
late pH 7.4) and resuspended at 1 x 10' cells/ml Cell viability
d to be greater than 95 5 as assessed by nigrosin dye exclusion,
-n was homogenised using a teflon glass, hand-held homogeniser
■sed by sonication with three 5 s pulses at maximal power. A 5 s
at 4°C was included between each burst. The resulting sonicate
.000 g for 20 min and the supernatant decanted. The supernatant),
lellets were collected and stored at -70CC until required,
ticorporation into DNA was measured with 0.19 MBqpHJmethyl
Following incubation for 4 h the cells were washed with phosphate
. harvested and 50 gl ahquots absorbed onto Millipore filters.
then washed sequentially with distilled water. 55 (w.'v)
acid, distilled water and methanol. Filters were then dried, and
peasured by scintillation counting.
d en:\rmt assays
e measured by high performance liquid chromatography follow ing
with monobromobimane (Calbiochem. Cambridge Science.
C) (31). The stability of the GSH was established by the addition
ints of GSH to a cell sample following harvesting GSH in the
nd to be stable for up to 1 month if stored at - 70 "C GST activities
bstrates 1 -chloro-2,4-dmitrobenzene and ethacrynic acid were
—the method of Habig el al. (32). The peroxidase activ ity of the
ards cumene hydroperoxide was assessed by measuring the
\DPH at 340 nm (33).
reductase and glutathione peroxidase activities were assayed
as described by Weiss ei al. (34). y-Glutamylcysieiny I synthetase
e determining enzy me of GSH biosy nthesis (35). was measured
trically using a coupled reaction involving the measurement of
n at 340 nm (36). The particulate fraction of the cell preparation
e assay of yGT activity (37) using 7-glutamyT7-aimno-4-methyl
tbstrate (Universal Biological Ltd. Cambridge. UK). All assays
it al 37 C Statistical significance was determined using the
tions w ere by the method of Low ry el al. 1381 using bovine serum
standard.
alysis
ere carried out using a modified version of that described by
39) as previously described by Adams ei al (40). Following
tmide gel electrophoresis and transfer to nitrocellulose, filters
two 10 mm periods in 50 mM Tns HC1 buffer. pH 7.9 containing
nd 0.055 (vv) Tween 20 (TBST). Filters were blocked with
T for 1 h followed by two 10 min washes with TBST. Specific


















Fig. 1. Comparison of glutathione-dependent enzyme activ ities between
PE01 and PE04 in confluent cultures. Experimental details are described in
the Materials and methods section and in the legend to Table I. The PE04
values show n are expressed as a percentage of those obtained for PE01.
15 min washes with TBST. The filters were then incubated (1 h) with goat anti-
rabbit IgG antibody conjugated to horseradish peroxidase Follow ing further washes
the bands were visualised using either 4-chloro-1 -naphthol as peroxidase substrate
or by autoradiography after labelling with 0.19M1W'-'ijprotein A.
Results
Measurements of GSH levels and glutathione-dependent enzymes,
in drug sensitive (PE01) and resistant (PE04) cell lines, were
initially carried out on confluent cultures (Table 1. Figure 1) and
in all cases where differences were observed the PE04 cell line
had higher activities. Glutathione levels were significantly higher
in this cell line (1.4-fold). Concomitant with the difference in
GSH. yGT activity was markedly elevated (6.3-fold). Increases
in GST (2.9 fold) and glutathione peroxidase (2.3-fold) activities
were also noted. The activities of glutathione reductase and yGCS
were essentially unchanged in both cell lines. In addition to the
increase in GST activity towards the general substrate CDN'B.
the metabolism of ethacrynic acid, and cumene hydroperoxide
was also significantly higher. The activities being 40.0 ± 6.8
and 58.4 ± 3.4 nmol/min/mg for ethacrynic acid and
Glutathione-depmdent enzymes and drug resistance
. Glutathione S-transferase and isozyme expression in cell lines PE01
204 50 /ig of supernatant protein was subjected to SDS-PAGE.
rred to nitrocellulose and probed with antibodies to the acidic fYfYf.
basic (B,B|) GST isozymes Blots were developed using I1-5 Protein
ler details are described in Materials and methods section
± 5.4 and ?6.1 ± 8.1 nmol/min/mg for cumcnc liydio-
ide for PE01 and PE04 respectively,
stern blots were carried out to establish the GST subunit
osition of the two ovarian adenocarcinoma cell lines and
ermine whether the difference in GST activity towards
■3. ethacrynic acid and cumene hydroperoxide could be
ated with differences in the expression of known GST
its (Figure 2). Both cell lines had high levels of the acidic
lunit. The basic Ya subunit could also be detected and was
-it at approximately 1/10th of the concentration of the acidic
-n. The neutral Yb GST subunit could not be detected in
cant concentration in either cell line. The content of the
d Ya-type subunits was similar in both cell lines, although
el of the Ya subunit did appear marginally higher in PE04.
data indicate that the levels of these subunits are not
isible for the large difference in GST enzvmic activity,
athione concentration has been shown to change during
11 cycle (26). We therefore investigated which of the
hone-dependent enzymes were also subject to such
ion. particularly as they could contribute to the differences
n the cell lines and also be a factor in their sensitivity to
tic drugs. A 2- to 3-fold increase in tritiated thymidine
/ration in both cell lines synchronized in logarithmic
i was observed (Table I. figure ?)). A large difference in
ine incorporation between PE01 and PE041 indicating a
rate of DNA synthesis in PE04-. this could be due to
ices in thymidine kinase activity or other enzy mes involved
4 synthesis.
ithione concentration was significantly elevated in both
?s in logarithmic growth (Table I. jEiguxe-T). The increase
.6- and 2.1-fold, relative to confluent cultures, for PE01
34 respectively . In cultures in logarithmic growth the GSH
of PE04 was 1.8-fold higher than an equivalent PE01
A significant increase in glutathione concentration
d) was also observed for the MCF-7 cell line during
imic growth from 34.2 ± 17.4 to 64.7 ± 17.0 nmol
tein. Concomitant with the increase in glutathione levels
to 2-fold) increase in yGCS activity was observed. The
enzymic activity being increased 1.8-fold in the MCF-7 cell line
from 7.1 ± 2.3 to 13.0 ± 3.7 nmol/min/mg protein.
Glutathione peroxidase activity using hydrogen peroxide as
substrate was also significantly elevated (1.9- and 3.4-fold) in
dividing cells in all three cell linesftuguie"3). GPX activity being
increased in the MCF-7 cell line from 34.1 ± 10.1 nmol GSH
oxidised/min/mg protein to 76.8 ±21.7 nmol GSH oxidised/
min/mg protein. "Hie fold elevation was higher in the PE01 than
in PE04 (Table I, The GST activity was not
significantly changed during the cell cycle.
Discussion
The two ovarian cell lines used in this study represent a valuable
in vivo model for the study of drug resistance (25). Karyotype
analysis showed that the cell lines were of the same clonal origin
but that they diverged from each other either before, or during,
drug treatment. Although it is not clear how representative the
cell lines are of the original tumour, the data in this paper provide
evidence that the tumour cells isolated from a patient who had
become resistant to drug therapy contained higher levels of
glutathione and a variety of glutathione-dependent enzymes than
those obtained from the same individual prior to the onset of drug
resistance. It is not clear whether the increased enzyme levels
in the resistant cell line was an intrinsic property of these cells
or was a consequence of the drug treatment. There is however
evidence which suggests that glutathione and GSH-dependent
enzymes increase as a result of chemical stress (4,11,21,42).
There is a growing body of evidence which indicates that the
glutathione content is an important factor in the susceptibility of
tumour cells to a range of distinct cytotoxic drugs. Resistance
to cis-platinum provides a good example of the relationship
between drug susceptibility and GSH levels (43—45). There is
strong evidence that glutathione plays an important role in
protection against alkylating agents. This is particularly the case
for ovarian cancer where Ozols and co-workers have
demonstrated that glutathione depletion will sensitize cells to the
toxic effects of melphalan. cri-platinum and adriamycin (46.47).
In addition, there are now several reports which demonstrate that
cell lines made resistant to alkylating agents or cts-platinum have
increased glutathione and GST activity (48). On the basis of the
current study, the elevation in glutathione content in PE04 may
be a direct consequence of a very substantia] increase in yGT
activity. This enzyme has been implicated in the regulation of
cellular levels of this cofactor (49-51). It is noteworthy that yGT
is elevated in rat liver preneoplastic foci which also have elevated
GSH levels. It has recently been shown that in mouse lymphoma
L1210 cells made resistant to L-phenylalanine mustard (L-PAM).
a close correlation between yGT levels and levels of GSH was
observed (50). It is worthy of note that glutathione reductase,
which is also involved in determining reduced GSH levels, was
not elevated in the drug resistant PE04 line.
A substantial difference betwen the cell lines was observed in
GST activity which was not directly attributable to expression
of any of the isoenzymes studied. Whether novel forms of these
enzy mes are present in ovarian tissue or whether the Western
blots do not reflect the active enzy me concentration is at present
unclear In recent studies we have identified acidic and basic GST
subunits as major GSTs in primary ovarian tumours (Lewis el at..
unpublished). There is an increasing body of evidence indicating
that the expression of these proteins within tumours will be an
important factor in their sensitivity to anticancer drugs such as
melphalan (7.16,1). cyclophosphamide (11.14) and probably
chlorambucil (15). Higher GST levels in the PE04 cell line may
.D.Hayes and C.R.Wolf
ntribute to the differences in drug sensitivity observed,
ard it is interesting that both cell lines contained
igh levels of the acidic subunit (sometimes known as
r) which has often been discussed in relation to the
>f cells to toxic compounds (7,12,42).
yn to the GST enzymes several other glutathione-
nzymes including glutathione peroxidase are involved
n from cytotoxic chemicals (52). Many of these are
inly studied in relation to drug resistance. It was
teresting that glutathione peroxidase levels were found
icantly higher in the PE04 cell line. This enzyme has
role in the reduction of organic and lipid hydro-
Such intermediates have been implicated in the
of action of a variety of anticancer drugs (9,10).
ne concentration and the activity of yGCS and
peroxidase were elevated in dividing cells. The
re observed in both ovarian cell lines and the MCF7
rhese experiments were carried out to determine
11 cycle effects on these enzymes could be a factor
ential drug sensitivity. PE01 and PE04 were affected
manner although the extent of the cell cycle effects
!y different. This could play a role in the relative
of the cell lines to cytotoxic drugs. Cell cycle
in the effects of cytotoxic drugs and carcinogens are
mted (27,28) and the over-expression of GSH could
increased resistance of dividing cells to certain
(53,54). The increase in GSH concentration in the
-ay be a direct consequence of the increased 7GCS.
cle effects observed here exemplify the need for
strolled conditions when measuring and comparing
■and related enzymes in cell culture,
ion evidence is presented demonstrating higher levels
-n of glutathione and glutathione-dependent enzymes
-a tumour cell line derived from a patient following
yn of resistance to cytotoxic drugs. It is perhaps of
-hat a variety of glutathione-dependent enzymes, in
e glutathione transferases, were also elevated. These
.■ also play an important role in intrinsic and acquired
ice.
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ABSTRACT
Glutathione dependent enzymes play a central role in the
protection of cells from cytotoxic chemicals and have been
implicated in the intrinsic and acquired resistance of tumors to
cytotoxic drugs. We have generated a CHO line resistant to
bifunctional nitrogen mustards and in this report have
characterized and isolated the protein which represents the major
observable phenotypic difference between the drug sensitive and
resistant cell lines. This purified protein is shown to be an
alpha class glutathione S-transferase comprising YcYc subunits and
possessing a pi value of approximately 8.0. The intracellular
level of the Yc subunit is elevated greater than 40-fold in the
drug resistant cell line which could account for the increase in
glutathione S-transferase activity towards both l-chloro-2,4-
dinitrobenzene and cumene hydroperoxide. Other glutathione
S-transferase subunits within this gene family are also elevated.
Southern analysis indicates that the genes coding for these
proteins are amplified 4-8 fold in the drug resistant cell line.
In addition, Y-9lutamyltransPePtidase activity is increased
3.6-fold in the drug resistant CHO cell line, which may explain
the increase in cellular glutathione level.
The above data indicates that gene amplification may play an
important role in drug resistance towards alkylating agents and
also that other enzymes in glutathione homeostasis are involved.
These observations underline the strong similarities between drug
resistance and the phenotypic changes which occur in
chemical-induced neoplasia.
3
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The ability to resist the chemical stresses imposed by our
environment represents a major evolutionary driving force. It is
clear that a wide variety of defense systems have evolved to
protect against such cytotoxic insults. Studies into tumor cell
drug resistance and carcinogenesis have greatly increased our
understanding of these systems and various defense mechanisms
appear to be important including, membrane permeability (1), DNA
repair (2), gene amplification (3), and drug detoxification (4).
For several decades glutathione and glutathione-dependent
enzymes have been implicated in drug detoxification reactions (5).
Increased glutathione content, resulting in increased drug
detoxification, was proposed as a mechanism of drug resistance in
tumor cells over twenty years ago (6, 7). However, it is only
recently that these observations have become a major topic of
study. There is now substantial evidence which indicates that the
overexpression of glutathione and glutathione-dependent enzymes is
an important mechanism of acquired drug resistance in both normal
and tumor cells (4-13) .
In a previous report we described a chlorambucil-resistant
CHO cell line, also cross resistant to other bifunctional nitrogen
mustards (14). These cells have elevated GSH and glutathione
S-transferase (GST) activity but do not exhibit differences in
drug accumulation or DNA repair (15). The major observable
phenotypic difference between the sensitive and resistant cell
line is in the expression of a protein of molecular weight
approximately 25000. Here we report the isolation and
characterization of this protein which is shown to be a GST whose
overexpression results from gene amplification. In addition,we
also show that other glutathione S-transferase subunits and
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y-glutamyltranspeptidase (TfGT) are elevated in the resistant line.
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MATERIALS AMD METHODS
All chemicals were purchased from commercial sources and were
of the highest grade available.
Cell Culture: The two cell lines used in this study have been
termed CHO-K1 (wild type) and CHO-Chlr. The latter cell line
exhibits a 24-,34- and 14-fold higher resistance to chlorambucil,
mechlorethamine and melphalan, respectively (14) . Cells were
maintained in Ham's F10 medium supplemented with 5% fetal calf
(and in some cases 5% newborn calf) serum (v:v), streptomycin (100
(ig/ml) and penicillin (100 IU/ml) and cultured in 100% humidity
and 5% C02 as monolayers at 37°C.
Isolation of Subcellular Fractions: Cells were harvested from
confluent cultures with 0.1% (w:v) trypsin and 0.001% (w:v)
versene, washed three times in phosphate buffered saline (140 mM
NaCl/ 2.7 mM KC1/ 8 mM NaP04/ 1.5 mM NaP04 pH 7.4; PBS) and
resuspended in 400 |ll of this buffer. Samples were then sonicated
with three 5 sec pulses at maximal power with a 5 sec cooling
period at 4°C between each step. The resulting sonicate was
centrifuged at 18,000 g for 20 min and the supernatant decanted.
Protein was estimated in freshly prepared cell fractions by the
method of Lowry et al (16), using bovine serum albumin as the
standard. Cell fractions were stored at -70°C before further
biochemical analyses were undertaken; samples were stable under
the storage conditions used.
Enzymic assays: GST activity towards the substrates
l-chloro-2,4-dinitrobenzene, ethacrynic acid and cumene
hydroperoxide were determined in the supernatant fractions by the
methods of Habig et al (17) and Stockman et a 1 (18) . Glutathione
reductase was assayed fluorometrically, as described by Weiss fit.
fit (19), and glutathione peroxidase activity determined
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spectrophotometrically (20). The activity of y-glutamyl cysteinyl
synthetase, the rate determining enzyme of GSH biosynthesis, was
determined using a coupled reaction by measuring the rate of
oxidation of NADH spectrophotometrically (21). The particulate
cell fraction of the cell preparation was taken for the assay of
7GT using y-L-glutamyl-7-amino-4-methyl coumarin as substrate
(Universal Biologicals Limited, Cambridge, UK) (22).
Western Blot Analysis: SDS-polyacrylamide slab gel electrophoresis
was performed according to the method of Laemmli (23). Western
blots were carried out using essentially the method described by
Towbin et al (24), as modified by Adams et al (25). The antibodies
employed were raised against the human pi class GST (X, YfYf
subunits) , human alpha class GST (B^, YaYa subunits), and human
mu class GST YbYb subunits). In addition, antisera to the rat
alpha class GST, YaYa or YcYc subunits were also used. Antisera
were prepared as described previously (26,27).
Two-dimensional electrophoresis was carried out according to
the method of O'Farrell (28) as modified by Robson et al (14). A
pH 5-8 gradient was employed in the isoelectric focussing step
which represented the first dimension. Either 100 |ig of total
cellular protein or 5 Jig of purified protein was loaded for each
experiment.
Purification of Glutathione S-transferases: Cells from the
CHO-Chlr (5 x 109 cells), were harvested, frozen at -70°C and lysed
as described by Soma et al (29). Briefly, the pellets were thawed
and suspended at 4°C in 40 mM Tris/HCl buffer, pH 7.4, containing
160 mM KC1, 4 mM EDTA and 5 mM dithiothreitol. The final volume
was 5 ml. The suspension was homogenized with a teflon/glass
homogenizer (25 strokes), centrifuged for 30 sec in an Eppendorf
Microfuge, and then centrifuged for a further 45 min at 35,000
rpm. The resulting supernatant was applied to a column of
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S-hexylglutathione (4 ml bed volume) equilibrated with 10 mM
Tris/HCl, pH 7.8, containing 0.2 M NaCl and 3 mM
2-mercaptoethanol. The column was washed with the above buffer
and the GST eluted by the addition of 5 mM S-hexylglutathione to
the running buffer. Using this procedure the majority of the GST
in the cell lysate were retarded by the affinity gel but eluted in
the wash fraction from the column. The enzyme-containing
fractions were combined, dialysed against 20 mM Tris/HCl, pH 7.8,
1 mM EDTA and 5 mM mercaptoethanol and reapplied to the
S-hexylglutathione-Sepharose column. The GST, which was now
retained by the affinity matrix following this second
chromatographic step, was then eluted with a solution ot b mM
S-hexylglutathione in the 20 mM Tris/HCl running buffer, pH 7.8.
Two proteins were detected in the eluate, a minor component which
eluted immediately and a major protein with GST activity. This
protein was of high purity as judged by SDS-polyacrylamide-gel
electrophoresis (see Results section).
DNA and RNA Analysis
A full length cDNA clone alpha class GST (pMP 37, 942bp) was
isolated from a human liver A.gtll library using an oligonucleotide
coding for the six NH2~terminal amino acids of the protein.
Over the coding region this cDNA had an identical sequence to that
published by Board & Webb (30). A full length rat liver y-glutamyl
transpeptidase cDNA clone was isolated from a cDNA library in
XGT10 using a cDNA to the rat kidney enzyme (31). Eco RI digest
of this clone yielded two fragments. The 5' fragment (pEGLl.l) of
1230bp was used as a probe.
DNA Isolation
107 cells were washed twice with phosphate buffered saline
(PBS) and then harvested by scraping into PBS. Cells were then
lysed in 0.5% SDS, 150mM NaCl, lOmM EDTA, lOmM Tris-HCl pH7.5
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(2mls) and treated with RNase A (lOOjig/ml)then followed by
proteinase K (250p.g/ml) at 37°C for lhr and 4hr respectively.
Samples were then extracted with phenol followed by
phenol/chloroform (1:1 v/v) and the DNA precipitated in 60% EtOH
containing ammonium acetate (1M). The precipitated DNA was wound
onto a glass rod, air dried and resuspended in lOmM Tris-HCl
pH7.5, ImM EDTA. DNA concentrations was determined from the
absorption at 260nm. Southern analysis was carried out as
described by Hill et al (32).
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RESULTS AND DISCUSSION
The levels of a variety of glutathione-dependent enzymes in
the drug sensitive and resistant CHO cell lines are shown in Table
1. In agreement with a previous report, both the GSH level and
the GST activity (towards CDNB) were significantly higher in the
chlorambucil resistant cell line (1.8- and 2.7-fold,
respectively). In addition, the peroxidase activity towards
cumene hydroperoxide was also elevated 5.1-fold. This increase
appeared to be completely due to differences in GST expression as
the selenium-dependent activity (determined using H2O2 as
substrate) was similar in both cell lines (Table 1). The majority
of the peroxidase activity towards cumene hydroperoxide in the
CHO-KI was mediated by the selenium-dependent enzyme. When this
contribution was subtracted from the values obtained, CHO-Chlr had
approximately 50-fold higher GST-mediated peroxidase activity than
the wild-type cell line.
A variety of enzymes are involved in maintaining reduced
glutathione levels within cells (33). Three of these; glutathione
reductase, y-glutamyltranspeptidase and y-glutamyl cysteinyl
synthetase were measured. Only yGT was elevated significantly in
the drug resistant cell line, suggesting that this protein may be
responsible for maintaining the elevated cellular GSH level.
Elevated yGT concentrations have been observed in cell lines
resistant to cytotoxic drugs (34,35). In addition, the fact that
preneoplastic foci in rat liver, which have elevated GSH content,
also have elevated yST levels (36), supports the hypothesis that
this enzyme is involved in maintaining increased cellular GSH
levels. It is interesting that in the models for drug resistance
induced by alkylating agents we have studied, yGT activity is
consistently elevated (35, and unpublished).
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Our initial studies indicated that altered expression of the
alpha class GST represented the major change in GST expression in
the CHO-Chlr cell line (15). In support of this the staining
pattern of cytosolic samples clearly showed an elevation in a
protein with a mobility similar to that of the rat Yc GST subunit
(Figure 1). This subunit could therefore be the polypeptide, with
an estimated Mr of 25000, which was shown previously to be
dramatically overexpressed in the CHO-Chlr cell line (15); more
recent work has estimated the Mr of the Yc subunit to be
27000-27500 (37).
In order to establish whether this was the case the
overexpressed protein was purified. In addition Western blots of
CHO cytosol with antibodies to known rat or human GST subunits
(Ya, Yb, Yc and Yf) were carried out. A two step purification
procedure (Figure 2) yielded a pure protein of similar mobility to
the rat Yc (Mr 27500) standard. This protein was shown to be a
GST based on its activity towards CDNB, cumene hydroperoxide and
ethacrynic acid, the turnover numbers for these substrates being
6031, 964 and 550 nmol/min/mg protein, respectively. The relative
activities of the Chinese hamster GST towards these three
substrates is similar to that exhibited by the rat Yc subunit
(38). Western blots showed that the purified protein and the
protein overexpressed in CHO-Chlr reacted strongly with antibodies
to the alpha class Yc GST subunit (Figure 3). This blot also
demonstrated a marked 40 fold difference in the expression of this
protein between the drug sensitive and resistant cell lines. In
order to confirm these findings the mobility of the purified
protein following electrophoresis in two-dimensional
polyacrylamide gels was compared with the over expressed protein
in the CHO-Chlr cells, following two-dimensional electrophoresis.
The two proteins were found to have identical mobilities in this
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system (Figure 4). The isoelectric point of the purified protein
being approximately pH 8.0.
In view of the observation that other GST subunits may be
involved in drug resistance Western blots were carried out with
antibodies to other GST enzymes (Ya, Yb and Yf) (Figure 5) . Slight
differences between CHO-K1 and CHO-Chlr in the expression of the
pi and mu class proteins were observed however these differences
were marginal. However, a significant elevation in Ya, another
alpha class subunit, was observed. This antibody also
cross-reacted weakly with the Yc subunit (Figure 5).
In order to establish the molecular mechanism for the over
expression of alpha class GST. DNA from the cell lines was
analyzed by Southern blot analysis (Figure 6). The complexity of
the banding pattern obtained is indicative of a multigene family
incorporating the Ya and Yc genes. In Chinese hamsters this gene
family appears to cover up to lOOkb of DNA. The intensity of most
of the bands was much higher for CHO-Chlr than the wild type
CHO-K1, and based limited dilution of CHO-Chlr DNA until the bands
were of equal intensity to CHO-K1 it appeared that there was a 4-8
fold elevation in gene copy number (not shown). Densitometric
scanning of the bands indicated that the increase may be up to
twenty fold. This elevation was however not uniform and some
bands were essentially unchanged. No difference between CHO-K1
and CHO-Chlr was observed when a y-glutamyltranspeptidase cDNA was
used as a probe (Figure 7B).
The above data provides strong evidence that the class alpha
GST are the major proteins over expressed in CHO cells made
resistant to chlorambucil. This increase in expression appears to
be a consequence of a gene amplification event. It is worthy of
note that DNA repair capacity and also drug accumulation are
unchanged in the CHO-Chlr cells (15) and that the mechanism of the
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drug resistance appears to be due to enhanced drug detoxification
which results in reduced DNA damage (15). The alpha class GST
subunits therefore appear to be important in this mechanism. In
support of this possibility GST's have been shown to catalyze the
conjugation of melphalan to GSH, leading to its detoxification
(39). Melphalan is a structural homologue of chlorambucil to
which CHO-CHlr is also resistant. Which GST subunit is
responsible for this reaction however has not been established.
The molecular mechanisms responsible for the changes in the
levels of GST and other glutathione-dependent enzymes have
remained elusive. However, we have now obtained evidence that
gene amplification may be an important part of this process, and
therefore may play an important role in drug resistance induced by
alkylating agents. The time point at which this amplification
occurs ie. whether some cells intrinsically contain amplified
sequences of whether gene amplification is induced by chemical
exposure is unclear.
The phenotypic changes observed in protein expression in drug
resistance, ie. in glutathione-dependent enzymes, P-glycoprotein
and DNA repair enzymes bear a remarkable similarity to those
observed in chemical-induced neoplasia in rat liver (12, 40-42) .
These changes are often independent of the chemical reagent used
and may well reflect the existence of a fundamental cellular
response mechanism to combat chemical insult. Whether common
genetic changes are involved in such a response is at present
unknown.
The role of glutathione-dependent enzymes in this adaptive
change is uncertain, however, the ubiquitous nature of the changes
observed in the expression of these proteins following cytotoxic
insult indicates that they play an important role. For example,
changes in levels of these enzymes have been reported to occur
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during oxidative stress in both bacteria (43) and rodent lung (44)
and also in chemical-induced stress in the mouse bone marrow (13,
45) . With particular regard to the GST it is known that in
preneoplasia in rat liver the Ya, Yb, Yc and Yf GST subunits are
overexpressed (12,40,41,46,47). The Yf subunit has also been
shown to be overexpressed in MCF7 cell lines made resistant to
adriamycin (48) or to a variety of other chemotherapeutic agents
(Hill et al. unpublished). The present study demonstrates that in
tumor cell drug resistance the expression of other GST subunits as
well as a variety of glutathione-dependent enzymes, could be of
significant importance in the resistance mechanism. Over
expression of these genes, for example, as a consequence of a gene
amplification, implies the presence of another form of the
multidrug resistance phenotype involving alkylating agents and
compounds which are themselves, or which generate, peroxides.
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flSURB 1; Protaln Staining Mttarn of CHO-K1 and rHO-rhir
Samples were separated by SDS-PAGE. 50 fig of soluble protein
was taken per track. The mobilities if the rat Yc, Yb and Yf
standrads are also shown. K1 and Chlr are the wild type (S) and
resistant (R) cell lines, respectively.
FIGURE 2: Purification of the overproduced protein of
molecular weight 27500 from CHO-Chlr calla
Samples were taken at various stages during the purification
and run on 11% SDS-PAGE gels and stained with Coomassie Blue.
Tracks 1,2,3, and 4 are respectively total cell extract, peak of
GST activity eluted from the S-hexylglutathione column, column
flow through in the presence of 0.2 M salt and the purified GST
obtained following rechromatography of sample in track 3
respectively.
FIGURE 3: Comparison of glutathione S-transferasa aubunit
content in CHO-K1 and CHO-Chlr and the purified protein
Western blots were carried out as described in the Materials
and Methods section. Yc = standard; K1 and Chlr are samples from
the sensitive and resistant cell lines; P is the purified GST
protein (5|lg) . The antibody used was to the rat Yc subunit.
FIGURE 4 : Two Dimensional Gel Electrophoresis of CHO-Chlr and
the Purified GST Protein
Gels were run as described in the Materials and Methods and
in reference 14. 100 fig of soluble protein from CHO Chlr (top
panel) or 5 fig of the purified GST enzyme (bottom panel) were
taken. The overexpressed protein in CH0-Chlr is indicated by a
curved arrow.
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FIGURE 5; Glutathione S-tranaferase Subunit Content in CHQ-K1
and CHO-Chlr
Western blots were carried out as described in the Materials
and Methods sections using 50 yig of soluble protein per track.
The bands were identified using the human antibodies to the
Yf, class pi; Ya, class alpha; and Yb, class mu GST subunits;
STD = Human GST standard (1 ng); K1 = CHO-K1; Chlr = CHO-Chlr.
FIGURE 6: DNA analysis of CHO-Kl and CHO-Chlrusina an Alpha
Class GST and yGT cDNA's as Probea
Two DNA samples from separate cultures for each cell line
were digested with restriction endonucleases according to the
manufacturers instructions. (Tracks 1 and 2 - CHO-Kl, 3 and 4 -
CHO-CHLr) . DNA (5|ig) was separated on a 1% agarose gel and
transferred to Hybond-N. Fragments hybridizing the human alpha
class GST cDNA (A) or the y-glutamyl transpeptidase cDNA (B) were
detected as described by Hill et al (32). On the basis of
absorption at 260nm 1.4 fold more DNA was loaded in track 4.
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The administration of interferon-a//? to female nude
(nu/nu) mice caused significant changes in the levels of
the cytosolic hepatic glutathione transferases. Anti¬
bodies raised against rat subunits, Ya, Yc, Ybi, Yb2,
and Yk, and the subunits of the human transferases, p
(Yb Yb), X (Yf YTf), and t (Bt Bi) all reacted with enzymes
in the mouse and were used to demonstrate suppression
and induction of transferase levels. Western blot anal¬
ysis followed by semiquantitation by laser scanning
showed the Ya, Ybi, Yb2, Yc, Yk, p, and Bi subunits to
be suppressed by 11, 11, 44, 30, 12, 14, and 47%,
respectively, by interferon treatment. In contrast to
these findings, the Yf subunit was induced 5—7-fold. A
concomitant 220% increase was observed in the spe¬
cific activity of the hepatic cytosol for ethacrynic acid,
a substrate for the Yf subunit. Changes in the levels of
transferase enzymes in normal and tumor cells may
have significant implications when cytotoxic drugs are
used in combination with interferons in cancer ther¬
apy. The Yf subunit, an enzyme found in human tumors
and in placenta (Polidoro, G., Di Mio, C., Del Boccio,
G., Zulli, P., and Fererici, G. (1980) Biochem. Phar¬
macol. 29, 1677—1680) has also been shown to be
elevated in hepatic preneoplastic lesions (Kitahara, A.,
Satoh, K., Nishimura, K., Ishikawa, T., Ruike, K.,
Sato, K., Tsuda, H., and Ito, N. (1984) Cancer Res. 44,
2698—2703). These data indicate that the Yf subunit
represents a potentially important interferon-induci¬
ble gene product.
The glutathione transferases play a central role in the
protection of cells from toxic and carcinogenic electrophiles,
as well as from reactive oxygen intermediates such as super¬
oxide and peroxides (1). In some cases they have also been
implicated in the activation of chemical carcinogens (2, 3).
These cytosolic enzymes are dimeric proteins coded by mul¬
tiple genes which are part of four or more clearly defined gene
families. They are predominantly localized in the liver but
have been detected in a large number of other tissues (4-8).
The relative distribution and regulation of these isozymes
* The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby
marked "advertisement" in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
§ Present address: Dept. of Microbiology, University of Leeds,
Leeds, UK.
|| Supported by Project No. G8126392SB from the Medical Re¬
search Council.
ft To whom correspondence should be addressed.
within both normal and tumor cells will be an important
factor in their susceptibility to toxins and carcinogens (9).
Our interest in the regulation of drug-metabolizing enzymes
by interferons stems from (a) the potential effects of viral
infection on the metabolism and disposition of drugs and
carcinogens and (b) the potential use of interferons in con¬
junction with chemotherapeutic agents, which are metabo¬
lized by these enzymes, in the treatment of cancer (10).
Interferons have anticancer activity in man, but this has only
been of therapeutic benefit in cancers such as hairy cell
leukemia, low grade lymphoma, and chronic myelogenous
leukemia (11). However, in animal models, when used in
conjunction with alkylating agents, or compounds such as
adriamycin, they cause a significant enhancement in antitu¬
mor activity (10-14). The underlying mechanism of this effect
is unclear, although a recent report suggested that the in¬
creased activity of combination therapy was due to effects on
the tumor rather than on host drug-metabolizing enzymes
(15). However, it has been clearly shown that significant
changes occur in both the hepatic cytochrome P-450 enzyme
system and glutathione transferase activities when interferon
is injected into mice (15, 16). Such changes may be of signif¬
icant importance in drug disposition and toxic side effects
when interferon-drug combinations are used in man.
The elevation of glutathione transferases in preneoplastic
nodules is thought to be an important aspect of chemical-
induced neoplasia (17) as well as in the acquired resistance of
tumor cells to chemotherapeutic agents (18). Salerno et al.
(19) have reported that administration of interferon in con¬
junction with 3-methylcholanthrene significantly reduced the
incidence of liver tumors in mice. This could be due to effects
on cytochrome P-450 or glutathione transferase expression.
For the above reasons we have characterized interferon-in-
duced changes in the expression of particular glutathione
transferase enzymes.
MATERIALS AND METHODS
Female 6-week-old BALB/c or nude (nu/nu) mice were used. Nude
mice were housed in negative pressure isolators and were specific
pathogen-free. Experiments were carried out on these animals be¬
cause they were those used in xenograft experiments described in
previous publications (10, 15). The nude mice were treated daily for
30 days (BALB/c mice for 3 days) with 2 X 105 pm of mouse EA cell
interferon kindly supplied by Dr. S. Moushowitz, Enzo Biochem, New
York (specific activity 5 X 107 pm/mg) or mouse C243 cell interferon
kindly supplied by Dr. E. Proietti, Instituto di Superiore Senita,
Rome (specific activity 2 X 106 pm/mg). Interferon injections were
given subcutaneously. The peak serum levels using this dose were 200
pm/m\ 2 h after injection. Interferons were assayed in a biological
assay that measured reduction in viral RNA synthesis and were
calibrated against mouse reference standard g 002-904-511 (National
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Table I
Effect of interferon on glutathione transferase activity
Mouse cytosol fractions were prepared from groups of three animals treated with interferon. Enzymic
were carried out at 37 °C as described under "Materials and Methods." Values are expressed as pmol of product/
min/mg of cytosoiic protein and are given as mean ± S.D. for three determinations.
Enzyme activity
Ethacrynic l-Chloro-2,4- p-Nitrophenyl i-4-Phenyl-3- 2,4-Dichloronitro- Bromosul- ^nitro^en ^
acid dinitrobenzene acetate buten-2-one benzene fophthalein 1.
oxyfpropane
nmolfmin/mg protein
Control 0.077 ± 0.016 7.00 ± 0.50 0.20 ± 0.03 0.0011 ± 0.0005 0.151 ± 0.017 0.013 ± 0.002 0.068 ± 0.018
Interferon 0.169 ± 0.014 7.45 ± 1.27 0.23 ± 0.04 0.0009 ± 0.0002 0.117 ± 0.006 0.010 ± 0.005 0.078 ± 0.010
Institute of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, MD).
Hepatic cytosol fractions were prepared as described previously
(15). Samples were stored at -70 °C before use. Protein determina¬
tions were by the method of Lowry et al. (20) using bovine serum
albumin as standard. Glutathione transferase activity toward the
substrates l-chloro-2,4-dinitrobenzene, ethacrynic acid, p-nitro-
phenyl acetate, t-4-phenyl-3-buten-2-one, bromosulfophthalein, and
l,2-epoxy-3-(p-nitrophenoxy)propane was carried out at 37 °C by the
methods described by Habig and Jakoby (21). Glutathione
transferases1 L (Ya Ya), A (Ybi Ybi), D (Yb2 Yb2), AA (Yc Yc), and
K (Yk Yk) were purified from rat liver and human transferases t (IT
Bi), g. (Yb Yb), and X (Yf Yf) from human liver or lung by methods
described previously (22-25). Antibodies against these proteins were
raised in rabbits and used for the "Western blot" procedure at a
dilution of 1:1,000. The antibodies used have been shown to react
with autologous proteins in the mouse (26). The Ya, Yb2, Yc, Yk, and
Yf antibodies used in this study were specific for their autologous
antigens (8). However, there was some reactivity between the Ybi
antibody and Yb2, between g and Yb2, and between the human basic
B] enzyme and Ya (8). Immunoprecipitation experiments were carried
out by incubating 100 g\ of hepatic cytosol with varying amounts of
X antiserum (1-100 pi) for 12 h at 4 °C. The volume was always made
up with preimmune serum. The control sample contained preimmune
serum only. After this period anti-rabbit IgG was added (30 pl/30 pi
sample) and after 3 h at 4 °C the sample spun at 13,000 rpm for 5
min. The clear supernatant was taken for the determination of
ethacrynic acid activity as described above. SDS2-polyacrylamide gel
electrophoresis followed by transfer to nitrocellulose and subsequent
peroxidase staining of antibody-reactive proteins was carried out
using a modified version of the method described by Towbin et al.
(27) and Adams et al. (28). 4-Chloro-l-naphthol was used as peroxi¬
dase substrate. All the samples from any particular antibody were
run on the same SDS gel so that a direct comparison could be made
between them. Semiquantitation of the peroxidase staining bands
was carried out by scanning using a Joyce-Loebel laser gel scanner.
Values were obtained by scanning the entire band, and the resulting
peak areas, which reflected band area and density, were integrated.
Results were expressed as percentages of relevant controls calculated
as the mean value ± the standard deviation for three experiments.
RESULTS
The effect of long-term treatment of mice with interferon
on the metabolism of various glutathione transferase sub¬
strates is shown in Table I. The metabolism of ethacrynic
acid was significantly increased to 219% of control values by
interferon treatment. The metabolism of 2,4-dichloro-l-nitro¬
benzene (DCNB) was significantly reduced (33%). In these
experiments no change in the metabolism of the other sub¬
strates tested was measured. The Coomassie Blue staining
pattern of mouse cytosoiic fractions from control animals or
animals treated with interferon is shown in Fig. 1. A signifi-
1 Glutathione transferase subunits Ya, Yc, Ybi, and Yb2 are those
described as 1, 2, 3, and 4, respectively (4). The human transferases
( (Bi Bd and X (Yf Yf) have been described as basic and acidic
glutathione transferase, respectively (4). The acidic form has also
been referred to as ir and p.




C IFN Yb! Yf Yn
Fig. 1. Effect of interferon on the Coomassie Blue staining
pattern of hepatic cytosoiic proteins following SDS electro¬
phoresis. Nude mice were treated with interferon (2 x 106 units/day
for 30 days). Electrophoresis was carried out on 12% gels with 30 fig
of cytosoiic protein/track. The rat Ya, Yc, and Ybi, and Yn subunits
and the human Yf subunit were run as standards. C = control, IFN
= interferon-treated samples.
cant induction of a low molecular weight band, Mr 24,800,
and the suppression of bands in the region Mr 26,000-26,500
were observed. There also appeared to be some induction of a
protein with an apparent M, of 28,000. To assess the gluta¬
thione transferase subunits affected by interferon treatment,
Western blots were probed with antibodies raised to the
isolated rat and human enzymes. The reactivity of these
antibodies with mouse cytosol and the molecular weights of
the proteins identified are shown in Fig. 2 and Table II. All
of the antibodies recognized structurally analogous proteins
in the mouse. The apparent molecular weights of proteins
identified were very similar to the rat or human counterparts
with the exception of a mouse polypeptide which cross-reacted
with antisera against the rat Yc subunit (Mr 27,500) but
exhibited a faster mobility in the mouse with an apparent Mr
of 25,000. The effect of interferon administration on the
relative levels of the mouse proteins is shown in Figs. 3 and
4. The expression of some of the transferase isozymes was
significantly suppressed by interferon administration. The
degree of suppression appeared to vary considerably, even
between isozymes, i.e. between Yb, and Yb2, within the same
gene subfamily. The Ya, Yb!, Yb2, Yc, Yk, Bi, and human Yb
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Ya Yb 1 Yb2 Yc YcYblYaYk Yk Basic Yf M
■-Standards-1
Fig. 2. Determination of mouse cytosolic glutathione trans¬
ferases structurally related to those in rat and human. A single
SDS gel was run with tracks containing either 30 gg of cytosolic
protein or pure rat transferases. Following transfer to nitrocellulose,
the paper was cut into several strips and each one stained with a
specific antibody. The molecular weights of the proteins identified
were calculated from the mobilities of the staining bands relative to
the mobilities of rat glutathione transferases used as standards.
Table II
Subunit molecular weights of mouse glutathione transferases
identified with antibodies to the rat or human enzymes
Experimental details are given in the legend to Fig. 2. Weakly
cross-reacting polypeptides are in parentheses.
'— C— 1— IFN— 1—C—"—IFN—1 1—C—''— IFIVI—1
\\ Basic Yf
Fig. 3. Effect of interferon on the expression of individual
glutathione transferase subunits in murine hepatic cytosol
structurally related to the human isozymes g (Yb Yb), X (Yf
Yf), and e (Basic). Test animals received 2 X 105 units/day for 30
days. 12% polyacrylamide gels were used with 30 gg of protein/track.
Western blots were carried out using a modified method of that
described by Towbin et al. (27) as described under "Materials and
Methods." Three separate experiments are shown for each determi¬
nation.
Glutathione Glutathione Molecular Molecular weight
Species transferase transferase weight in rat or of cross-reacting
class Subunit in man protein in mouse
Rat I Ya 25,500 26,000
o
e
I Yc 27,500 (25,800) u
I Yk 25,000 (25,800/27,500)
II Ybi 26,300 26,400 "33>
II Yb2 26,300 26,400 _OJ
C/J
Man Basic B, 26,000 26,000
CO
0)
Neutral M 26,700 26,400 cCD
Acidic Yf 24,800 24,800 £
100
75
polypeptides were suppressed 11, 11, 44, 30, 12, 47, and 14%,
respectively. In contrast to these findings, a significant ele¬
vation in the level of the Yf subunit was measured. In three
separate determinations this subunit was elevated to levels
an average of five times higher than control animals (Figs. 3
and 4), a 7-fold increase being the maximum observed. In
order to determine whether this change was observed on
shorter interferon treatment, BALB/c mice were treated for
3 days with the same dose of interferon (Fig. 5). As with the
nude mice, a significant elevation in the expression of the Yf
subunit was measured in the interferon-treated animals. In
order to establish that the elevation in the Yf subunit would
account for the increase in ethacrynic acid activity, the en¬
zyme was immunoprecipitated from the cytosol using the
human antibody (Fig. 6). In agreement with previous findings
(26), this enzyme is primarily responsible for ethacrynic acid
activity in mouse cytosol. Indeed, all the activity could be
immunoprecipitated using the human antibody to the acidic
subunit.
DISCUSSION
The induction of mammalian glutathione transferases by
exogenous agents is well documented (4). The results of this
present study demonstrate that these enzymes are also regu¬


















Yf contYa Yb 1 Yb2 Yc Yk Basic g
Fig. 4. Determination of relative changes in mouse hepatic
glutathione transferase levels following interferon adminis¬
tration. Experimental details are given in Fig. 3. Western blots were
photographed and then scanned with a Joyce-Loebel laser gel scanner.
The entire band for each determination was scanned, and relative
values were obtained by integration of the peak areas obtained. The
values obtained are the means ± S.D. from three separate experi¬
ments.
feron-a/f) caused a significant suppression of the levels of
certain glutathione transferases in the mouse liver. This was
a differential effect where certain isozymes were only margin¬
ally suppressed, whereas others were reduced by up to 50%.
Each glutathione transferase has a unique spectrum of en-
zymic activity (4), and these observations indicate that viral
infection and other factors which induce interferon produc¬
tion will alter the detoxification of chemical toxins and car¬
cinogens within the liver and possibly other tissues. The
isozyme recognized by the antibody to transferase g was
suppressed to a similar extent to the Ybi subunit, and the
cross-reactivity of this antibody with Ybi3 suggests that two
antibodies are recognizing the same protein. Antisera raised
against the human basic glutathione transferase (BO and rat
3 P. K. Stockman and J. D. Hayes, unpublished.
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1 2 3 4 5 6
i 11 i
C +IFN
Fig. 5. Effect of interferon treatment on the expression of
the glutathione transferase Yf subunit in female BALB/c mice
treated for 3 days, 2 x 105 units/day. The Western blot was
carried out on hepatic cytosol using the antibody to transferase X (Yf
Yf) as described under "Materials and Methods." Lanes 1-3 are
cytosol from untreated animals. Lanes 4-6 are cytosol from animals
treated with interferon.
Fig. 6. Effect of immunoprecipitation of the Yf subunit on
cytosolic ethacrynic acid activity. Mouse liver cytosol (100 gl)
from interferon-treated animals was incubated for 12 h at 4 °C with
varying amounts of antibody to the human acidic (X) subunit (1-15
^1) and the volume made up with preimmune serum. After this period,
30 g\ of sheep anti-rabbit serum was added to 30 gl of the sample and
the mixture left for a further 3 h. The sample was then spun, and
aliquots were taken for the determination of ethacrynic acid activity
as described under "Materials and Methods." The control value was
146 nmol of conjugate formed/min/mg of protein.
Ya glutathione transferase subunits both cross-react with the
mouse Bi B,, Mr 26,000 glutathione transferase subunit, but
the suppression observed with anti-basic was much more
marked than that observed using the antibody to Ya; this
probably reflects a closer immunochemical identity between
the human and mouse glutathione transferase than between
the corresponding rat and mouse enzymes. Slight variation
between the molecular weights of the proteins identified was
also measured, but these differences are within the limits of
experimental error. In contrast to the suppression of some of
the glutathione transferases, the marked induction of the Yf
subunit (at least 5-fold) by interferon treatment was particu¬
larly striking. The changes in protein levels were to some
degree qualitatively confirmed by changes in substrate metab¬
olism. The metabolism of ethacrynic acid which was clearly
mediated by the Yf subunit (Fig. 6) (26) was elevated, and the
metabolism of DCNB, a substrate for the neutral (Yb) sub-
units, was reduced. The reason why CDNB activity did not
change significantly could be explained by the balance be¬
tween enzyme induction and suppression. The differential
induction of mRNAs coding glutathione transferase has been
reported by Pickett et al. (29), but there are few data in the
literature describing suppression of glutathione transferase.
The Yf glutathione transferase subunit is only expressed at
low levels in the livers of most species, including female mice,
but is present in several extrahepatic tissues (8). It has been
isolated and characterized from human placenta and lung
(30). Very little is known about the regulation of the Yf
subunit, and it appears to be refractory to induction by
exogenous inducing agents. The induction of this subunit by
interferon is therefore intriguing. The level of the Yf subunit
is significantly increased in hepatic preneoplastic lesions,
although other glutathione transferases are also elevated (33,
34). The increased levels of the transferases in these lesions
will increase the resistance of these cells to cytotoxic insult.
These changes are therefore thought to provide the preneo¬
plastic cells a selective advantage important for neoplastic
transformation (17, 30).
In various other examples of resistance to cytotoxic agents,
glutathione transferases have been shown to be elevated.
These include the resistance of normal bone marrow granu¬
locytes to the cytotoxic effects of cyclophosphamide (35, 36)
and the acquired resistance of tumor cells to cytotoxic drugs
(18, 37, 38). An acidic transferase polypeptide, probably the
Yf subunit, has recently been identified in an MCF 7 breast
tumor cell line made resistant to adriamycin (18). We have
also observed an elevation of this subunit in drug-resistant
tumor cells.4 This isozyme therefore appears closely related
to the resistance of both normal and neoplastic cells to cyto-
toxins.
The induction of the Yf subunit both by interferon and in
response to chemical insult raises the intriguing possibility
that there may be some common molecular changes in drug
resistance and interferon-induced resistance to viral infection.
Interferons selectively change molecular events in the cell.
Although the overall rate of RNA and protein synthesis is
unchanged, up to 100 mRNAs are induced and others are
inhibited by interferon treatment (39, 40). To date, only a
relatively few interferon-inducible gene products have been
identified. These include two enzymes, a protein kinase and
2',5'-oligoadenylate synthetase as well as molecules of the
major histocompatibility complex, metallothionein II, and
thymosin (39, 40).
It is known that viral infection can give rise to very high
localized tissue concentrations of interferon. As interferons
have the capacity to alter both cellular glutathione transferase
as well as cytochrome P-450 levels (15, 16), viral infection or
inflammation may alter the response of cells to cytotoxins
and chemical carcinogens. This could be either in the rate of
activation of the compounds to ultimate carcinogens or in the
rate of their detoxification. We are currently studying these
possibilities.
The use of interferon in conjunction with cytotoxic drugs
in cancer chemotherapy is being tested in clinical trials. The
effects of interferon on drug-metabolizing enzymes may sig¬
nificantly change the metabolism and disposition of chemo-
therapeutic agents administered concomitantly. These data
suggest that care must be taken when using such regimens to
avoid side effects that may arise because of an altered capacity
to detoxify and eliminate the cytotoxic drugs used.
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Reduced Levels of Drug-induced DNA Cross-Linking in Nitrogen Mustard-
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ABSTRACT
We have reported previously (C. N. Robsoo et al-, Guicer Res., 46:
6290-6294, 1986) the isolation of a Chinese hamster ovary cell line,
designated CHO-ChF, that exhibits resistance to bifunctional nitrogen
mustards while maintaining the normal parental level of sensitivity to
several other alkylating agents. We have compared the rate of formation
and repair of DNA cross-links induced by mechlorethamine in CHO-
Chr and parental CHO-K1 cells, both in intact cells and in isolated
nuclei. Equimolar doses of mechlorethamine induce significantly fewer
DNA interstrand cross-links in CHO-ChF cells than in CHO-K1 cells,
but levels of DNA-protein adducts are approximately equivalent in the
two lines. There is a correlation between the relative resistance of CHO-
Chr cells to mechiorethamine (34-fold) and the amount of drug required
to induce approximately equal numbers of DNA interstrand cross-links
in the two ceil lines. This strongly implicates DNA-DNA adducts in the
cytotoxic action of mechiorethamine. DNA cross-linking studies on iso¬
lated nuclei reveal only minor differences between the two lines even with
identical drug treatments. The rate of cross-link repair is comparable in
the two cell lines. These results, taken together with our earlier obser¬
vation that the rate of drug accumulation is identical in these two lines,
suggest that enhanced cytoplasmic drug detoxification is the underlying
resistance mechanism in CHO-Chf cells. We have measured cellular
glutathione 5-transferase activity, using both the general substrate 1-
chloro-2,4-dinitrobenzene, and substrates with some specificity for the
different classes of transferase isoenzymes. Total enzyme activity (as
measured with l-chk>ro-2,4-dinitrobenzene) is elevated 3-fold in the
resistant cells. A 2- and 5-fold increase, respectively, in activity against
ethacrynic acid and cumene hydroperoxide is detectable in CHO-Chf
cells. This elevation in catalytic activity in the resistant cells is reflected
in higher levels of both the Yr and Y.-type transferase subunits.
compound, GSH. However, mammalian cells have evolved a
supergene family of enzymes, the GSTs, which catalyze this
conjugation reaction (11). The GSTs are believed to be respon¬
sible for catalyzing the conjugation of GSH to electrophilic
metabolites formed from nitrogen mustards (12, 13). The re¬
sultant decrease in the steady state level of reactive drug metab¬
olites spares critical intracellular targets such as DNA from
levels of alkylation that cannot be repaired effectively.
We reported recently the isolation of a CHO cell line (CHO-
Chlr) with acquired resistance to bifunctional nitrogen mustards
(14). This subline was isolated on the basis of chronic exposure
to chlorambucil and exhibits resistance not only to chlorambucil
(24-fold) but also to melphalan (14-fold) and mechlorethamine
(34-fold). In contrast to the chlorambucil-resistant Walker rat
carcinoma (WR) cell line (15), CHO-ChIr cells are not cross-
resistant to other bifunctional alkylating agents, such as mito¬
mycin C, cu-diamminedichloroplatinum(II) or cyclophospha¬
mide, nor are they collaterally sensitive to nitrosoureas.
We have investigated the mechanism of resistance to nitrogen
mustards in CHO-ChT cells. Evidence is presented that the
principal alteration found in the resistant cells following expo¬
sure to drug is a reduction in the extent of damage to DNA.
This reduction is accompanied by an apparent increased rate of
drug detoxification that is a consequence of an elevation in




Alkylating agents represent an important class of antitumor
drugs. However, as with several other groups ofclinically useful
cytotoxic agents, their effectiveness is limited by the emergence
of subpopulations of resistant tumor cells. Several mechanisms
of resistance to alkylating agents in human and rodent cell lines
have been reported, including reduced membrane permeability,
increased efficiency of DNA repair, and enhanced drug detox¬
ification (1-10). Indeed, the mechanism responsible for nitro¬
gen mustard resistance is frequently multifactorial. For exam¬
ple, a melphalan-resistant CHO2 cell line was reported to have
an increased level of sulfhydryl groups, enhanced drug efflux,
and a decrease in drug-induced DNA cross-linking (1).
Several alkylating agents are sufficiently electrophilic to react
directly with the major cellular non-protein thiol-containing
Received 5/20/87; revised 8/21/87; accepted 8/25/87.
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' The abbreviations used are: CHO, Chinese hamster ovary; GST, glutathione
S-transferase; GSH, glutathione; PBS, phosphate-buffered saline; TBST, 50 mM
Tris-HCl (pH 7.9)-0.15 m NaCl-0.05% (v/v) Tween 20.
Cell Culture and Media. Cells were routinely maintained in Ham's
F-10 medium supplemented with 5% fetal calf serum, 5% newborn calf
serum, glutamine (3 mm), and antibiotics (penicillin, 100 units/ml;
streptomycin, 100 tig/ml; and nystatin, 50 units/ml). Cells were grown
as monolayers at 37"C in a humidified atmosphere containing 5% COy.
Cell Labeling and Alkaline Elution. Cellular DNA was labeled by
incubating cells with [2-'4C]thymidine (0.02 /iCi/ml) for 48 h. Following
growth in isotope-free medium for 16 h, cells were exposed to mechlor¬
ethamine for 1 h and, where indicated, then incubated in drug-free
medium to follow the time course of DNA repair.
DNA-protein and DNA-DNA interstrand cross-links were assayed
by the method of alkaline elution, essentially as described by Kohn et
al. (16). Briefly, approximately 5 x 105 cells (which were X-irradiated
on ice prior to elution) were impinged onto polyvinyl chloride filters
(2-um pore), lysed with 40 mm EDTA-2 m NaCl-0.2% sodium dodecyl
sarkosine (pH 10.0), and, where indicated, exposed to 0.5 mg/ml
proteinase K for I h. The DNA was eluted from the filters at a rate of
0.035 ml/min using a solution of 20 mm EDTA (free acid) adjusted to
pH 12.1 with tetrapropylammonium hydroxide (for the measurement
of total cross-links). For DNA-DNA cross-links, the elution buffer
contained 0.1% sodium dodecyl sulfate. Fractions were collected at 90-
min intervals over 15 h.
The use of a Watson-Marlow 202U/AA 16 channel constant speed
peristaltic pump gave highly reproducible flow rates in all channels.
Nuclei were prepared by the method of Glisson et al. (17). Isolated
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nuclei were exposed to drug in PBS at 37"C and then harvested and
resuspended in ice-cold PBS prior to X-irradiation (600 rads).
Cross-linking factors are defined as the ratio of the log fraction DNA
retained after 9 h in the irradiated control and the log fraction DNA
retained in the sample treated with both mechlorethamine and radia¬
tion. as described by Ross et al. (18).
Glutathione S-Transferase Assays. GST activity towards the sub¬
strates l-chloro-2.4-dinitrobenzene and ethacrynic acid was measured
by the method of Habig and Jakoby (19). Peroxidase activity towards
cumene hydroperoxide was carried out as described by Stockman el al.
(20). Cell suspensions were sonicated and spun for 5 min at 13,000
rpm in an Eppendorf microfuge, and the supernatants were assayed.
Dot Blots. This was performed to measure the relative levels of the
different classes of GSTs in the 2 cell lines. The antisera used were
raised in rabbits against the human proteins GST A, GST fi. and GST
B,Bi. which are members of the families referred to as "acidic," "neu¬
tral." and "basic" class GSTs. respectively. The specificities of these
antisera towards purified rat, mouse, guinea pig. and hamster GSTs
have been described elsewhere (21. 22).
Cvtosolic proteins from CHO-Chl' and CHO-K1 cells were dotted
onto nitrocellulose filters, washed for two 10-min periods in TBST,
and blocked for 1 h with 3% (w/v) bovine serum albumin in TBST.
Two further 10-min washes with TBST were carried out. after which
filters were incubated for 1 h with a specific human antibody to each
of the three GST isoenzyme classes. Following four 15-min washes
with TBST. the filters were incubated for I h with anti-rabbit IgG
conjugated to horseradish peroxidase antibody. The filters were washed
and dots were visualized either using 4-chloro-l-naphthol or by auto¬
radiography after labeling with 0.19 MBq '"I-protein A.
Immunocv tochemistry . Immunocytochemical staining of air-dried cy-
tocentrifuge preparations of intact cells was performed using an adap¬
tation of the method of Swirsky et al. (23). Briefly, cells were fixed for
2 min in methanofacetone (1:1, v/v) and then washed with PBS. A
100-mI aliquot of primary antibody (raised against human acidic, neu¬
tral. or basic forms of GST) was added to each slide and incubated at
room temperature for 45 min. Control slides were incubated with
Earle's balanced salt solution. Following incubation, slides were washed
with PBS and immersed for 10 min in 100 ml of methanol:7 ml of 30%
(v/v) hydrogen peroxide. After further washing with PBS. 100 j<l of
secondary antibody (swine anti-rabbit antibody conjugated with horse¬
radish peroxidase diluted 1:40 in Earle's balanced salt solution contain¬
ing 5% normal inactivated human serum) were added to each slide and
incubated for 45 min. Further washing with PBS was followed by
development of peroxidase for 10 min in a mixture of 50 mg of 3.3 -
diaminobenzidine in 100 ml of PBS and 20 a\ of H;0;. Slides were
then washed in distilled water and counterstained with hematoxylin.
RESULTS
DNA Cross-Linking in Resistant and Parental CHO Cells.
DNA cross-linking induced by mechlorethamine was measured
in CHO-Chl' and CHO-K1 cells using alkaline elution (16).
Representative elution profiles for CHO-K1 cells following a
1-h exposure to different concentrations of drug are shown in
Fig. 1. The effect of increasing doses of mechlorethamine is to
reduce the rate of DNA elution. reflecting the formation of
DNA cross-links.
The level of both DNA interstrand and DNA-protein cross¬
links was measured in resistant and parental cells. DNA inter-
strand cross-linking frequencies were determined by including
proteinase k in the elution protocol, in order to eliminate DNA-
protein adducts. The level of DNA interstrand cross-linking
induced by equimolar doses of mechlorethamine is very signif¬
icantly higher (P < 0.001) in CHO-K1 cells than in CHO-Chlr
cells (Fig. 2). CHO-ChT cells have previously been shown in
clonogenic survival assays to be 34-fold resistant to mechlor¬
ethamine (14). Based on this degree of resistance, it can be seen
(Fig. 2) that approximately equitoxic doses of drug induce the
Fig. 1. Representative filter elution profiles for CHO-K1 cells following a 1-h
exposure to different concentrations (as indicated) of mechlorethamine. In all
cases, cells were X-irradiated with 600 rads immediately prior to cell lysis and
elution.
Mechlorethamine (pg/ml)
Fig. 2. Levels of DNA interstrand cross-links induced in CHO-K1 (•) and
CHO-Chf (O) cells, as a function of mechlorethamine concentration. Cross-
linking factors were determined as described in "Materials and Methods." Points.
means of at least 3 independent experiments: bars, SE.
same level of DNA-DNA adducts in the 2 cell lines. For
example, mechlorethamine doses of 0.12 and 4 Mg/ml, respec¬
tively, produce a cross-linking factor of 2 in parental and
resistant cells.
Levels of DNA-protein cross-links were assessed by calculat¬
ing the difference between total cross-links (absence of protein¬
ase K) and DNA interstrand cross-links. Both lines accumulate
similar numbers of DNA-protein cross-links, although the re¬
sistant cells show a small but consistently increased level of
these adducts (data not shown). Thus, the strikingly higher level
of DNA cross-links seen in CHO-K1 cells appears to be solely
a consequence of an increase in the number of DNA-DNA
adducts.
Repair of DNA Cross-Links. To assess the DNA repair pro¬
ficiency of the two lines, cells were exposed for 1 h to a dose of
mechlorethamine that induced the same level of DNA inter¬
strand cross-links, before being washed and returned to drug-
free medium. At intervals, samples were taken and the degree
of cross-linking was determined. Fig. 3 shows that the rate of
cross-link repair is not significantly different in parental and
resistant cells.
Cross-Linking in Isolated Nuclei. To determine whether the
low level of drug-induced DNA damage in CHO-Chl' cells is a
consequence of a reduced level of active drug being accumulated
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Mechlorethamine (/jg/ml)
Fig. 4. Levels of DNA interstrand cross-links induced in nuclei isolated from
either CHO-K1 cells (•) or CHO-Chlr cells (O), as a function of mechlorethamine
concentration. Points. means of at least 3 independent experiments: bars, SE.
CDNB . ETHACRYNIC CUfvENE
Fig. 5. Histogram of 1 -chloro-2.4-dinitrobenzene (CD.\B). ethacrvnic acid,
and cumene hydroperoxide activities in CHO-K 1 (O) and CHO-Chlr(B).
S R STDS
trobenzene reflects overall levels of the different transferase
isoenzymes. Fig. 5 shows that CHO-Chl' cells have a 3-fold
higher total GST activity. In order to obtain an indication of
the enzyme subgroups that are overexpressed. assays were per¬
formed using substrates that show a degree of specificity for the
neutral (n, YbYb), acidic (A, YfYr), or basic (<, B|Bi) isoenzyme
forms. No activity against styrene oxide (for the neutral isoen¬
zymes) was detected. However, a significant elevation in both
cumene hydroperoxide (5-fold) and ethacrynic acid (2-fold)
activities was seen. These activities are indicative of the basic
and acidic GST isoenzymes, respectively, although more than
1 class of GST may show significant activity with these sub¬
strates.
Immunological Measurements of GST Levels. To confirm that
the increased catalytic activity against ethacrynic acid and cu¬
mene hydroperoxide was reflected in increased GST levels,
immunological measurements of GST levels were performed.
Higher levels of cross-reaction with the Yf-specific antisera









Time of repair (hours)
Fig. 3. Kinetics of repair of DNA interstrand cross-links induced by mechlor-
ethamine in CHO-K I (•) and CHO-ChT (O) cells. Points, means of 2 independent
determinations.
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in the nucleus of w hole cells, cross-linking measurements were
repeated using isolated nuclei. In this case, far lower concentra¬
tions of mechlorethamine were required to give measurable
levels of cross-links. Although slightly higher numbers of cross¬
links were induced in nuclei isolated from parental CHO-K 1
cells than those from the resistant cells (Fig. 4). the difference
is not significant (P > 0.05) and far less striking than that seen
in similar studies with intact cells.
These results suggest either that lower levels of drug are
accumulated intracellularly by CHO-Chl' cells or that drug
detoxification in the cell cytoplasm occurs more efficiently. The
former possibility can be discounted inasmuch as we have
previously shown that the rate of drug accumulation is not
significantly different in CHO-Chl' cells (14). Thus, drug de¬
toxification would appear to be the most likely mechanism of
resistance.
The GST family of isoenzymes has been reported to be
involved in the detoxification of a variety of xenobiotics, in¬
cluding alkylating agents, via conjugation with reduced GSH
(11. 12). The levels of these enzymes in the two cell lines were
therefore measured.
Measurements of GST Activity. Initially, transferase activity
using l-chloro-2.4-dinitrobenzene as substrate was measured in







Fig. 6. Autoradiogram of "dot blots'* of cytosolic proteins from CHO-K 1 (S)
and CHO-ChT (/?) cells. Either 2.5 ng (upper dot) or 0.25 ug of cellular protein
was dotted onto nitrocellulose filters, which were processed as described in
"Materials and Methods." The column labeled STDS represents GST standards
(0.25 and 0.025 ng in each case) of the different classes of GST.
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Fig. 7. Immunocvtochemical analysis of
fixed CHO-KI (.4. C. £. and G) and CHO-
Chlr (B, D. F. and //) cells. Cells were exposed
to either no antibody (A and B) or antibodies
specific for the human basic (C and D). neutral
(£ and £), or acidic (G and H) isoenzyme
forms. Treatment conditions are outlined in
"Materials and Methods." The intensity of
staining is an indication of the intracellular
GST concentration.
are seen in CHO-Chl' cells, as revealed by either dot blotting
(Fig. 6) or immunocytochemical analysis (Fig. 7).
DISCUSSION
We have studied the level of DNA damage induced by me-
chlorethamine in cell lines resistant or sensitive to bifunctional
nitrogen mustards. The striking difference between cross-link
levels seen in intact cells, but not in isolated nuclei, is indicative
of reduced intranuclear accumulation of active drug in the
resistant cells. Because total drug uptake into whole cells is
apparently unchanged in CHO-Chl' cells (14) it appears likely
that an increase in cytoplasmic drug detoxification is the un¬
derlying mechanism of drug resistance in these cells.
Intracellular glutathione has a major role in the detoxification
of reactive metabolic intermediates. Although spontaneous re¬
actions with electrophilic molecules can occur readily in vitro,
mammalian cells contain a variety of GST isoenzymes that
appear to catalyze these reactions in vivo. A large number of
distinct GST isoenzymes have been purified from human,
mouse, and rat cells, and in each species the different forms
have been shown to be members of three separate families. In
humans, mice and rats, GSTs that are members of the same
family display immunochemical cross-reactivity, exhibit similar
catalytic properties, and possess sequence homology (11. 24).
The GSTs in the Chinese hamster have not been well charac¬
terize (25. 26). but out data indicate that the three families are
represented in this species.
Changes in the intracellular level of GST activity have been
reported previously in alkylating agent-resistant cell lines. For
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example, the chlorambucil-resistant Walker carcinomaWR cell
line has 2-fold higher GST activity than the parental WS line,
although in 2 cases (ethacrynic acid and fra/w-4-phenyl-3-buten-
2-one), subunit specific activities are higher in the parental cells
(7). In a Yoshida cell line resistant to cyclophosphamide, an
approximately 6-fold higher GST activity was seen compared
to the sensitive parental line (4). An in vivo model for drug
resistance in ovarian cancer also implicates elevated GSH and
GST levels (27). In our CHO-Chl' cells, GST activity is elevated
3-fold, which appears to be a consequence of an increase in the
level of 2 enzyme forms. Whether the M, 25,000 protein pre¬
viously reported to be overproduced in CHO-Chlr cells (14) is
a GST subunit and associated with the observed increase in
GST activity in these cells is currently under investigation.
Although CHO-Chl' and the WalkerWR cells show comparable
levels of resistance to nitrogen mustards (14, 15), CHO-Chlr
cells differ from WR cells in being sensitive to other classes of
bifunctional alkylators, such as c/5-diamminedichloroplati-
num(Il) and mitomycin C. The narrow range of drugs to which
CHO-Chl' are resistant indicates that this line may represent a
good model for studying the substrate specificities of the differ¬
ent transferase isoenzymes and their cellular function. This may
be particularly relevant because of the apparent lack of accom¬
panying changes in the resistant cells, such as membrane perme¬
ability.
Analysis of DNA damage showed a dramatic reduction in
the level of DNA cross-linking induced by mechlorethamine in
CHO-Chl' cells. This difference was almost entirely due to the
formation ofDNA-DNA cross-links, not DNA-protein adducts.
Indeed, it appears that slightly more DNA-protein cross-links
were seen in the resistant than the parental cells at equimolar
drug doses. If the GSTs were inactivating nitrogen mustard-
derived nucleophiles, it may be expected that monoadducts as
well as cross-links would be prevented or quenched, and hence
the level of DNA protein cross-links would also be reduced in
CHO-Chl' cells. It is possible that GSTs are able to inactivate
monoadducts already bound to DNA by conjugation with GSH
or that the GSH-conjugated nitrogen mustard derivatives are
still capable of monovalent attack and that this could produce
equivalent levels of DNA protein cross-links in the two lines.
Further experiments are required to address these possibilities.
There is evidence that GSH-conjugated nitroimidazole deriva¬
tives can still radiosensitize (28) and certain GSTs are bound
to interchromatic regions of the cell nucleus (nonhistone pro¬
tein BA is a YbiYb, glutathione transferase) (29).
Our results support the contention that the principal lethal
lesion generated by nitrogen mustards is the DNA interstrand
cross-link. There appears to be no correlation between the
formation of DNA-protein adducts and the cytotoxic effects of
mechlorethamine. The apparent relationship between increased
drug detoxification and a reduction in the level of DNA cross-
linking provides additional evidence that GST can directly
protect cells against the lethal effects of alkylating agents. The
minor difference in cross-link levels seen in experiments with
isolated nuclei may reflect the presence of low levels of GST in
the nuclei of normal cells or of contamination by cytoplasmic
components of the prepared nuclei.
Our previous observation that the steady state intracellular
GSH content of CHO-ChT cells is elevated approximately 2-
fold (14) indicates that acquired drug resistance in these cells
is presumably mediated both by this increase in acceptor sulfhy-
dryl concentration and the overexpression of specific GST
subunits.
The rate of repair of DNA-DNA adducts is apparently un¬
changed in the resistant cells. In contrast to that seen previously
in a melphalan-resistant CHO cell line (1), the rate of repair of
mechlorethamine-induced cross-links is relatively rapid in our
cells and cross-link numbers did not reach a peak 3 h after the
removal of drug. It is difficult to make definitive statements
concerning the similarity in DNA repair capacity of 2 cell lines,
particularly when the levels of cross-links measured represent
a balance between continuing formation and loss by repair.
However, it would appear that there are no gross changes in
DNA repair capacity in CHO-Chl' cells.
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The role of glutathione in determining the response of normal and tumour cells to
anticancer drugs
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The treatment ofcancer with anticancer drugs has progressed
very slowly over recent years with only a few tumour types
that can be cured with drugs alone. Some tumours are
intrinsically resistant to drug therapy, whereas others which
are initially sensitive to their effects after a period of time
become resistant to the drugs used. This acquired drug
resistance is one of the major reasons why ovarian, breast
and small cell lung tumours cannot be cured. There are
many mechanisms providing an explanation of the acqui¬
sition of drug resistance, including changes in tumour cell
population, altered tumour cell growth rate of oxygenation.
In addition, phenotypic changes may occur within the
tumour cells as a direct result of drug treatment, which
make them resistant. It is the latter form of acquired resist¬
ance which forms the basis of the studies outlined below.
The effectiveness of an anti-cancer drug is dependent on the
toxicity of the drug to the tumour relative to the normal cells
of the body. The cells of the bone marrow are the major
susceptible normal tissue. Most other tissues are also affected
by one drug or other; however, the rapidly dividing cells of
the grastrointestinal tract and the hair follicles are also
prime targets.
Glutathione (GSH) and GSH-dependent enzymes, such
as the glutathione transferases and glutathione peroxidase,
provide a primary defence mechanism in cells against the
lethal effects of toxic chemicals (Meister & Anderson, 1983).
Abbreviations used: GSH. glutathione: GSSG, oxidized glutathione;
BSO. buthionine sulphoximine: MESNA. mercaptoethane sulphonate.
+Present address: Department of Radiotherapy. University of
Newcastle upon Tyne. Newcastle upon Tyne NE1 4LP. U.K.
^Present address: Department of Microbiology. University of Leeds.
Leeds LS2 9JT. U K
We therefore have been studying the regulation of these
enzymes in both normal and tumour cells after their
exposure to anticancer drugs. The anticancer drugs where
GSH may play an important role in detoxification can be
split into two major categories: drugs which are detoxified
by direct conjugation with GSH and drugs where formation
of reactive oxygen intermediates, such as superoxide and
hydroxyl radicals, are involved. In the latter case, GSH
detoxifies these reactive intermediates through oxidation to
GSSG catalysed by glutathione peroxidases. To date there
have been very few studies on the role of glutathione in the
conjugation of anticancer drugs; however, there are some
reports which indicate its potential importance (Hirono,
1960: Calcutt & Connors, 1963; Connors, 1966; Arrick &
Nathan, 1984; Green et al., 1984; Adams etal., 1985; Hamil¬
ton el al., 1985; Carmichael et al„ 1986a; Wolf et al., 1986)
(Table 1). The involvement of GSH in the dismutation of
peroxides is unquestioned. It is also clear that several anti¬
cancer drugs will cause the formation of reactive oxygen
intermediates. Whether cellular GSH concentrations are
critical to the susceptibility of the cells to these compounds is
still not clear. There are. however, some reports which
suggest that this is the case (Doroshow et al., 1980).
The relative concentration ofGSH in normal and tumour
cells will therefore be an important factor in determining
therapeutic index. In addition, any changes in cellular GSH
which occur within normal and/or tumour cells after drug
treatment which make them resistant to the further drug
administration, could also be a critical factor in therapy
with chemotherapeutic agents. In order to study GSH regu¬
lation in normal cells after cytotoxic insult we have adopted
a model where the prior administration of a low dose of
cyclophosphamide to mice can protect against a normally
lethal dose of the same compound, and in some cases other
compounds (Millar et al.. 1975). In this case the protection
is associated with protection of the bone marrow. This
property has been termed drug priming'. In view of the
potential involvement ofGSH in detoxification ofcyclophos¬
phamide (Berrigan et al., 1982) we studied whether the
resistance of the bone marrow to high concentrations of
cyclophosphamide after 'priming' might be related to changes
in GSH homoeostasis. On days 5, 6 and 7 after a priming"
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dose of cyclophosphamide (75mg/kg intraperitoneal^)
male CBA mice become almost completely resistant to a
lethal dose of this compound (Kimball el al., 1976). Bone
marrow GSH levels were initially markedly suppressed;
however, on days 5. 6 and 7, glutathione levels were
increased 2-3-fold above control values. As this mirrored
the days where maximum protection against a lethal dose
was observed, the changes in GSH homoeostasis could
therefore represent a mechanism for the protection of the
bone marrow. In substantiation of this possibility when
mice were treated with buthionine sulphoximine (BSO) (a
compound which depletes cellular GSH levels), the pro¬
tection afforded by drug priming was partially reversed
(Carmichael el al.. 19866). Although this evidence is not
conclusive, it demonstrates that GSH plays a role in the
protection of cells against cyclophosphamide metabolites
and also that the elevation in GSH in the bone marrow may
be part of the protection mechanism. In addition to these
conclusions it is perhaps more important that cells when
exposed to a cytotoxin over-produce glutathione. As the
glutathione transferase enzymes were also elevated at the
same time points, this indicates that the changes observed
may represent a general stress response (see also below). In
order to determine which subpopulation of the bone mar¬
row was involved in this response, different bone marrow
cell populations were sorted using a fluorescence-activated
cell sorter after priming. The erythrocyte and lymphocyte
GSH levels were unchanged; however, a 2-fold elevation in
granulocyte GSH and glutathione transferase activity was
measured (Carmichael el al., 1986a). This finding was in
agreement with the observation that the lethal effects of
cyclophosphamide are related to granulocytopenea. In
addition to changes in bone marrow granulocytes, GSH and
GST activity were also elevated in granulocytes isolated
from the peripheral circulation (Fig. 1).
The overproduction ofGSH in cells has been observed in
various other models involving resistance of cells to cyto-
toxins, for example, in preneoplastic lesions in the liver
(Demle & Oesterie, 1980) and in lungs of rats made tolerant
to a lethal dose of oxygen (Kimball et al., 1976). As sug¬
gested above the overproduction of GSH may therefore be
a general response of cells to stress. Enzymes involved in





Bone marrow Peripheral Peritoneal
F'g Comparison ofgranulocyte GSH levels in untreated mice
(O) or mice treated with cyclophosphamide IU)
Marrow and circulating granulocytes were obtained by fluore¬
scence-activated cell sorting. Peritoneal granulocytes were
induced by the injection of casein (2%) 4h before withdrawal
of the cells. Values were obtained 5 days after cyclophos¬
phamide administration (75 mg/kg)
stress response in bacteria (Christman el al., 1985). We are
currently evaluating the role of the glutathione transferases
as stress response proteins.
GSH levels in tumour cells will be a factor in their suscep¬
tibility to anticancer drugs. In this regard, we have been
studying both the regulation of GSH and GSH-depcndent
enzymes in drug-sensitive and drug-resistant tumour cell
lines in culture. Two ovarian cell lines, PE01 and PE04, have
been derived from a patient before and after she becomes
resistant to cis-platinum (Wolf ei al., 1987). Karyotyping
showed the lines to be of the same clonal origin but to have
diverged from each other. The cell lines showed differences
in their sensitivity to cis-platinum and the alkylating agent
chlorambucil. GSH levels were approx. 2-fold higher in the
drug-resistant line. In addition, a variety ofGSH-dependent
enzymes were also changed. Glutathione transferase activity
was elevated 2-fold and y-glutamyltranspeptidase 10-fold.
Similar to the normal and preneoplastic cell models, it
would appear that a cluster of genes relating to glutathione
metabolism may be important in making the cells drug
resistant. Indeed there are now a variety of reports in the
literature showing an elevation in GSH and glutathione
transferase levels in tumour cell lines made resistant to
anticancer drugs in vitro (Hirono. 1960; Calcutt & Connors,
1963; Batist et al., 1985; Wang & Tew, 1985; Wolf et al.,
1985; McGowan & Fox, 1986).
In view of the central role of GSH in detoxification there
is obvious interest in manipulating GSH levels in cells in a
manner which will alter the normal to tumour cell GSH
ratio and therefore sensitize the tumour cells to anticancer
drugs. In order to do this one must first understand how
GSH is regulated in cells. In this regard we have been
studying levels ofGSH in ovarian and other cell lines during














Fig. 2. GSH. glutathione peroxidase (GPX) and glutathione
transferase (GST) in confluent cells (C) compared with cells in
logarithmic growth (L)
GSH was determined by h.p.l.c. after monobromobimane
derivatization. glutathione peroxidase was measured fluori-
metncally using H.O: as substrate and glutathione transferase
measured using l-chloro-2.4-dinitrobenzene (CDNB) as sub¬





in logarithimic growth, significantly higher levels of GSH
are measured relative to non-dividing cells. In addition, the
enzyme glutathione peroxidase is also elevated in dividing
cells (Fig. 2). At the present time data for the glutathione
transferases is inconclusive, although activities were also
found to be elevated in dividing cells. Attempts to modulate
cellular GSH levels have centred around the glutathione
synthetase inhibitor BSO. As described above, admini¬
stration of this compound will sensitize cells to the effects of
cyclophosphamide. This compound has also been shown to
sensitize tumour cells to anticancer drugs (Green el al.,
1984; Somfai-Relle et al.. 1984; Hamilton et al.. 1985; Crook
ei al.. 1986). Hamilton el al. (1985) have demonstrated that
BSO will sensitize ovarian cell lines to the drug melphalan.
The dependence of all cells on GSH as a protection mech¬
anism against chemical or oxygen-radical damage, indicates
that care should be taken in the use of potent GSH synthesis
inhibitors such as BSO in cancer therapy. There has recently
been a report which indicates that administration of BSO to
mice increases the incidence of cataracts (Calvin et al..
1986).
As an alternative to the depletion of GSH in the tumour
as a method of sensitization towards anticancer drugs,
another approach would be to reduce toxicity to normal
tissues by administrating compounds which either selectively
elevate GSH levels in normal cells (Anderson et al., 1985) or
otherwise protect them from the drugs being used (Connors,
1966). Some compounds which contain sulphydryl group¬
ings are currently being used clinically in this manner.
For example, the compound mercaptoethane sulphonate
(MESNA) is used to protect the bladder against the toxic
side-effects of cyclophosaphamide and ifosphamide (Brack
et al., 1982). The compound .V-acetylcysteine has also been
shown to be effective in this regard (Berrigan et al., 1982).
MESNA is a drug which is selectively taken up into cells of
the gastrointestinal tract and kidney (Ormstad et al., 1983).
The gastrointestinal tract and the kidney are two major
targets for the toxic effects of cis-platinum, which is an
antitumour drug which is poorly tolerated by patients due
to the nausea it induces. In recent work we have shown that
MESNA dosed orally or intraperitoneally into mice can
significantly reduce the toxicity of cis-platinum to the gas¬
trointestinal trace (Allan et al.. 1986). In addition. MESNA
administration also significantly reduced ris-platinum leth¬
ality. A problem associated with the use of compounds
which reduce toxicity to normal tissues is the possibility of
reduced antitumour effect. When MESNA was dosed to
mice already administered the leukaemia cell line LI2I0. the
effectiveness of cis-platinum to increase survival time was
not compromised (Calvin et al.. 1986). This indicates that it
is possible to reduce the toxicity to normal tissues without
reducing the therapeutic efficacy.
In conclusion, the regulation ofGSH and GSH-dependent
enzymes in normal and tumour cells is a potentially import¬
ant determinant in therapeutic response in cancer chemo¬
therapy. In many cases, exposure of cells to toxic chemicals
results in the concentration of these components after an
initial depletion to become elevated either in a transient or
permanent manner. The resistance of these cells to further
drug administration may be a result of these changes but
perhaps more importantly may reflect an underlying protec¬
tion mechanism (stress response) in eukaryotic cells. The
potential of antagonizing this response or otherwise manipu¬
lating GSH and GSH-dependent enzymes in order to sen¬
sitize tumours to anticancer drugs represents an intriguing
area for future research.
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Glutathione reductase from Escherichia coli: mutation, cloning and sequence analysis of the gene
RICHARD N PERHAM
Department of Biochemistry. University of Cambridge.
Tennis Court Road. Cambridge CB2 I QW. U.K.
Glutathione reductase (EC 1.6.4.2) is a member of an
important class of enzymes, the flavoprotein oxido-
Abbreviation used: kbp, kilo base-pair
reductases. Other members are thioredoxin reductase
(EC 1.6.4.5). dihydrolipoamide dehydrogenase (EC 1.16.1.1).
Glutathione reductase catalyses the reduction of oxidized
glutathione by NADPH:
GSSG -l- NADPH + H* -• NADP+ + 2GSH
Reduced glutathione plays a critical part in the maintenance
of reduced thiol groups in the cell and has particular import-
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INTRODUCTION
The glutathione S-transferasea (GST) play a central role In
the protection of cells from cytotoxic and carcinogenic
compounds either by catalyzing the conjugation of GSH with
reactive electrophlles or by reducing reactive organic
peroxides. The former reaction prevents electrophlles from
reacting with macromolecules that possess critical cellular
functions and the latter reaction protects against
oxidative stress.
In cancer therapy there is increasing evidence that
anticancer drugs interact with glutathione (GSH) In a
manner which can either potentiate or decrease cytotoxicity
(Arrick and Nathan, 1984, Wolf et^ al., 1986). For example,
there is evidence that cyclophosphamide and other nitrogen
mustards form electrophlllc derivatives that can form a
thioether linkage with GSH (Berrlgan et_ al. , 1982; Adams
et aj^., 1985). Alternatively, compounds such as adrlamycln
and bleomycin can be metabolised to toxic peroxides that
My be reduced by CSH (Doroshow e£ al., 1980).
The effectiveness of current cancer chemotherapy Is
determined by the relative toxicity of the drug to normal
tissues, In particular the bone marrow and gut, relative to
the toxicity to the tumour cells. Tumour cell
susceptibility to these agents can be broadly split Into
the following three categories: a) tumours which can be
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cured with antlcanctr drug*; b) tumour* which are
Initially **n*ltlva to therapy but after an Initial
raapona* beeoaf realatant to th* drug*, I.e. acquired
raalatanca; c) tumour* which ara lntrlnelcally realatant
to tharapy. In th* caae of acquired drug realatance there
ara several poaalble nechanleme which would explain the
generation of drug realatant call*; two of theae Involve
selection procaaaaa. Th* flrat mechanism quires the
existence of a haterogenaoua call popul« within the
tumour that axhlblt differential aenalt «a to cytotoxic
drug*. In thl* lnatance Initial traatn 'rh an
antlcancar drug raault* In th* dastrurr sensitive
calls leaving predominantly viable drug tant cells.
The drug-resistant calls become th* majo- population
within the tumour. In th* second propo* isnlam of
resistance, administration of the drug « phenotyplc
changas either In enzymaa or membrane at ithln the
tumour (possibly also by aalactlon) that • cell
resistant to further drug treatment. In th- d caae
adaptive change accounts for tha acquired di -nee.
In view of their role In detoxification we h*
Investigating tha potential role of glutathlr
glutathione S-transferasea and other glutathf
anaymes In th* acquisition of drug resistance
and normal calls. The atudlea have mainly fo
expression of the GST In cells of th* bone mar
tumour cells sensitive or resistant to chemo
aganta.
2. METABOLISM AND RESISTANCE TO CYTOTOXIC
The GST enzymes represent a aupergene
protein*. Tha three cytosollc classes of
dlmsrlc and in man comprise binary combine
kDe), Tb (26.7 kDa) and Yf (26.8 kDa) tv>
respectively; (Hayes and Mantle, 1986)
that comprise Ya, Yb and Yf aubunlt* h*
basic, neutral and acidic GST, reapecti-
baaic Ya-type aubunlt* exist and theae
B, and Bj (Stockmen *t a_l_. , !983). A <
microsomal GST has also been dee-'- *
polypeptide*, each of 17,0 kD«. The
enbuntt.s possess a unique sobatrate epa¬
th*refor* their relative —tretlon v!
cell's detoxification caper ,
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effectiveness of cancer chemotherapeutlc agents there have
been very few studies to establish the Importance of CST-
medlated ' toxlflcatIon and the relative role of Individual
ieos-
ent studies, we have obtained evidence that GST
may a role in the detoxification of altozantrone (Wolf
*t 986), an anthraqulnone derivative which Is
cut undergoing clinical trials for the treatment of
br» cer. In this caae, evidence has been obtained
In conjugation of mltozantrone with GSH catalysed
by -oal GST and glucuronic acid, catalysed by UDP
gl- yl transferase. These two reactions may
re; important detoxification pathways for
an' ones. The formation of the glutathione conjugate
reqt he presence of hepatic microsomes and NADPH and
cou hlblted by carbon monoxide. Indicating that a
cyt P-A50 oxidation was first required. The
fo, >f the GSH conjugate was Inhibited either by
bo! a microsomes or by Incubation with the GST
auba> « *a, hexachloro-1,3-butadlene and 1-chloro-2-A-
dlnltrobenzene (CDNB). The structure of the mltozantrone-
GSH conjugate Is still unknown. Conjugate formation was
not found to be Increased by Inducers of cytochrome P-A50
or by the addition of hepatic cytosol to the Incubations
Indicating that the reaction catalysed by microsomal GST,
la the rate limiting step.
This finding may Indicate that metabolites of the
anthraqulnn'-'.o.! «-■ 'ftc substrates for the microsomal
GST. There, 'logy, other quinnone anticancer
drugs, e.g. adrlsaycin, may also be detoxified by this
mechanism. There Is also some evidence which Indicates s
role for the GST enzyme system in the detoxification of
cyclophosphamide metabolites (McGowan and Fox, 1986).
3. EXPRESSION OF GST IN TUMOUR CELLS
Relatively little Is known about GSH levels and GST
expression in tumour cells. A recent report by Kjdate et
al (1986) suggests that th* acidic Yf GST subunlt
is highly elevated In human colonic adenomas and
adenocarcinoma tissue. In th* cell lines derived from
different types of mamma)lan tumour we have found a large
variation In CST activity determined using CDNB ss
substrate Figure 1.
iOi C.R. Wolf at al.
*
JThe human cytosollc CST can ba classified as basic
(*• neutral C-*"' ♦) and acidic (pi*»«). The autologous
protalns In rat and mouse comprise polypeptides of similar
apparent Mr I.e. Ys, Yb and Yf-type eubunlts but possess
aarkadly different pi values. In this text the human
cytoeollc enzymes are referred to as basic, neutral and
acidic GST whereas GST from other species are designated by
the type of aubunlt they comprise]
Flgurel. Activity of various tumour cell lines In the
conjugation of l-chloro-2,4-dlnltrobenzenp with GSH
Confluent cells (C) or cells In logarithmic growth (L) were
harvested and sonicated In 0.5ml, SOmM phosphate buffer, pH
7.4 The samples were centrlfuged and the supernatant taken
for CST assay using CDNB as substrate.
— LC LC LC LC LC LC
HEPA1 EJ H322 H358 EF484 PE04 MCF7
The CDHB-GSH-conJugatlng activity In the human breast
cancer line MCF7 was extremely low and was approximately
100-fold leas than was obsurved In either the human ovarian
cell line PE04 or the human lung non-small cell carcinoma
line H358. In these studies no significant difference was
observed between CDNB activity In confluent cells versus
cells In logarithmic growth. The very low level of activity
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In the MCF7 cells Is of Interest in view of the reports In
the increase In GST activity In these cells made resistant
to adrlamycin (Batlst et al., 1985). Western blots of the
soluble fraction from these cell lines using antibodies
raised against the human basic (£.,YaYa) neutral C—, YtYb)
and acidic ( A.YfYf) GST showed high levels of the acidic
YfYf-contalnlng enzyme In moat of the cell lines studied
Figure 2.
Figure 2. Expression of acidic Glutathione transferase
(Yf Yf) in various tumour cell lines
30 ug of soluble cellular protein was loaded per track and
Western blots were carried out using a peroxidase labelled
second antibody and 4-chloro-l-nsphthol as substrate. All
the cell lines examined are of human origin, with the
exception of HEPA 1.
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In agreement with the data obtained with CDNB the ovarian
adenocarclnoaa cell line PEO* (Wolf at. al., 1985) and the
■358 call llnaa had the hlgheat levels of the acidic
subunlt• The human bladder carcinoma call line (EJ) also
contained high levels of the Tf polypeptide. The nouae
hepatoma call line contained extremely low anounts of the
Tf aubunlt and no visible band could be seen In MCF7 cells.
None of the cell lines shown In Figure 2 contained any
datactabla Ta CST basic. However, preliminary evidence
doaa Indicate that the Ya-type subunlts are expressed In
certain CHO calls (see below). The neutral enzyme-**<Yb Yb),
was only detected In the MCF7, the He pa 1 and foetal
fibroblast cell lines. However, as GST Is polymorphic In
nan (Hayes at al^., 1986; Seldagard et^ al., 1985) the
failure to Identify Yb subunlts In PE077 EJ6, NCI H322 and
NCI H358 lines many slnply raflact the fact that
approxlaataly 53Z of the population fall to express this
CST. Surprisingly, the CST-^(Yb Yb)-IgG recognised a
second polypeptide of faster nobility (approx. 23.5 kDa) In
all the samples tested. Whether this represents another
CST ensyae subunlt remains to be determined.
These data show that dlffarent tumour cell lines show
narked differences In their CST content. Indeed, we have
lnltal Information which Indicates that this Is also the
case In solid tumours samples. These variations In the
levels of particular GST enzymes could be a reason why
certain tumour types are refractory to chemotherapy.
*. EXPRESSION OF GST IH ACQUIRED DRUG RESISTANCE
In addition to studies of the constitutive levels of
CST In tumours, Investigations Into GST regulation In
tumour cells which have become resistant to cytotoxic
drugs have slso been undertaken. In this regard two models
have bean established. Firstly two ovarian adenocarclnoata
cell lines (PE01 and FE04), derived from peritoneal aacltes
samples, have been obtained from a patient, before and
after she became resistant to chemotherapy (Wolf et al.,
1985).
karyotyping showed the two lines to be of the same clonal
origin and In vitro clonogenlc assays showed them to have
different sensitivities to a variety of drugs Including
cls-platlnum, adrlamycln. The other model studied was a
Chinese hamster ovary cell line that was selected J_n vitro
for resistance to chlorambucil (Robson et al.. 1986).
Comparison of GSH concentrations and CST enzyme levels as
well es the levels of a variety of other enzymes Involved
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In glutathione homeostasis showed significant differences
between the resistant and sensitive cell lines.
Figure 3 Comparison of glutathione transferase activity
In drug sensitive and drug resistant cell lines













The drug sensitive ovarian cell line PE01 contained
approximately half the glutathione content, glutathione
S-transferase and glutathione peroxidase activity compared
to PE04 (Figure 3). In addition i -glutamyl transpeptidase
was ten-fold higher In the drug resistant PE04 cells. The
drug-resistant CHO cells also had elevated glutathione and
CST levels, the activity towards CDNB being seven-fold
higher than In the chlorambucil sensitive cell line.
Initial studies Indicate that In both the ovarian and CHO
cell lines the Yf GST subunlt Is elevated In the drug
resistant cells. In addition, dot blot analysis Indicated
the Ya CST aubunlt la significantly elevated In the drug-
resistant CHO lines. Whether the elevation In the levels
of these Isozymes Is the primary reason for the drug-
resistance of these cells Is still unclear. However, it la
Interesting that In other cell models, where cells
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axpossd to cytotoxic compounds btcoM rcalatant to further
cytotoxic Insult, for example, In other tumour cell models
(Batlst et »!., 1985); Hang and Tev, 1985; Tew et.al., this
Issue) or In preneoplestlc nodulas In the liver (see also
below), glutathione and GST levels havs also been shown to
be markedly elevated (Kltahara et al., 1985; Buchmann et
al,, 1985), Although a great deal of emphasis has been
placed on the acidic Yf GST subunlt In this regard the
changes observed are not restricted to this protein but are
also observed In Ya and Yb type subunlts (Buchmann ejt al,,
1985), The changes In GST levels may therefore represent a
stress response,
5. REGULATION OF GST IN NORMAL CELLS AS A STRESS
RESPONSE
The response of normal cells to stress Is not as easy
to Investigate as the changes observed are often transient.
The stress response of normal calls towards cytotoxic drugs
may be studied using cyclophoaphamlde-prlmed cells. In
this model It has been observed that when mice are dosed
with a low 'priming' dose of cyclophosphamide, they then
become resistant to a subsequent potentially lethal dose
given 5 to 6 days later (Miller et al., 1975). The lethal
effects of cyclophosphamide have been associated with
toxicity to the granulocytes of bone marrow. Therefore
adaptive changee appear to have occurred In this cell
population which have made them resistant to further
cyclophosphamide treatment. Recent studies have shown that
at the time points where maximum protection Is obtained
against cyclophosphamide significant elevations In
granulocytic GSH and GST levels are observed (Adams e_t
al., 1985, Carmlchael et al., 1986). As both GSH and GST
Kave been Implicated In the detoxification of the cytotoxic
metabolites of cyclophosphamide the changes In the levels
of theaa components could represent the mechanism of
resistance. SDS/PAGE analysis of bone marrow proteins
following 'priming' with cyclophosphamlds Is shown In
Figure A. An elevation of a polypeptide that comlgrated
with authentic rat Yb subunlts was observed. An elevation
In the levels of the Yb subunlt was confirmed by Western
blot experiments (Fig 5). Slight elevation In the Ya
subunlt was also observed. The elevation In the Yb subunlt
was shown to occur within the granulocyte cell population
(not shown) and could be observed In perlferal cells as
wall as cells from the bone narrow.
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Figure A SDS-PAGE of mouse bone marrow In animals
treated 5 or 6 days previously with cyclophosphamide
(75ng/kg)
100 ug of marrow soluble protein was loaded per track
C-control, P~cyclophoephanlde-prlmed The standards are
rat lung GST (Yf, Yb, Yc, Acidic, neutral and basic
respectively)
lP_CJlPCj
Day 5 Day 6
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The granulocytes fall to axpraaa the Yf aubunlt; which
could explain why Yf aubunlte vera not elevated In theee
celle. By contract, lynphocytaa contained high levela of
the Yf aubunlt and low lavala of the Yb aubunlt. However,
the lavela of GST In thaaa calls ware unchanged following
cyclophosphamide prlalng. The changes observed In the
■arrow granulocytes were only observed over a two to three
day period. Because of the llaltatlons In sampling It, It
was not possible to assess whether the Increase levels of
CST were transient within a cell, or whether the return to
basal levels was because the affected granulocytes had been
raleaaed Into the circulation.
6. EMDOCKNOUS REGULATION OF CST
Other models have been described where GST levels are
elevated In normal cells following administration of
cytotoxic compounds. For example. In the liver following
the administration of hepatotoxln carbon tetrachloride
(DlSlmpllclo, 1982). Such examples also Indicate CST
anaymes aa stress responre proteins. He are currently
studying tha regulation of specific CST subunlts In the
alternative models such as heat shock and oxidative stress.
Aa a result of Its potential role In drug resistance and
preneoplasla there Is a great daal of current research
effort being directed towards the Yf GST subunlt. The
resistance of cells to viruses through the action of
Interferon could also be considered a stress response.
He Initiated studies on the effects of Interferon on GST
expression not for this reason however, but primarily
because of the potential use of Interferons In combination
with cytotoxic drugs In cancer therapy. In previous reports
Interferons have been shown to cause significant reduction
In hepatic cytochrome P-A50 levela (lanton et (1-, 1978,
Balkwlll et al., 198A) and affecta on either cytochrome P-
*50 or CST levels could significantly affect the
disposition and effectiveness of the drugs used. In a
preliminary study it was found that Interferons could
affect CST activity (Balkwlll it il., 198*). He have
subsequently quantltated the levels of various hepatic
glutathione transferases In mice (Adams e£ al., 1987)
following administration of alpha/beta Interferon.
Interestingly, In a manner similar to the cytochrome P-
*50'a, the levels of the various CST enzymes were reduced.
In particular proteins which reacted with the human basic
(Bj or Ya-type subunlts and the rat Ybj subunlts. The
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Figure 5. Hestern blots of mouse bone marrow following
drug priming
The neutral Yb antibody was used for the top blots. The
bottom panel shows three blots that were probed using
antibodies Indicated and visualized using I -labelled
protein A followed by autoradiography
C-control P-cyclophosphamlde primed
-NEUTRAL
|P Cj |P C| Bid
Day a Day a
|P C I [P C| Bid
Day a Day a
ACIDIC
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■oat significant change, however, wee In the level* of
the Tf eubunlt which was slsvated five to seven fold
following Interferon administration. This was paralleled
by an lncraas* in the athacrynlc acid - GSH-conjugatlng
activity; ethacrynlc acid la a substrata for the Yf
subunlt. The Increased levels of the Yf aubunlt may not
b* part of the type of stresa reaponas described above, but
th* Increase Is of lnterast because conventional
saoganous Inducing agents do not affect the hepatic level*
of the Yf-contalnlng enzyme* The GST Yf aubunlt
■ay have additional functions In cells other than the
conjugation of electrophlllc foreign compounds*
In conclusion, glutathione, glutathione transferases
and various other glutathlone-dependent enzymes have been
shown to be elevated In a variety of cells exposed to
cytotoxic chemicals. These changes are observed In a
transient manner In a variety of normal cells and In an
apparently laaortallzed fashion In preneoplasla and drug
rsslstant tumour cells* (see, Adama et al■, 1985;
Caralchael et al., 1986). The apparently universal nature
of this response suggests that the elevated levels
of this group of enzymes represent a type of stress
response. In view of the Importance of these components In
the protection of cells from environmental chemicals, or.
In the case of tumours, froa anticancer drugs, further
characterization of these changes, the underlying
■achanlaas which regulate them and how they relate to
cellular resistance represent Important areas for further
atudy.
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The diverse reaponaa of a heterogeneous tunor cell
population to cheaotharapy haa continued to coapllcate
effective anticancer treatnent. Selection of subpopula-
tlone with Increased hoaogenelty haa resulted In both the
establlshaent of resistant cell populations following drug
exposure (acquired resistance) and the existence of tissue
types refractory to cheaotherapy (Intrinsic reslstsnce).
Several alterations In call function have been proposed as
explanations for cellular resistance and these Include
gene aapllflcatlon, decreased drug uptske, Increased DNA
repair, decreased drug aetsbollsa and Increased drug
detoxification.
The role of detoxification enzymes In cellular resis¬
tance haa recently received much consideration because of
numerous reports of elevated glutathlone-S-transferase
(CST) activity In drug resistant tumor cells. For
example, the multidrug resistant MCF-7 breast carcinoma
cell line exhibits a 45 fold Increase In GST activity when
compared to the parent cell line (Batlst 1986); Walker 256
rat breast carcinoma cells resistant to nitrogen mustards
demonstrate elevated levels of CST as compared to sensi¬
tive cells of the same cell line (Wang and Tew 1985).
According to Carmlchael et al. (1985), administration of a
low dose of cyclophosphamide results In Increased GST
activity In mouae bone marrow granulocytes which may
contribute to observed protection against a subsequent
lethal cyclophosphamide dosage. Whether this response to
drug treatment is specific to CST or part of a more
generalized cell reaponse to stress remains to be deter¬
mined. However, examination of liver GST demonstrated
specificity In the enhanced expression of particular GST
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Two ovarian cell lines were derived from the ascites of a
patient before and after the onset of resistance to chemother¬
apy involving cis-platinum, chlorambucil and S-fluorouracil.
Characterization of these lines shows them to have various
features in common and some significant differences. Cytolog-
ically the lines cannot be distinguished and they both contain
high concentrations of oestrogen receptor. However, they do
differ with respect to their growth characteristics, karyotype,
glutathione content and sensitivity to cis-platinum. The
karyotypes of the 2 lines show several marker chromosomes
in common but the resistant line contained a chromosome 8
and a 17 which were absent from the earlier sensitive line.
This suggests a clonal origin with subsequent divergence to a
heterogeneous population.
Ovarian adenocarcinoma is responsive to a variety of che-
motherapeutic agents (Rodenberg and Cleton, 1984). How¬
ever. the remissions which result from treatment are often
short, and following relapses the patients are usually resistant
to subsequent chemotherapy (Rodenberg and Cleton, 1984).
There are numerous possible explanations for the refractori¬
ness of tumours to treatment (Hill, 1982). Firstly, there may
be alterations in drug disposition not related to the tumour
cells themselves. Secondly, there is the possibility that the
tumor cells, when exposed to cytotoxic compounds, acquire
resistance to them. The phenomenon of acquired resistance
has been extensively studied and is well characterized for
many cell culture model systems (Schimke. 1984; Louie et al.,
1985). In the majority of reports, resistant cells have been
produced in vitro by selection, i.e. by growing the cell lines in
the presence of the drug under investigation (Fojo et al.,
1985). In view of the relative difficulty in obtaining tissue
samples and transferring them successfully into culture (Ber-
toncello et al., 1982). only a few reports have unequivocally
indicated that acquired drug resistance is an important factor
in the failure of chemotherapy (Bell et al., 1985). A third
explanation for resistance is the presence of minor cell popu¬
lations within the original tumour which are intrinsically more
resistant to chemotherapy and which, following initial treat¬
ment. become the major population within the tumour. This
represents the basis of the Goldie and Coldman model (1979)
and is supported by many reports of tumour-cell heterogeneity
(Heppner, 1984).
In order to investigate these possibilities, we have obtained
ascites samples from a patient before and after the onset of
clinical drug resistance. Two cell lines have been established
from these samples, characterized, and tested for drug
sensitivity.
relapse 14 months later. A sample of ascitic fluid was obtained
at this time and the cells were isolated and placed into tissue
culture (cell line PE01). The patient then received 6 further
courses of treatment (February-August 1982) as described
above and responded well with clearing of ascites. A comput¬
erized axial tomography scan of the abdomen performed in
August 1982 was normal. In November 1982 the patient re¬
lapsed with further ascites and she was then treated with a
higher dose of cis-platinum (100 mg/m2) but did not respond.
A cell line was derived from a second ascites sample (PE04)
taken in December 1982. The patient died in February 1983.
The cell lines were derived in the following manner. The
freshly obtained ascites samples were mixed with 100 units of
preservative-free heparin and the cells sedimented by centrif-
ugation. After the cells had been washed twice with phosphate-
buffered saline (PBS), red cells were removed using a Ficoll
Hypaque gradient. Tumour cells at the interface were aspirated
off. washed twice with PBS and checked for viability by
nigrosin staining. Aliquots of 105 cells per ml were then
cultured at 37°C, 100% humidity and 5% C02 in RPMI 1640
+ 10% foetal calf serum (v/v) with added insulin (2.5 /tg/ml),
streptomycin (100 /xg/ml), penicillin (100 IU/ml) and 3-[N-
morpholinojpropanesulphonic acid (12.5 mm). PE01 and PE04
were subcultured after 21 and 4 weeks respectively. Confluent
cultures were passaged by 1:5 or 1:10 splits. Periodic assays
for Mycoplasma were negative.
Cytology
Cells at passages I and 79 of PE01 and 2 and 48 of PE04
were harvested and grown on sterile 22 x 22 mm coverslips
in 35-mm wells (6-well plates, Sterilin, Teddington, UK).
When regular and satisfactory growth was obtained, the cells
were fixed and stained with PAP to reveal gross morphology
or with PAS-diastase to stain for mucin.
Karyotyping
Chromosome preparations were made from the patient's
peripheral blood as well as from cell lines PE01 and PE04 at
■"Present address: Imperial Cancer Research Fund. Laboratory of Mo¬
lecular Pharmacology and Drug Metabolism, Dept. of Biochemistry, Hugh
Robson Building, George Square. Edinburgh.
^Present address: Dept of Microbiology, University of Leeds, Leeds.
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material and methods
Source of ascites samples and cell lines
The patient, who was diagnosed as having stage-Ill ovarian
6To whom reprint requests should be sent.
adenocarcinoma in April 1980, was treated with 7 courses of Mbnviations: HSR. homogeneously staining region: PBS. Dulbecco s
c n „ i ,cnn _ /_2 , , • . -i ■ , phosphate-buttered saline; PAP. Papanicolaou: PAS-diastase, periodic acid5-fluorouracu (500 mg/m t.v.), cis-platinum (30 mg/m i.v.) K ^
and chlorambucil (0.1 mg/kg oral) over a period of 7 months.
A complete response—determined by second-look laparot-
omy—was obtained and no further treatment was given until Received: October 30, 1986 and in revised form December 27, 1986.
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various passages in culture. A minimum of 20 spreads of each
preparation were examined by staining with spermidine bis-
acridine by the Q-band technique of Van de Sande et al.
(1979).
Drug sensitivity assay
Drug sensitivity assays were carried out at the same time for
the 2 cell lines. Cells were taken at passages 77 to 82 and 46
to 51 for PE01 and PE04 respectively.
(J) Clonogenic assay in soft agar
The in vitro soft-agar assay of Courtenay et al. (1978) was
used. A single-cell preparation was obtained by vigorous as¬
piration and passage through a 19-gauge needle. Viability was
checked with nigrosin stain, then 5 x 103 and 1 x 103 cells/
ml in a test tube for PE01 and PE04 respectively were incu¬
bated with drug in the agar for 21 days, with 1 ml of fresh
medium added on days 7 and 14. Colonies of more than 50
cells were scored visually.
(2) Clonogenic assay on plastic
Assay conditions were modified from those described by
Parsons and Brown (1979) to suit these ovarian cell lines.
Cells were plated out in 35-mm wells (6-well Linbro plates.
Flow, Irvine, Scotland) at 2 x 103 and 103 cells/well for PE01
and PE04 respectively in medium containing ImM pyruvate to
give 100 to 200 colonies in control wells. After 2 days, when
cells had firmly attached but had not yet divided, drugs were
added to wells in triplicate and left on for 3 days. Medium was
changed every 2 to 3 days. After 12 to 14 days colonies were
counted visually.
Colony-forming efficiency and doubling time
The colony-forming efficiency of the lines in agar and on
plastic was determined in the Courtenay assay and the assay
on plastic as described. Doubling time was determined by
plating at 5 x 103 cells pier well in a 24-weil plate (NUNC,
Gibco, Paisley, UK) and harvesting rows of 4 wells at the
same time each day for 12 days. Harvested cells were counted
with a Coulter counter.
Glutathione and glutathione transferase assavs
Glutathione levels were determined by HPLC following
derivitization with monobromobimane (Gaetjens et al., 1984).
Glutathione transferase activity with l-chloro-2.4-dinitroben-
zene as substrate was determined by the method of Habig et
al. (1974). Cells used were in log phase and the values »
expressed per 106 viable cells.
Hormone receptor assays
Oestrogen and progesterone receptor assays were car
out on confluent cell cultures maintained for 6 to 10 day
steroid-stripped medium (Hawkins eta/., 1981; Hamiltoi
al., 1983).
DNA content
DNA content was measured on a fluorescence-activated
sorter using human lymphocytes as an internal diploid marl
Only a single G| peak was observed.
RESULTS
(1) Cytology
The cytology of the ascites samples and of the cell li
derived from them is shown in Figure 1. In contrast to
original ascites sample taken in April 1980, the 2 later sam|
from which cell lines PE01 and PE04 were derived w
largely devoid of both macrophages and lymphocytes,
ascitic fluids contained groups of cells as well as single c
of adenocarcinomatous type, characterized by large nu
eccentrically situated in the cytoplasm and occasional sigi
ring cells due to the presence of a large vacuole-contair
mucopolysaccharide. The latter property is consistent \
ovarian metastases. Cytological examination of the cell li
showed them to be very similar to the cells of the ascitic f
(Fig. Id and e). Both cell lines had large oval nuclei
prominent, sometimes multiple, nucleoli; they contained
net-ring cells and were mucin-secreting. No cytological dif
ence between the cell lines or between different passage;
the cell lines was apparent even at the ultrastructural level
electron microscopy (results not shown).
(2) Drug sensitivity
The sensitivity of PE01 and PE04 to the cytotoxic dr
used clinically, i.e. cis-platinum, chlorambucil and 5-fluort
acil, tested using clonogenic assays in agar and on plastic
shown in Figures 2-4. Two different assays were used to |
us greater confidence in the significance of the drug-sensiti'
differences between the 2 cell lines. A 3-fold difference in
sensitivities of the lines to cis-platinum was measured u:
either assay. Both assays gave similar results, the LD50 val
Figure 1 - Cytology ofascites and cell line samples. Samples were prepared and stained with Papanicolaou stain as described in "Mate
and Methods." (a) Ascites cells, April 1980. (b) Ascites cells. February 1982. (c) Ascites cells. December 1982. (d) Cell line PE01. pass
79. (e) Cell line PE04. passage 48. (Scale bar represents 40 iim).
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Cis-platinum cone (/xM) Cis - platinum cone (^M)
Figure 2 - Drug sensitivity for cell lines PE01 and PE04 using cis-platinum. (a) Clonogenic assay in soft agar according to Courtenay et al.
(1978). Points, means of 1-2 experiments PE01 and 2-6 experiments PE04; bars represent the standard error. (6) Clonogenic assay on plastic.
Assay conditions as described in "Material and Methods" section. Points, means of 2-4 experiments; bars represent the standard error.
being 8.0 x 10~8m and 2.7 X 10~7m in the agar assay and
6.4 x 10~8m and 2.0 x 10~7m in the assay on plastic for
PE01 and PE04 respectively. For chlorambucil the sensitivity
difference was 3-fold in the plastic assay and only 1.3-fold in
the assay on agar. In the case of 5-fluorouracii, no differences
between the cell lines were measured by either assay. Al¬
though there was more variation between experiments in mea¬
suring sensitivity to 5-fluorouracil, probably due to variation
in the nucleosides in serum batches, no differences between
the cell lines within an experiment were observed. Both cell
lines appeared more sens.tive to 5-fluorouracil in the agar
assay.
(3) Cell line characteristics
A summary of the general properties of the 2 cell lines is
shown in Table I and Figure 5. PE04 had a higher colony
efficiency. Both glutathione and glutathione transferase activ¬
ity, components central to the deactivation of alkylating agents
(Mitchell et al., 1982), were approximately twice as high in
PE04 as in PE01. Both cell lines had high levels of oestrogen
receptor, the value for PE04 being slightly higher than that for
PE01, and undetectable levels of progesterone receptors after
10 days' culture in steroid-stripped medium (Hamilton et al.,
1983).
(4) Karyotype
Karyotypes of the cell lines and peripheral blood are shown
in Figure 6.
The cells from the peripheral blood showed a normal 46.XX
karyotype even after chemotherapy, whereas the cell lines
from the ascites were hypodiploid. However, their DNA con¬
tent was slightly greater than that of normal diploid human
lymphocytes. The modal chromosome numbers from different
spreads varied between 39 and 42. Examples of the chromo¬
some complement of PE01 and PE04 with 41 chromosomes
are illustrated (Figs. 6a,b). Figure 6a shows a Q-banded
karyotype made from a normal peripheral blood cell taken
from the patient 4 weeks before she died. The cultured ascites
cells, in addition to being hypodiploid. contained many abnor¬
mal chromosomes. The chromosomes that are considered to
be normal are marked with a white square. PE01 has only 20
such chromosomes. None of the cells analysed contained a
normal 8 or 17 chromosome or any material that could be
considered as coming from either of these chromosomes, al¬
though this cannot be excluded because of many rearranged
chromosomes. PE01 had 12 consistent abnormalities which
were: both 3s inv(3)(p—q + ), 5p-, 9p + , Up+, both 13s
13q— and 13q + , 22q+ and 4 chromosomes of unknown
698 WOLF ET AL.
Chlorambucil cone I^M) Chlorambucil cone (mM)
Figure 3 - Drug sensitivity for cell lines PEOI and PE04 using chlorambucil. Legend as for Figure 2. Points, means of 2-5 experiments: bars
represent the standard error.
origin. The number and appearance of the other abnormal
chromosomes varied. Of the 4 chromosomes of unknown
origin, 2 marker chromosomes had a similar appearance—2
prominent bands on the distal long arm but the pericentric
chromatin which was very pale, uniformly staining and remi¬
niscent of homogeneously staining regions (HSR). These re¬
gions were not C-band-positive. The 2 other chromosomes
appeared to be isochromosomes. being metacentric with a very
similar banding pattern on each side of the centromere, one
being half the size of the other.
In contrast, PE04 had an apparently normal member of each
chromosome pair, including a chromosome 8 and 17 but ex¬
cepting an X and a 13 chromosome. However, the 13q —
chromosome now has material translocated to the brilliant pll
which could make this chromosome complete although rear¬
ranged. Of the consistent abnormalities seen in PEOI. the
following are seen in PE04: inv(3)(p-q-t-) with the brilliant
Q-band, 5p—. 9p + , llp + , 13q + . 22q + , one of the marker
chromosomes with the possible HSR: in many cells the smaller
of the 2 isochromosomes was seen. PE04 had acquired a ring
chromosome which was approximately the size of a D-group
chromosome, and also other rearranged chromosomes.
The "normal" 22 in both PEOI and PE04 has lost the intense
satellites. Deletion of satellites or the whole of an acrocentric
short arm is often found as a constitutional "abnormality" in
normal individuals.
DISCUSSION
Two ovarian adenocarcinoma cell lines have been estab¬
lished from ascites obtained before and after the onset of
resistance to chemotherapy. A marked difference was ob¬
served in the sensitivity of these lines to cis-platinum. one of
the chemotherapeutic agents used for treating the patient. Al¬
though the difference in sensitivity of these lines to cis-plati-
num was only 3-fold, we believe that changes in drug
sensitivity of this order of magnitude would be clinically im¬
portant (Ozols et al.. 1984; Hamilton et al.. 1984). No change
in drug sensitivity with in vitro passaging was observed. While
not the only possible explanation, our in vitro data suggest that
the tumour-cell population or subpopulations changed in the
patient during the drug treatment and the difference in drug
sensitivity could explain the resistance of this patient to further
treatment. In support of such in vivo change is the fact that the
PE04 cell line was established more rapidly and with much
less difficulty than the PEOI line. The LD50 levels reported
here are at the lower end of the range for cis-platinum toxicity
values (0.03-3 /x.m) reported in the literature for ovarian (Hol-
zel et al., 1985; Buick et al.. 1985; Van Putten et al.. 1986)
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Figure 4 - Drug sensitivityfor cell lines PE01 and PE04 using 5-fluorouracil. Legend as for Figure 2. A typical experiment is shown. Points,











TABLE I - CELL LINE CHARACTERISTICS


















Figure 5 - Glutathione and glutalhione-S-lransferase activity in cell
lines PEOI and PE04. Glutathione and glutathione-S-transferase ac¬
tivity was measured as described in "Material and Methods." Hatched
columns represent glutathione content and open columns glutathione-
S-transferase activity. Values are means of 3 separate experiments
earned out in triplicate; bars represent the standard error.
Characteristics PEOI PE04
Doubling time (hr) 53 59
Mucin production + +
Colony-forming 3.9 ± 2.3 8.1 ± 3.8
efficiency (plastic)
Colony-forming 3.9 ± 2.5 18.3 ± 10.4
efficiency (agar)
DNA content 1.1 x diploid 1.1 x diploid
Modal chromosome 41 41
number
Abnormal chromosomes + +
Oestrogen receptor 145 ± 34 203 ± 23
(fmol/mg protein)
Progesterone receptor Not detectable Not detectable
(fmol/mg protein)
and other human cell lines (B.T. Hill et al.. 1984) and below
that reported for normal human bone-marrow cells (0.9 nm)
(Umbach et al., 1985).
Although the cell lines were cytoiogically similar, there
were significant differences in their karyotypes. Chromosome
abnormalities found in the tumour cells of other patients with
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Figure 6 - Karyotypes ofperipheral lymphocytes, and cell lines PEOI and PE04. (a) Q-banded karyotype of a normal cell from a periphera
blood culture, showing the Q-band polymorphisms, (b) Karyotype of a cell from PE01. The chromosomes marked with a white square are con
sidered to be normal. The abnormal chromosomes which are arrowed are also found in PE04. (c) Karyotype of a cell from PE04. Symbols ar
as in (b) above. Chromosomes found only in PE04 are marked with a white spot for normal chromosomes and a cross for abnormal chromosomes
of the chromosomal rearrangements in these tumours have
involved the same chromosomes as in the present case (Ham¬
ilton et al., 1983; Freedman et al., 1978; S.M. Hill et al.,
1984; Kakati et al., 1975; Van der Reit-Fox et al., 1979;
Woods et al., 1979). However, we did not find the (6; 14)
translocation which, it is suggested, may characterize this
carcinoma (Trent and Salmon, 1981), although we did observe
a 3p-marker similar to that observed by others (Panani and
Ferti-Passantonopoulou, 1985; Mackillop et al., 1983).
No double minutes were found in these cells. The appear¬
ance of 2 marker chromosomes in PE01 was consistent with
their carrying homogeneously staining regions (HSRs). HSRs
have been, but need not necessarily be, associated with the
acquisition of drug resistance (Schimke, 1984). It is interesting
that the number of HSRs was reduced in PE04. PE04 appears
to contain more "normal" chromosomes than the earlier PE01
culture. Since both cell lines have several rearranged chromo¬
somes in common and were cytogenetically very heteroge¬
neous. it could be argued that the 2 lines probably arose from
a common ancestor, both diverged and co-existed in the body,
but that PE01 was more susceptible to the initial drug treat¬
ment and was overgrown by PE04. It is very unlikely that
PE04 evolved from PE01 as it would be almost impossible to
regain a normal 8 and 17 having once lost them. The 2 cell
lines therefore represent a model for the study of human
tumour-cell heterogeneity. There is no evidence that the karyo¬
type or properties of the cells changed during passaging in
vitro.
Variation in sensitivity to cis-platinum due to tumour-cel
heterogeneity has been observed in clonal human glioma line
isolated from a single untreated tumour (Yung et al., 1982)
This sort of heterogeneity has been observed by others (Tsurui
and Fidler, 1981) and has also been found in primary ovariai
cancer samples (Siracky, 1979). Our results, which sugges
PE04 is not a lineal descendent of PE01, emphasize the impor
tance and relevance of sub-population heterogeneity in druj
resistance.
PE01 and PE04 contained extremely high levels of oestro
gen receptor but undetected levels of progesterone receptors
Whether progesterone receptors, could be induced by oestro
gen, specifically excluded from the assay here, is as yet un
known. Oestrogen and progesterone receptor-positive ovariai
tumours and cell lines have been reported (Hamilton et al.
1983; Lazo et al. ,1984) but the levels of oestrogen recepto
detected here are very high compared with those in mos
reports [e.g.. mean of 18 and maximum of 163 fmol receptor
mg cytosolic protein in 56 ovarian tumour samples reporter
by Lazo et al. (1984)).
Two assays were used in this investigation of drug sensitiv
ity, to increase our confidence in sensitivity differences mea
sured. These were a relatively simple assay involving colon)
counting of attached colonies in 6-well plates, and the mor<
complex assay involving colony growth in soft agar. Th<
comparative sensitivity of the cell lines determined with thesi
assays was similar although some differences were apparent
The reason why chlorambucil gave a larger sensitivity differ
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ence between PE01 and PE04 in the assay on plastic is unclear,
but preliminary experiments suggest it may be related to the
increased oxygen tension (20% 02 vs. 5% 02). The growth
conditions in agar are clearly different from those in mono¬
layer on plastic. In particular, anchorage dependence (Ste¬
phens et al., 1980), oxygen tension (Gupta and Krishnan,
1982) and the addition of rat red blood cells in the Courtenay
assay (Endresen et al., 1985) have all been shown to affect
chemosensitivity measurements for some cells. Moreover, the
metabolic state of the cells when treated in suspension after
trypsinization or after attachment is important (Twentyman,
1979).
These conditions may also explain the difference in sensitiv¬
ity to 5-fluorouracil between the 2 assays, although other
factors such as the presence of thymidine (Engelbrecht et al.,
1984) in the Ham F-12 medium (and not in RPMI-I640) used
in the Courtenay assay or the length of time (3 days vs. 21
days) of drug exposure (Sobrero and Bertino, 1983) may also
influence the results. Our data suggest that great care should
be taken in relating in vitro assay results back to a patient since
different assays can give different results, as here with chlor¬
ambucil. Both cell lines have been successfully xenografted in
immune-deprived mice, and in experiments currently in prog¬
ress comparisons are being made between in vivo and in vitro
growth characteristics and drug sensitivities.
It is interesting to note the difference in glutathione levels in
our cell lines. The role of glutathione in the protection of cells
from cis-platinum is not clear. However, the role of this
peptide in the detoxification of alkylating agents in general is
well established (Mitchell et al., 1982). Furthermore, some
evidence suggests that thiol-containing compounds can in¬
crease the survivals of cis-platinum-treated mice and also re¬
duce both the kidney and gastrointestinal tract toxicity of cis-
platinum (Allan et al., 1986; Borch and Pleasants, 1979). The
potential importance of intracellular thiols is illustrated in a
recent report by Green et al. (1984) where an ovarian cell line
resistant to melphalan was made sensitive to this compound by
suppression of glutathione biosynthesis. In our cell lines the
glutathione levels are similar to those of other ovarian cell
lines as reported by Louie et al. (1985). Other workers have
suggested that glutathione metabolism may be more important
for melphalan and chlorambucil toxicity than for cis-platinum
(Andrews et al., 1985). However, the higher thiol level in
PE04 may be a contributing factor to its increased resistance
demonstrated in the present study.
The overall sensitivity or relative resistance of ovarian can¬
cer to cis-platinum is multifactorial. Differences in thiol levels
are just one of these factors. Tumour heterogeneity, demon¬
strated here cytogenetically, is also clearly important. The cell
lines described in this report have been cryopreserved and
satisfactorily retrieved from storage; they are now stable cell
lines available for continued study. In view of the relative
restrictedness of working with fresh ascites, we believe that
these cell lines constitute an appropriate and useful model for
the further study of mechanisms of drug resistance in this
important human tumour.
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